U.S. patent application number 16/454661 was filed with the patent office on 2019-10-17 for pyrazolopyridine compounds and uses thereof.
The applicant listed for this patent is Incyte Corporation. Invention is credited to Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Wenqing Yao, Hai Fen Ye, Qinda Ye.
Application Number | 20190315743 16/454661 |
Document ID | / |
Family ID | 59901622 |
Filed Date | 2019-10-17 |
![](/patent/app/20190315743/US20190315743A1-20191017-C00001.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00002.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00003.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00004.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00005.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00006.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00007.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00008.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00009.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00010.png)
![](/patent/app/20190315743/US20190315743A1-20191017-C00011.png)
View All Diagrams
United States Patent
Application |
20190315743 |
Kind Code |
A1 |
Liu; Kai ; et al. |
October 17, 2019 |
PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
Abstract
Disclosed are compounds of Formula (I), methods of using the
compounds for inhibiting HPK1 activity and pharmaceutical
compositions comprising such compounds. The compounds are useful in
treating, preventing or ameliorating diseases or disorders
associated with HPK1 activity such as cancer.
Inventors: |
Liu; Kai; (Bel Air, MD)
; Pan; Jun; (Media, PA) ; Sokolsky; Alexander;
(Philadelphia, PA) ; Vechorkin; Oleg; (Wilmington,
DE) ; Ye; Hai Fen; (Newark, DE) ; Ye;
Qinda; (Claymont, DE) ; Yao; Wenqing; (Chadds
Ford, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Incyte Corporation |
Wilmington |
DE |
US |
|
|
Family ID: |
59901622 |
Appl. No.: |
16/454661 |
Filed: |
June 27, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15698753 |
Sep 8, 2017 |
|
|
|
16454661 |
|
|
|
|
62385620 |
Sep 9, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 519/00 20130101;
C07D 471/04 20130101; A61P 35/00 20180101 |
International
Class: |
C07D 471/04 20060101
C07D471/04; C07D 519/00 20060101 C07D519/00 |
Claims
1. A compound of Formula I: ##STR00128## or a pharmaceutically
acceptable salt thereof, wherein: R.sup.1 is selected from
Cy.sup.1, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, halo, CN, NO.sub.2, OR.sup.a, SR.sup.a,
C(O)R.sup.b, C(O)NR.sup.cR.sup.d, C(O)OR.sup.a, OC(O)R.sup.b,
OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d, NR.sup.cC(O)R.sup.b,
NR.sup.cC(O)OR.sup.a, NR.sup.cC(O)NR.sup.cR.sup.d,
C(.dbd.NR.sup.e)R.sup.b, C(.dbd.NOR.sup.a)R.sup.b,
C(.dbd.NR.sup.e)NR.sup.cR.sup.d,
NR.sup.cC(.dbd.NR.sup.e)NR.sup.cR.sup.d, NR.sup.cS(O)R.sup.b,
NR.sup.cS(O).sub.2R.sup.b, NR.sup.cS(O).sub.2NR.sup.cR.sup.d,
S(O)R.sup.b, S(O)NR.sup.cR.sup.d, S(O).sub.2R.sup.b, and
S(O).sub.2NR.sup.cR.sup.d; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.10;
Cy.sup.1 is selected from C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein each 4-10 membered heterocycloalkyl and 5-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of 5-10 membered heteroaryl and 4-10
membered heterocycloalkyl is optionally substituted by oxo to form
a carbonyl group; and wherein the C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10; Cy.sup.A is
selected from C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein
the 5-10 membered heteroaryl has at least one ring-forming carbon
atom and 1, 2, 3, or 4 ring-forming heteroatoms independently
selected from N, O, and S; wherein the N and S are optionally
oxidized; wherein a ring-forming carbon atom of the 5-10 membered
heteroaryl is optionally substituted by oxo to form a carbonyl
group; and wherein the C.sub.6-10 aryl and 5-10 membered heteroaryl
are each optionally substituted with 1, 2, 3 or 4 substituents
independently selected from R.sup.20; R.sup.2 is selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, C.sub.3-10
cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
OR.sup.a7, SR.sup.a7, C(O)R.sup.b7, C(O)NR.sup.c7R.sup.d7,
C(O)OR.sup.a7, NR.sup.c7R.sup.d7, NR.sup.c7C(O)R.sup.b7,
NR.sup.c7C(O)OR.sup.a7, NR.sup.c7S(O)R.sup.b7,
NR.sup.c7S(O).sub.2R.sup.b7, NR.sup.c7S(O).sub.2NR.sup.c7R.sup.d7,
S(O)R.sup.b7, S(O)NR.sup.c7R.sup.d7, S(O).sub.2R.sup.b7, and
S(O).sub.2NR.sup.c7R.sup.d7; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.30; each R.sup.10 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
NO.sub.2, OR.sup.a1, SR.sup.a1, C(O)R.sup.b1,
C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1, OC(O)R.sup.b1,
OC(O)NR.sup.c1R.sup.d1, NR.sup.c1R.sup.d1, NR.sup.c1C(O)R.sup.b1,
NR.sup.c1C(O)OR.sup.a1, NR.sup.c1C(O)NR.sup.c1R.sup.d1,
C(.dbd.NR.sup.e1)R.sup.b1, C(.dbd.NOR.sup.a1)R.sup.b1,
C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1,
NR.sup.c1C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1, NR.sup.c1S(O)R.sup.b1,
NR.sup.c1S(O).sub.2R.sup.b1, NR.sup.c1S(O).sub.2NR.sup.c1R.sup.d1,
S(O)R.sup.b1, S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.11; or two R.sup.10 substituents
taken together with the carbon atom to which they are attached form
a spiro 3-7-membered heterocycloalkyl ring, or a spiro C.sub.3-6
cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl
ring has at least one ring-forming carbon atom and 1, 2 or 3
ring-forming heteroatoms independently selected from N, O, and S;
wherein a ring-forming carbon atom of each spiro 3-7-membered
heterocycloalkyl ring is optionally substituted by oxo to form a
carbonyl group; and wherein the spiro 3-7-membered heterocycloalkyl
ring and spiro C.sub.3-6 cycloalkyl ring are each optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.11; each R.sup.11 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, C.sub.3-10
cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
OR.sup.a3, SR.sup.a3, C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3,
C(O)OR.sup.a3, NR.sup.c3R.sup.d3, NR.sup.c3C(O)R.sup.b3,
NR.sup.c3C(O)OR.sup.a3, NR.sup.c3S(O)R.sup.b3
NR.sup.c3S(O).sub.2R.sup.b3, NR.sup.c3S(O).sub.2NR.sup.c3R.sup.d3,
S(O)R.sup.b3, S(O)NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.12; each R.sup.12 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, 4-7 membered
heterocycloalkyl, halo, CN, OR.sup.a5, SR.sup.a5, C(O)R.sup.b5,
C(O)NR.sup.c5R.sup.d5, C(O)OR.sup.a5, NR.sup.c5R.sup.d5,
NR.sup.c5C(O)R.sup.b5, NR.sup.c5C(O)OR.sup.a5,
NR.sup.c5S(O)R.sup.b5, NR.sup.c5S(O).sub.2R.sup.b5,
NR.sup.c5S(O).sub.2NR.sup.c5R.sup.d5, S(O)R.sup.b5,
S(O)NR.sup.c5R.sup.d5, S(O).sub.2R.sup.b5, and
S(O).sub.2NR.sup.c5R.sup.d5; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl and 4-7 membered
heterocycloalkyl, are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g; each R.sup.20
is independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
NO.sub.2, OR.sup.a2, SR.sup.a2, C(O)R.sup.b2,
C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2, OC(O)R.sup.b2,
OC(O)NR.sup.c2R.sup.d2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2,
NR.sup.c2C(O)OR.sup.a2, NR.sup.c2C(O)NR.sup.c2R.sup.d2,
C(.dbd.NR.sup.e2)R.sup.b2, C(.dbd.NOR.sup.a2)R.sup.b2,
C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2,
NR.sup.c2C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2, NR.sup.c2S(O)R.sup.b2,
NR.sup.c2S(O).sub.2R.sup.b2, NR.sup.c2S(O).sub.2NR.sup.c2R.sup.d2,
S(O)R.sup.b2 S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.21; or two adjacent R.sup.20
substituents on the Cy.sup.A ring, taken together with the atoms to
which they are attached, form a fused 4-, 5-, 6- or 7-membered
heterocycloalkyl ring, or a fused C.sub.3-7 cycloalkyl ring;
wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
has at least one ring-forming carbon atom and 1, 2, 3, or 4
ring-forming heteroatoms independently selected from N, O, and S;
wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl
ring are each optionally substituted with 1, 2, 3 or 4 substituents
independently selected from R.sup.21; each R.sup.21 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
OR.sup.a4, SR.sup.a4, C(O)R.sup.b4, C(O)NR.sup.c4R.sup.d4,
C(O)OR.sup.a4, NR.sup.c4R.sup.d4, NR.sup.c4C(O)R.sup.b4,
NR.sup.c4C(O)OR.sup.a4, NR.sup.c4S(O)R.sup.b4,
NR.sup.c4S(O).sub.2R.sup.b4, NR.sup.c4S(O).sub.2NR.sup.c4R.sup.d4,
S(O)R.sup.b4, S(O)NR.sup.c4R.sup.d4, S(O).sub.2R.sup.b4, and
S(O).sub.2NR.sup.c4R.sup.d4; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22; or two R.sup.21 substituents
taken together with the carbon atom to which they are attached form
a spiro 3-7-membered heterocycloalkyl ring, or a spiro C.sub.3-6
cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl
ring has at least one ring-forming carbon atom and 1, 2 or 3
ring-forming heteroatoms independently selected from N, O, and S;
wherein a ring-forming carbon atom of each spiro 3-7-membered
heterocycloalkyl ring is optionally substituted by oxo to form a
carbonyl group; and wherein the spiro 3-7 membered heterocycloalkyl
ring and spiro C.sub.3-6 cycloalkyl ring are each optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.22; each R.sup.22 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl,
4-7 membered heterocycloalkyl, halo, CN, OR.sup.a6, SR.sup.a6,
C(O)R.sup.b6, C(O)NR.sup.c6R.sup.d6, C(O)OR.sup.a6,
NR.sup.c6R.sup.d6, NR.sup.c6C(O)R.sup.b6, NR.sup.c6C(O)OR.sup.a6,
NR.sup.c6S(O)R.sup.b6, NR.sup.c6S(O).sub.2R.sup.b6,
NR.sup.c6S(O).sub.2NR.sup.c6R.sup.d6, S(O)R.sup.b6,
S(O)NR.sup.c6R.sup.d6, S(O).sub.2R.sup.b6, and
S(O).sub.2NR.sup.c6R.sup.d6; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; each R.sup.30 is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl, 4-7 membered heterocycloalkyl, halo, CN,
OR.sup.a8, SR.sup.a8, C(O)R.sup.b8, C(O)NR.sup.c8R.sup.d8,
C(O)OR.sup.a8, NR.sup.c8R.sup.d8, NR.sup.c8C(O)R.sup.b8,
NR.sup.c8(O)OR.sup.a8, NR.sup.c8(O)R.sup.b8,
NR.sup.c8S(O).sub.2R.sup.b8, NR.sup.c8S(O).sub.2NR.sup.c8R.sup.d8,
S(O)R.sup.b8, S(O)NR.sup.c8R.sup.d8, S(O).sub.2R.sup.b8, and
S(O).sub.2NR.sup.c8R.sup.d8; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; each R.sup.a and R.sup.c is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.10; each R.sup.d is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.10; or any R.sup.c and R.sup.d attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.10;
each R.sup.b is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10; each R.sup.e is
independently selected from H, CN, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfonyl, C.sub.1-6
alkylcarbonyl, C.sub.1-6 alkylaminosulfonyl, carbamyl, C.sub.1-6
alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, aminosulfonyl, C
.sub.1-6 alkylaminosulfonyl and di(C.sub.1-6 alkyl)aminosulfonyl;
each R.sup.a1, R.sup.c1 and R.sup.d1 is independently selected from
H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl, are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.11; or
any R.sup.c1 and R.sup.d1 attached to the same N atom, together
with the N atom to which they are attached, form a 4-, 5-, 6- or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
3, or 4 substituents independently selected from R.sup.11; each
R.sup.b1 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.11; each R.sup.e1 is
independently selected from H, CN, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfonyl, C.sub.1-6
alkylcarbonyl, C.sub.1-6 alkylaminosulfonyl, carbamyl, C.sub.1-6
alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl and di(C.sub.1-6 alkyl)aminosulfonyl;
each R.sup.a2, R.sup.c2 and R.sup.d2, is independently selected
from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.21; or any R.sup.c2 and R.sup.d2 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.21; each
R.sup.b2 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.21; each R.sup.e2 is
independently selected from H, CN, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfonyl, C.sub.1-6
alkylcarbonyl, C.sub.1-6 alkylaminosulfonyl, carbamyl, C.sub.1-6
alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl and di(C.sub.1-6 alkyl)aminosulfonyl;
each R.sup.a3, R.sup.c3 and R.sup.d3, is independently selected
from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6 membered
heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.12; or any R.sup.c3
and R.sup.d3 attached to the same N atom, together with the N atom
to which they are attached, form a 4-, 5-, 6- or 7-membered
heterocycloalkyl group optionally substituted with 1, 2 or 3
substituents independently selected from R.sup.12; each R.sup.b3 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl,
phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl;
wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl, are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.12; each
R.sup.a4, R.sup.c4 and R.sup.d4, is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl
and 4-7 membered heterocycloalkyl; wherein said C.sub.1-6 alkyl
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22; or any R.sup.c4 and R.sup.d4
attached to the same N atom, together with the N atom to which they
are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl
group optionally substituted with 1, 2 or 3 substituents
independently selected from R.sup.22; each R.sup.b4 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl,
phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl;
wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.22; each
R.sup.a5, R.sup.c5 and R.sup.d5, is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g; each R.sup.b5
is independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g; each R.sup.a6, R.sup.c6 and R.sup.d6, is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl, C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g; each R.sup.b6 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.g;
each R.sup.a7, R.sup.c7, and R.sup.d7 is independently selected
from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.30; or any R.sup.c7 and R.sup.d7 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.30; each
R.sup.b7 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.30; each R.sup.as, R.sup.c8 and
R.sup.d8, is independently selected from H, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; or any R.sup.c8 and R.sup.d8
attached to the same N atom, together with the N atom to which they
are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl
group optionally substituted with 1, 2 or 3 substituents
independently selected from R.sup.g; each R.sup.b8 is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.g; and each R.sup.g
is independently selected from OH, NO.sub.2, CN, halo, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-2 alkylene,
C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-3 alkoxy-C.sub.1-3
alkyl, C.sub.1-3 alkoxy-C.sub.1-3 alkoxy, HO--C.sub.1-3 alkoxy,
HO--C.sub.1-3 alkyl, cyano-C.sub.1-3 alkyl, H.sub.2N--C.sub.1-3
alkyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, thio,
C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfinyl, C.sub.1-6
alkylsulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, carboxy, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkoxycarbonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6
alkylsulfonylamino, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl,
di(C.sub.1-6 alkyl)aminosulfonyl, aminosulfonylamino, C.sub.1-6
alkylaminosulfonylamino, di(C.sub.1-6 alkyl)aminosulfonylamino,
aminocarbonylamino, C.sub.1-6 alkylaminocarbonylamino, and
di(C.sub.1-6 alkyl)aminocarbonylamino; provided that: 1) R.sup.1 is
other than CH.sub.3; 2) R.sup.1 is other than
2-morpholinopyridin-4-yl; 3) when Cy.sup.A is phenyl, then R.sup.1
is other than (2-chloropyridin-4-yloxy)methyl; and 4) when R.sup.1
is halogen-substituted phenyl, then Cy.sup.A is other than
unsubstituted or substituted 4H-1,2,4-triazol-3-yl.
2. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is selected from Cy.sup.1, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, CN,
NO.sub.2, OR.sup.a, SR.sup.a, C(O)R.sup.b, C(O)NR.sup.cR.sup.d,
C(O)OR.sup.a, OC(O)R.sup.b, OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d,
NR.sup.cC(O)R.sup.b, and NR.sup.cC(O)OR.sup.a; wherein said
C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.10.
3. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is selected from Cy.sup.1, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, and CN;
wherein said C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.10.
4. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is selected from Cy.sup.1, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl; wherein said C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.10.
5. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is Cy.sup.1.
6. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Cy.sup.1 is selected from C.sub.6-10 aryl and 5-10
membered heteroaryl; wherein the 5-10 membered heteroaryl has at
least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming
heteroatoms independently selected from N, O, and S; wherein the N
and S are optionally oxidized; wherein a ring-forming carbon atom
of 5-10 membered heteroaryl is optionally substituted by oxo to
form a carbonyl group; and wherein the C.sub.6-10 aryl and 5-10
membered heteroaryl are each optionally substituted with 1, 2, 3 or
4 substituents independently selected from R.sup.10.
7. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Cy.sup.1 is phenyl, pyridinyl, pyrazolyl, or
pyrimidinyl; wherein the phenyl, pyridinyl, pyrazolyl, or
pyrimidinyl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10.
8. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Cy.sup.1 is phenyl, pyridin-4-yl, 1H-pyrazol-4-yl,
pyridin-3-yl, or pyrimidin-5-yl; wherein the phenyl, pyridin-4-yl,
1H-pyrazol-4-yl, pyridin-3-yl, or pyrimidin-5-yl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.10.
9. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Cy.sup.1 is phenyl, pyridin-4-yl, or
1H-pyrazol-4-yl; wherein the phenyl, pyridin-4-yl, and
1H-pyrazol-4-yl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10.
10. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.10 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, CN, NO.sub.2,
OR.sup.a1, SR.sup.a1, C(O)R.sup.b1, C(O)NR.sup.c1R.sup.d1,
C(O)OR.sup.a1, OC(O)R.sup.b1, OC(O)NR.sup.c1R.sup.d1,
NR.sup.c1R.sup.d1, NR.sup.c1C(O)R.sup.b1, NR.sup.c1C(O)OR.sup.a1,
NR.sup.c1S(O)R.sup.b1, NR.sup.c1S(O).sub.2R.sup.b1,
NR.sup.c1S(O).sub.2NR.sup.c1R.sup.d1, S(O)R.sup.b1,
S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11.
11. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.10 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, CN, OR.sup.a1,
SR.sup.a1, C(O)R.sup.b1, C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1,
NR.sup.c1R.sup.d1, and NR.sup.c1C(O)R.sup.b1; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl, and
5-10 membered heteroaryl are each optionally substituted with 1, 2,
3, or 4 substituents independently selected from R.sup.11.
12. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.10 is independently selected from
C.sub.1-6 alkyl, 4-10 membered heterocycloalkyl, C(O)R.sup.b1, and
C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl and 4-10
membered heterocycloalkyl are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.11.
13. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.10 is independently selected from
C.sub.1-6 alkyl, piperazinyl, piperidinyl, morpholinyl,
C(O)R.sup.b1 and C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6
alkyl, piperazinyl, and piperidinyl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.11.
14. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.10 is independently selected from
C.sub.1-6 alkyl, piperazinyl, piperidinyl, C(O)R.sup.b1, and
C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl, piperazinyl,
and piperidinyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11.
15. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.11 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, CN, OR.sup.a3,
SR.sup.a3, C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3, C(O)OR.sup.a3,
S(O)R.sup.b3, S(O)NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.12.
16. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.11 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, halo, OR.sup.a3, C(O)R.sup.b3, and S(O).sub.2R.sup.b3;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6
alkynyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.12.
17. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.11 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, halo, C(O)R.sup.b3, and S(O).sub.2R.sup.b3; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.12.
18. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.11 is independently selected from
C.sub.1-6 alkyl, OR.sup.a3, C(O)R.sup.b3, and
S(O).sub.2R.sup.b3.
19. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.11 is independently selected from
C.sub.1-6 alkyl, C(O)R.sup.b3, and S(O).sub.2R.sup.b3.
20. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.10 is independently selected from
4-methylpiperazin-1-yl, N-methylaminocarbonyl, methyl,
N-(1-methylpiperidin-4-yl)aminocarbonyl,
(4-methylpiperazin-1-yl)carbonyl, N-phenylaminocarbonyl,
piperidin-4-yl, 1-(methylsulfonyl)piperidin-4-yl,
1-acetyl-piperidin-4-yl, morpholinyl, 4-ethylpiperazin-1-yl, or
2-hydroxypropan-2-yl.
21. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.10 is independently selected from
4-methylpiperazin-1-yl, N-methylaminocarbonyl, methyl,
N-(1-methylpiperidin-4-yl)aminocarbonyl,
(4-methylpiperazin-1-yl)carbonyl, N-phenylaminocarbonyl,
piperidin-4-yl, 1-(methylsulfonyl)piperidin-4-yl, and
1-acetyl-piperidin-4-yl.
22. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Cy.sup.A is C.sub.6-10 aryl optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.20.
23. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Cy.sup.A is 5-10 membered heteroaryl; wherein the
5-10 membered heteroaryl has at least one ring-forming carbon atom
and 1, 2, 3, or 4 ring-forming heteroatoms independently selected
from N, O, and S; wherein the N and S are optionally oxidized;
wherein a ring-forming carbon atom of the 5-10 membered heteroaryl
is optionally substituted by oxo to form a carbonyl group; and
wherein the 5-10 membered heteroaryl is optionally substituted with
1, 2, 3 or 4 substituents independently selected from R.sup.20.
24. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein Cy.sup.A is phenyl, 1H-indazol-4-yl, pyridin-3-yl,
pyridin-4-yl, pyrimidin-5-yl, 1H-pyrazolo[4,3-b]pyridin-6-yl,
pyridin-2(1H)-on-5-yl, 3H-imidazo[4,5-b]pyridin-6-yl,
pyrido[3,2-b]pyrazin-7-yl, oxazolo[5,4-c]pyridin-7-yl,
1H-pyrazol-4-yl, pyrazolo[1,5-a]pyridin-3-yl, quinolin-5-yl,
isoquinolin-4-yl, 1H-indol-4-yl, and imidazo[1,2-a]pyridin-8-yl,
each of which is optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.20.
25. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: each R.sup.20 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, CN, NO.sub.2,
OR.sup.a2, SR.sup.a2, C(O)R.sup.b2, C(O)NR.sup.c2R.sup.d2,
C(O)OR.sup.a2, OC(O)R.sup.b2, OC(O)NR.sup.c2R.sup.d2,
NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, NR.sup.c2C(O)OR.sup.a2,
NR.sup.c2S(O)R.sup.b2, NR.sup.c2S(O).sub.2R.sup.b2, S(O)R.sup.b2,
S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.21; or two adjacent
R.sup.20 substituents on the Cy.sup.A ring, taken together with the
atoms to which they are attached, form a fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring, or a fused C.sub.3-7 cycloalkyl
ring; wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring has at least one ring-forming carbon atom and 1, 2, 3, or 4
ring-forming heteroatoms independently selected from N, O, and S;
wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl
ring are each optionally substituted with 1, 2, 3 or 4 substituents
independently selected from R.sup.21.
26. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: each R.sup.20 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, CN,
OR.sup.a2, SR.sup.a2, C(O)R.sup.b2, C(O)NR.sup.c2R.sup.d2,
C(O)OR.sup.a2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2,
NR.sup.c2C(O)OR.sup.a2, NR.sup.c2S(O)R.sup.b2,
NR.sup.c2S(O).sub.2R.sup.b2, S(O)R.sup.b2, S(O)NR.sup.c2R.sup.d2,
S(O).sub.2R.sup.b2, and S(O).sub.2NR.sup.c2R.sup.d2; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10
aryl, and 5-10 membered heteroaryl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.21; or two adjacent R.sup.20 substituents on the Cy.sup.A
ring, taken together with the atoms to which they are attached,
form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a
fused C.sub.3-7 cycloalkyl ring; wherein each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring is optionally substituted by oxo to form a carbonyl group; and
wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
and fused C.sub.3-6 cycloalkyl ring are each optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.21.
27. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: each R.sup.20 is independently selected from
C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.6-10 aryl, 5-10
membered heteroaryl, halo, CN, OR.sup.a2, C(O)NR.sup.c2R.sup.d2,
C(O)OR.sup.a2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, and
NR.sup.c2S(O).sub.2R.sup.b2; wherein said C.sub.1-6 alkyl,
C.sub.6-10 aryl, and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21; or two adjacent R.sup.20 substituents on the
Cy.sup.A ring, taken together with the atoms to which they are
attached, form a fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring, or a fused C.sub.3-7 cycloalkyl ring; wherein each fused 4-,
5-, 6- or 7-membered heterocycloalkyl ring has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring is optionally substituted by oxo to form a carbonyl group; and
wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
and fused C.sub.3-6 cycloalkyl ring are each optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.21.
28. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: each R.sup.20 is independently selected from
methoxy, methyl, fluoro, trifluoromethyl, amino, methoxy,
hydroxymethyl, ethoxycarbonyl, methanesulfonamino, hydroxyl,
N-methylaminocarbonyl, dimethylamino, cyano, methoxycarbonyl,
acetylamino, phenyl, 2-oxazolyl, tert-butyl, aminocarbonyl,
N-benzylaminocarbonyl, N-(pyridin-4-ylmethyl)aminocarbonyl, ethyl,
methylaminomethyl; or two adjacent R.sup.20 substituents on the
Cy.sup.A ring, taken together with the atoms to which they are
attached, form a fused 5- or 6-membered heterocycloalkyl ring, or a
fused C.sub.5 cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1 or 2 ring-forming heteroatoms independently selected from N and
O; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.5 cycloalkyl ring are each
optionally substituted with 1 or 2 substituents independently
selected from amino, methylamino, 2-hydroxyethylamino, and
N-benzylamino.
29. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: each R.sup.20 is independently selected from
methoxy, methyl, fluoro, trifluoromethyl, amino, methoxy,
hydroxymethyl, ethoxycarbonyl, methanesulfonamino, hydroxyl,
N-methylaminocarbonyl, dimethylamino, cyano, methoxycarbonyl,
acetylamino, phenyl, 2-oxazolyl, tert-butyl, aminocarbonyl,
N-benzylaminocarbonyl, N-(pyridin-4-ylmethyl)aminocarbonyl, and
ethyl; or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 5- or 6-membered heterocycloalkyl ring, or a fused C.sub.5
cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1 or 2 ring-forming heteroatoms independently selected from N and
O; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.5 cycloalkyl ring are each
optionally substituted with 1 or 2 substituents independently
selected from amino, methylamino, 2-hydroxyethylamino, and
N-benzylamino.
30. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is selected from H, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo,
CN, OR.sup.a7, SR.sup.a7, C(O)R.sup.b7, C(O)NR.sup.c7R.sup.d7,
C(O)OR.sup.a7, NR.sup.c7R.sup.d7, NR.sup.c7C(O)R.sup.b7,
S(O)R.sup.b7, S(O)NR.sup.c7R.sup.d7, S(O).sub.2R.sup.b7, and
S(O).sub.2NR.sup.c7R.sup.d7; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.30.
31. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is selected from H, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo,
and CN; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.30.
32. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is H, C.sub.1-6 alkyl, or CN.
33. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is H or C.sub.1-6 alkyl.
34. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is H.
35. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is CN.
36. The compound of claim 1 having Formula IIa or Formula IIb:
##STR00129## or a pharmaceutically acceptable salt thereof, wherein
n is 1, 2, 3, or 4; and m is 1, 2, or 3.
37. The compound of claim 1 having Formula IIIa or Formula IIIb:
##STR00130## or a pharmaceutically acceptable salt thereof.
38. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: R.sup.1 is selected from Cy.sup.1, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, CN,
NO.sub.2, OR.sup.a, SR.sup.a, C(O)R.sup.b, C(O)NR.sup.cR.sup.d,
C(O)OR.sup.a, OC(O)R.sup.b, OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d,
NR.sup.cC(O)R.sup.b, NR.sup.cC(O)OR.sup.a,
NR.sup.cC(O)NR.sup.cR.sup.d, C(.dbd.NR.sup.e)R.sup.b,
C(.dbd.NOR.sup.a)R.sup.b, C(.dbd.NR.sup.e)NR.sup.cR.sup.d,
NR.sup.cC(.dbd.NR.sup.e)NR.sup.cR.sup.d, NR.sup.cS(O)R.sup.b,
NR.sup.cS(O).sub.2R.sup.b, NR.sup.cS(O).sub.2NR.sup.cR.sup.d,
S(O)R.sup.b, S(O)NR.sup.cR.sup.d, S(O).sub.2R.sup.b, and
S(O).sub.2NR.sup.cR.sup.d; wherein said C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.10; Cy.sup.1 is
selected from C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein each 4-10 membered heterocycloalkyl and 5-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of 5-10 membered heteroaryl and 4-10
membered heterocycloalkyl is optionally substituted by oxo to form
a carbonyl group; and wherein the C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10; Cy.sup.A is
selected from C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein
the 5-membered heteroaryl has at least one ring-forming carbon atom
and 1 or 2 ring-forming heteroatoms independently selected from N,
O, and S and the 6-10 membered heteroaryl has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of the 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.20; R.sup.2 is
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl,
C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
OR.sup.a7, SR.sup.a7, C(O)R.sup.b7, C(O)NR.sup.c7R.sup.d7,
C(O)OR.sup.a7, NR.sup.c7R.sup.d7, NR.sup.c7C(O)R.sup.b7,
NR.sup.c7C(O)OR.sup.a7, NR.sup.c7S(O)R.sup.b7,
NR.sup.c7S(O).sub.2R.sup.b7, NR.sup.c7S(O).sub.2NR.sup.c7R.sup.d7,
S(O)R.sup.b7, S(O)NR.sup.c7R.sup.d7, S(O).sub.2R.sup.b7, and
S(O).sub.2NR.sup.c7R.sup.d7; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.30; each R.sup.10 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl,
piperazinyl, piperidinyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
NO.sub.2, OR.sup.a1, SR.sup.a1, C(O)R.sup.b1,
C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1, OC(O)R.sup.b1,
OC(O)NR.sup.c1R.sup.d1, NR.sup.c1R.sup.d1, NR.sup.c1C(O)R.sup.b1
NR.sup.c1C(O)OR.sup.a1, NR.sup.c1C(O)NR.sup.c1R.sup.d1,
C(.dbd.NR.sup.e1)R.sup.b1, C(.dbd.NOR.sup.a1)R.sup.b1,
C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1,
NR.sup.c1C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1, NR.sup.c1S(O)R.sup.b1,
NR.sup.c1S(O).sub.2R.sup.b1, NR.sup.c1S(O).sub.2NR.sup.c1R.sup.d1,
S(O)R.sup.b1, S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
piperazinyl, piperidinyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.11; or two R.sup.10 substituents
taken together with the carbon atom to which they are attached form
a spiro 3-7-membered heterocycloalkyl ring, or a spiro C.sub.3-6
cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl
ring has at least one ring-forming carbon atom and 1, 2 or 3
ring-forming heteroatoms independently selected from N, O, and S;
wherein a ring-forming carbon atom of each spiro 3-7-membered
heterocycloalkyl ring is optionally substituted by oxo to form a
carbonyl group; and wherein the spiro 3-7-membered heterocycloalkyl
ring and spiro C.sub.3-6 cycloalkyl ring are each optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.11; each R.sup.11 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, C.sub.3-10
cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
OR.sup.a3, SR.sup.a3, C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3,
C(O)OR.sup.a3, NR.sup.c3R.sup.d3, NR.sup.c3C(O)R.sup.b3,
NR.sup.c3C(O)OR.sup.a3, NR.sup.c3S(O)R.sup.b3
NR.sup.c3S(O).sub.2R.sup.b3, NR.sup.c3S(O).sub.2NR.sup.c3R.sup.d3,
S(O)R.sup.b3, S(O)NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.12; each R.sup.12 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, 4-7 membered
heterocycloalkyl, halo, CN, OR.sup.a5, SR.sup.a5, C(O)R.sup.b5,
C(O)NR.sup.c5R.sup.d5, C(O)OR.sup.a5, NR.sup.c5R.sup.d5,
NR.sup.c5C(O)R.sup.b5, NR.sup.c5C(O)OR.sup.a5,
NR.sup.c5S(O)R.sup.b5, NR.sup.c5S(O).sub.2R.sup.b5,
NR.sup.cSS(O).sub.2NR.sup.c5R.sup.d5, S(O)R.sup.b5,
S(O)NR.sup.c5R.sup.d5, S(O).sub.2R.sup.b5, and
S(O).sub.2NR.sup.c5R.sup.d5; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl and 4-7 membered
heterocycloalkyl, are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g; each R.sup.20
is independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
NO.sub.2, OR.sup.a2, SR.sup.a2, C(O)R.sup.b2,
C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2, OC(O)R.sup.b2,
OC(O)NR.sup.c2R.sup.d2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2,
NR.sup.c2C(O)OR.sup.a2, NR.sup.c2C(O)NR.sup.c2R.sup.d2,
C(.dbd.NR.sup.e2)R.sup.b2, C(.dbd.NOR.sup.a2)R.sup.b2,
C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2,
NR.sup.c2C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2, NR.sup.c2S(O)R.sup.b2,
NR.sup.c2S(O).sub.2R.sup.b2, NR.sup.c2S(O).sub.2NR.sup.c2R.sup.d2,
S(O)R.sup.b2 S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.21; or two adjacent R.sup.20
substituents on the Cy.sup.A ring, taken together with the atoms to
which they are attached, form a fused 4-, 5-, 6- or 7-membered
heterocycloalkyl ring, or a fused C.sub.3-7 cycloalkyl ring;
wherein each fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
has at least one ring-forming carbon atom and 1, 2, 3, or 4
ring-forming heteroatoms independently selected from N, O, and S;
wherein a ring-forming carbon atom of each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl
ring are each optionally substituted with 1, 2, 3 or 4 substituents
independently selected from R.sup.21; each R.sup.21 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene, 5-10 membered heteroaryl-C.sub.1-3 alkylene, halo, CN,
OR.sup.a4, SR.sup.a4, C(O)R.sup.b4, C(O)NR.sup.c4R.sup.d4,
C(O)OR.sup.a4, NR.sup.c4R.sup.d4, NR.sup.c4C(O)R.sup.b4,
NR.sup.c4C(O)OR.sup.a4, NR.sup.c4S(O)R.sup.b4,
NR.sup.c4S(O).sub.2R.sup.b4, NR.sup.c4S(O).sub.2NR.sup.c4R.sup.d4,
S(O)R.sup.b4, S(O)NR.sup.c4R.sup.d4, S(O).sub.2R.sup.b4, and
S(O).sub.2NR.sup.c4R.sup.d4; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22; or two R.sup.21 substituents
taken together with the carbon atom to which they are attached form
a spiro 3-7-membered heterocycloalkyl ring, or a spiro C.sub.3-6
cycloalkyl ring; wherein each spiro 3-7-membered heterocycloalkyl
ring has at least one ring-forming carbon atom and 1, 2 or 3
ring-forming heteroatoms independently selected from N, O, and S;
wherein a ring-forming carbon atom of each spiro 3-7-membered
heterocycloalkyl ring is optionally substituted by oxo to form a
carbonyl group; and wherein the spiro 3-7 membered heterocycloalkyl
ring and spiro C.sub.3-6 cycloalkyl ring are each optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.22; each R.sup.22 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl,
4-7 membered heterocycloalkyl, halo, CN, OR.sup.a6, SR.sup.a6,
C(O)R.sup.b6, C(O)NR.sup.c6R.sup.d6, C(O)OR.sup.a6,
NR.sup.c6R.sup.d6, NR.sup.c6C(O)R.sup.b6, NR.sup.c6C(O)OR.sup.a6,
NR.sup.c6S(O)R.sup.b6, NR.sup.c6S(O).sub.2R.sup.b6,
NR.sup.c6S(O).sub.2NR.sup.c6R.sup.d6, S(O)R.sup.b6,
S(O)NR.sup.c6R.sup.d6, S(O).sub.2R.sup.b6, and
S(O).sub.2NR.sup.c6R.sup.d6; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; each R.sup.30 is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl, 4-7 membered heterocycloalkyl, halo, CN,
OR.sup.a8, SR.sup.a8, C(O)R.sup.b8, C(O)NR.sup.c8R.sup.d8,
C(O)OR.sup.a8, NR.sup.c8R.sup.d8, NR.sup.c8C(O)R.sup.b8,
NR.sup.c8C(O)OR.sup.a8, NR.sup.c8S(O)R.sup.b8,
NR.sup.c8S(O).sub.2R.sup.b8, NR.sup.c8S(O).sub.2NR.sup.c8R.sup.d8,
S(O)R.sup.b8, S(O)NR.sup.c8R.sup.d8, S(O).sub.2R.sup.b8, and
S(O).sub.2NR.sup.c8R.sup.d8; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; each R.sup.a and R.sup.c is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.10; each R.sup.d is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.10; or any R.sup.c and R.sup.d attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.10;
each R.sup.b is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10; each R.sup.e is
independently selected from H, CN, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfonyl, C.sub.1-6
alkylcarbonyl, C
.sub.1-6 alkylaminosulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl,
di(C.sub.1-6 alkyl)carbamyl, aminosulfonyl, C.sub.1-6
alkylaminosulfonyl and di(C.sub.1-6 alkyl)aminosulfonyl; each
R.sup.a1, R.sup.c1 and R.sup.d1 is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl, are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.11; or
any R.sup.c1 and R.sup.d1 attached to the same N atom, together
with the N atom to which they are attached, form a 4-, 5-, 6- or
7-membered heterocycloalkyl group optionally substituted with 1, 2,
3, or 4 substituents independently selected from R.sup.11; each
R.sup.b1 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.11; each R.sup.e1 is
independently selected from H, CN, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfonyl, C.sub.1-6
alkylcarbonyl, C.sub.1-6 alkylaminosulfonyl, carbamyl, C.sub.1-6
alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl and di(C.sub.1-6 alkyl)aminosulfonyl;
each R.sup.a2, R.sup.c2 and R.sup.d2, is independently selected
from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.21; or any R.sup.c2 and R.sup.d2 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.21; each
R.sup.b2 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.21; each R.sup.e2 is
independently selected from H, CN, C.sub.1-6 alkyl, C.sub.1-6
haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfonyl, C.sub.1-6
alkylcarbonyl, C.sub.1-6 alkylaminosulfonyl, carbamyl, C.sub.1-6
alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl and di(C.sub.1-6 alkyl)aminosulfonyl;
each R.sup.a3, R.sup.c3 and R.sup.d3, is independently selected
from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6 membered
heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.12; or any R.sup.c3
and R.sup.d3 attached to the same N atom, together with the N atom
to which they are attached, form a 4-, 5-, 6- or 7-membered
heterocycloalkyl group optionally substituted with 1, 2 or 3
substituents independently selected from R.sup.12; each R.sup.b3 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl,
phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl;
wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl, are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.12; each
R.sup.a4, R.sup.c4 and R.sup.d4, is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl
and 4-7 membered heterocycloalkyl; wherein said C.sub.1-6 alkyl
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22; or any R.sup.c4 and R.sup.d4
attached to the same N atom, together with the N atom to which they
are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl
group optionally substituted with 1, 2 or 3 substituents
independently selected from R.sup.22; each R.sup.b4 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl,
phenyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl;
wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.22; each
R.sup.a5, R.sup.c5 and R.sup.d5, is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g; each R.sup.b5
is independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g; each R.sup.a6, R.sup.c6 and R.sup.d6, is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl, C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g; each R.sup.b6 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.g;
each R.sup.a7, R.sup.c7, and R.sup.d7 is independently selected
from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.30; or any R.sup.c7 and R.sup.d7 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.30; each
R.sup.b7 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl, are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.30; each R.sup.as, R.sup.c8 and
R.sup.d8, is independently selected from H, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; or any R.sup.c8 and R.sup.d8
attached to the same N atom, together with the N atom to which they
are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl
group optionally substituted with 1, 2 or 3 substituents
independently selected from R.sup.g; each R.sup.b8 is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.g; and each R.sup.g
is independently selected from OH, NO.sub.2, CN, halo, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-2 alkylene,
C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy, C.sub.1-3 alkoxy-C.sub.1-3
alkyl, C.sub.1-3 alkoxy-C.sub.1-3 alkoxy, HO--C.sub.1-3 alkoxy,
HO--C.sub.1-3 alkyl, cyano-C.sub.1-3 alkyl, H.sub.2N--C.sub.1-3
alkyl, amino, C.sub.1-6 alkylamino, di(C.sub.1-6 alkyl)amino, thio,
C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfinyl, C.sub.1-6
alkylsulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, carboxy, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkoxycarbonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6
alkylsulfonylamino, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl,
di(C.sub.1-6 alkyl)aminosulfonyl, aminosulfonylamino, C.sub.1-6
alkylaminosulfonylamino, di(C.sub.1-6 alkyl)aminosulfonylamino,
aminocarbonylamino, C.sub.1-6 alkylaminocarbonylamino, and
di(C.sub.1-6 alkyl)aminocarbonylamino.
39. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: R.sup.1 is selected from Cy.sup.1, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, CN,
NO.sub.2, OR.sup.a, SR.sup.a, C(O)R.sup.b, C(O)NR.sup.cR.sup.d,
C(O)OR.sup.a, OC(O)R.sup.b, OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d,
NR.sup.cC(O)R.sup.b, NR.sup.cC(O)OR.sup.a, NR.sup.cS(O)R.sup.b,
NR.sup.cS(O).sub.2R.sup.b, NR.sup.cS(O).sub.2NR.sup.cR.sup.d,
S(O)R.sup.b, S(O)NR.sup.cR.sup.d, S(O).sub.2R.sup.b, and
S(O).sub.2NR.sup.cR.sup.d; wherein said C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.10; Cy.sup.1 is
selected from C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein
the 5-10 membered heteroaryl has at least one ring-forming carbon
atom and 1, 2, 3, or 4 ring-forming heteroatoms independently
selected from N, O, and S; wherein the N and S are optionally
oxidized; wherein a ring-forming carbon atom of 5-10 membered
heteroaryl is optionally substituted by oxo to form a carbonyl
group; and wherein the C.sub.6-10 aryl and 5-10 membered heteroaryl
are each optionally substituted with 1, 2, 3 or 4 substituents
independently selected from R.sup.10; Cy.sup.A is selected from
C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein the
5-membered heteroaryl has at least one ring-forming carbon atom and
1 or 2 ring-forming heteroatoms independently selected from N, O,
and S and the 6-10 membered heteroaryl has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of the 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.20; R.sup.2 is
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, halo, CN, OR.sup.a7, SR.sup.a7,
C(O)R.sup.b7, C(O)NR.sup.c7R.sup.d7, C(O)OR.sup.a7,
NR.sup.c7R.sup.d7, NR.sup.c7C(O)R.sup.b7, and
NR.sup.c7C(O)OR.sup.a7; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.30;
each R.sup.10 is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, piperazinyl, piperidinyl, C.sub.6-10 aryl,
5-10 membered heteroaryl, halo, CN, NO.sub.2, OR.sup.a1, SR.sup.a1,
C(O)R.sup.b1, C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1,
NR.sup.c1R.sup.d1, NR.sup.c1C(O)R.sup.b1, NR.sup.c1C(O)OR.sup.a1,
S(O)R.sup.b1, S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
piperazinyl, piperidinyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11; each R.sup.11 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, CN, OR.sup.a3,
SR.sup.a3, C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3, C(O)OR.sup.a3,
NR.sup.c3R.sup.d3, NR.sup.c3C(O)R.sup.b3, NR.sup.c3C(O)OR.sup.a3,
S(O)R.sup.b3, S(O)NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.12; each R.sup.12 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, CN, OR.sup.a5, SR.sup.a5, C(O)R.sup.b5,
C(O)NR.sup.c5R.sup.d5, C(O)OR.sup.a5, NR.sup.c5R.sup.d5,
NR.sup.c5C(O)R.sup.b5NR.sup.c5C(O)OR.sup.a5, S(O)R.sup.b5,
S(O)NR.sup.c5R.sup.d5, S(O).sub.2R.sup.b5, and
S(O).sub.2NR.sup.c5R.sup.d5; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g; each R.sup.20 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, CN, NO.sub.2,
OR.sup.a2, SR.sup.a2, C(O)R.sup.b2, C(O)NR.sup.c2R.sup.d2,
C(O)OR.sup.a2, OC(O)R.sup.b2, OC(O)NR.sup.c2R.sup.d2,
NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, NR.sup.c2C(O)OR.sup.a2,
NR.sup.c2S(O)R.sup.b2, NR.sup.c2S(O).sub.2R.sup.b2,
NR.sup.c2S(O).sub.2NR.sup.c2R.sup.d2, S(O)R.sup.b2,
S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.21; or two adjacent
R.sup.20 substituents on the Cy.sup.A ring, taken together with the
atoms to which they are attached, form a fused 5- or 6-membered
heterocycloalkyl ring, or a fused C.sub.3-7 cycloalkyl ring;
wherein each fused 5- or 6-membered heterocycloalkyl ring has at
least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming
heteroatoms independently selected from N, O, and S; wherein a
ring-forming carbon atom of each fused 5- or 6-membered
heterocycloalkyl ring is optionally substituted by oxo to form a
carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl ring are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.21; each R.sup.21 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, halo,
CN, OR.sup.a4, SR.sup.a4, C(O)R.sup.b4, C(O)NR.sup.c4R.sup.d4,
C(O)OR.sup.a4, NR.sup.c4R.sup.d4, NR.sup.c4C(O)R.sup.b4,
NR.sup.c4C(O)OR.sup.a4, S(O)R.sup.b4, S(O)NR.sup.c4R.sup.d4,
S(O).sub.2R.sup.b4, and S(O).sub.2NR.sup.c4R.sup.d4; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl, and
5-10 membered heteroaryl are each optionally substituted with 1, 2,
3, or 4 substituents independently selected from R.sup.22; each
R.sup.22 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, CN, OR.sup.a6,
SR.sup.a6, C(O)R.sup.b6, C(O)NR.sup.c6R.sup.d6, C(O)OR.sup.a6,
NR.sup.c6R.sup.d6, NR.sup.c6C(O)R.sup.b6, NR.sup.c6C(O)OR.sup.a6,
S(O)R.sup.b6, S(O)NR.sup.c6R.sup.d6, S(O).sub.2R.sup.b6, and
S(O).sub.2NR.sup.c6R.sup.d6; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g; each R.sup.30 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, phenyl, halo, CN, OR.sup.as, SR.sup.as, C(O)R.sup.b8,
C(O)NR.sup.c8R.sup.d8, C(O)OR.sup.as, NR.sup.c8R.sup.d8,
NR.sup.8C(O)R.sup.b8, NR.sup.c8C(O)OR.sup.as, S(O)R.sup.b8,
S(O)NR.sup.c8R.sup.d8, S(O).sub.2R.sup.b8, and
S(O).sub.2NR.sup.c8R.sup.d8; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and phenyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; each R.sup.a and R.sup.c is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl, C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.10; each R.sup.d is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.10;
each R.sup.b is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6
alkynyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10; each R.sup.a1,
R.sup.c1 and R.sup.d1 is independently selected from H, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
4-10 membered heterocycloalkyl, and C.sub.6-10 aryl; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, 4-10
membered heterocycloalkyl and C.sub.6-10 aryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; or any R.sup.c1 and R.sup.d1 attached to the same N
atom, together with the N atom to which they are attached, form a
4-, 5-, 6- or 7-membered heterocycloalkyl group optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; each R.sup.b1 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, and 4-10 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and 4-10
membered heterocycloalkyl are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.11; each
R.sup.a2, R.sup.c2 and R.sup.d2, is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.21;
each R.sup.b2 is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6
alkynyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.21; each R.sup.a3,
R.sup.c3 and R.sup.d3, is independently selected from H, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl, and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.12; each R.sup.b3
is independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.12; each R.sup.a4, R.sup.c4 and R.sup.d4, is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.22; each R.sup.b4 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.22;
each R.sup.a5, R.sup.c5 and R.sup.d5, is independently selected
from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and
C.sub.1-6 haloalkyl; each R.sup.b5 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and C.sub.1-6
haloalkyl; each R.sup.a6, R.sup.c6 and R.sup.d6, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl; each R.sup.b6 is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl; each R.sup.a7, R.sup.c7, and
R.sup.d7 is independently selected from H, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl; each
R.sup.b7 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl; each R.sup.as,
R.sup.c8 and R.sup.d8, is independently selected from H, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; each R.sup.b8 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; and each R.sup.g is independently selected from OH,
NO.sub.2, CN, halo, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-3 alkoxy-C.sub.1-3 alkyl, C.sub.1-3
alkoxy-C.sub.1-3 alkoxy, HO--C.sub.1-3 alkoxy, HO--C.sub.1-3 alkyl,
cyano-C.sub.1-3 alkyl, H2N--C.sub.1-3 alkyl, amino, C.sub.1-6
alkylamino, di(C.sub.1-6 alkyl)amino, thio, C.sub.1-6 alkylthio,
C.sub.1-6 alkylsulfinyl, C.sub.1-6 alkylsulfonyl, carbamyl,
C.sub.1-6 alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, carboxy,
C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkylcarbonylamino, C.sub.1-6 alkylsulfonylamino, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl, and di(C.sub.1-6
alkyl)aminosulfonyl.
40. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: R.sup.1 is selected from Cy.sup.1, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, and CN;
wherein said C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.10; Cy.sup.1 is selected from
C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10
membered heteroaryl has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of 5-10 membered heteroaryl is optionally
substituted by oxo to form a carbonyl group; and wherein the
C.sub.6-10 aryl and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.10; Cy.sup.A is selected from C.sub.6-10 aryl and 5-10
membered heteroaryl; wherein the 5-membered heteroaryl has at least
one ring-forming carbon atom and 1 or 2 ring-forming heteroatoms
independently selected from N, O, and S and the 6-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of the 5-10 membered heteroaryl is
optionally substituted by oxo to form a carbonyl group; and wherein
the C.sub.6-10 aryl and 5-10 membered heteroaryl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20; R.sup.2 is selected from H, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
halo, and CN; each R.sup.10 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, piperazinyl, piperidinyl, halo, CN, OR.sup.a1,
C(O)R.sup.b1, C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1, and
NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, piperazinyl, and piperidinyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; each R.sup.11 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, halo, OR.sup.a3, C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3,
C(O)OR.sup.a3, NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; each R.sup.20 is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, halo, CN, OR.sup.a2, C(O)R.sup.b2,
C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.2, NR.sup.c2R.sup.d2,
NR.sup.c2C(O)R.sup.b2, and NR.sup.c2S(O).sub.2R.sup.b2; wherein
said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.6-10 aryl, and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21; or two adjacent R.sup.20 substituents on the
Cy.sup.A ring, taken together with the atoms to which they are
attached, form a fused 5- or 6-membered heterocycloalkyl ring, or a
fused C.sub.3-7 cycloalkyl ring; wherein each fused 5- or
6-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 5- or 6-membered heterocycloalkyl ring is
optionally substituted by oxo to form a carbonyl group; and wherein
the fused 5- or 6-membered heterocycloalkyl ring and fused
C.sub.3-6 cycloalkyl ring are each optionally substituted with 1,
2, 3 or 4 substituents independently selected from R.sup.21; each
R.sup.21 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.6-10 aryl,
5-10 membered heteroaryl, halo, OR.sup.a4, C(O)R.sup.b4,
C(O)NR.sup.c4R.sup.d4, C(O)OR.sup.a4, NR.sup.c4R.sup.d4,
NR.sup.c4C(O)R.sup.b4, S(O).sub.2R.sup.b4, and
S(O).sub.2NR.sup.c4R.sup.d4; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, and 5-10
membered heteroaryl are each optionally substituted with 1, 2, 3,
or 4 substituents independently selected from R.sup.22; each
R.sup.22 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, OR.sup.a6,
C(O)R.sup.b6, C(O)NR.sup.c6R.sup.d6, C(O)OR.sup.a6,
NR.sup.c6R.sup.d6, NR.sup.c6C(O)R.sup.b6, S(O).sub.2R.sup.b6, and
S(O).sub.2NR.sup.c6R.sup.d6; each R.sup.a1, R.sup.c1 and R.sup.d1
is independently selected from H, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, 4-10 membered
heterocycloalkyl, and C.sub.6-10 aryl; wherein said C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, 4-10 membered
heterocycloalkyl and C.sub.6-10 aryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; or any R.sup.c1 and R.sup.d1 attached to the same N
atom, together with the N atom to which they are attached, form a
4-, 5-, 6- or 7-membered heterocycloalkyl group optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; each R.sup.b1 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, and 4-10 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and 4-10
membered heterocycloalkyl are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.11; each
R.sup.a2, R.sup.c2 and R.sup.d2, is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.21;
each R.sup.b2 is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl; each
R.sup.a3, R.sup.c3 and R.sup.d3, is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; each R.sup.b3 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; each R.sup.a4, R.sup.c4 and R.sup.d4, is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6
alkyl C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.22; each R.sup.b4 is independently selected from
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; each R.sup.a6, R.sup.c6 and R.sup.d6, is
independently selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl and C.sub.1-6 haloalkyl; and each R.sup.b6 is
independently selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl.
41. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: R.sup.1 is Cy.sup.1; Cy.sup.1 is selected from
C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein the 5-10
membered heteroaryl has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of 5-10 membered heteroaryl is optionally
substituted by oxo to form a carbonyl group; and wherein the
C.sub.6-10 aryl and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.10; Cy.sup.A is selected from C.sub.6-10 aryl and 5-10
membered heteroaryl; wherein the 5-membered heteroaryl has at least
one ring-forming carbon atom and 1 or 2 ring-forming heteroatoms
independently selected from N, O, and S and the 6-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of the 5-10 membered heteroaryl is
optionally substituted by oxo to form a carbonyl group; and wherein
the C.sub.6-10 aryl and 5-10 membered heteroaryl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20; R.sup.2 is H or CN; each R.sup.10 is
independently selected from C.sub.1-6 alkyl, piperazinyl,
piperidinyl, C(O)R.sup.b1 and C(O)NR.sup.c1R.sup.d1; wherein said
C.sub.1-6 alkyl, piperazinyl, and piperidinyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; each R.sup.11 is independently selected from
C.sub.1-6 alkyl, OR.sup.a3, C(O)R.sup.b3, and S(O).sub.2R.sup.b3;
each R.sup.20 is independently selected from C.sub.1-6 alkyl,
C.sub.1-6 haloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl,
halo, CN, OR.sup.a2, C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2,
NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, and
NR.sup.c2S(O).sub.2R.sup.b2; wherein said C.sub.1-6 alkyl,
C.sub.6-10 aryl, and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21; or two adjacent R.sup.20 substituents on the
Cy.sup.A ring, taken together with the atoms to which they are
attached, form a fused 5- or 6-membered heterocycloalkyl ring, or a
fused C.sub.3-7 cycloalkyl ring; wherein each fused 5- or
6-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 5- or 6-membered heterocycloalkyl ring is
optionally substituted by oxo to form a carbonyl group; and wherein
the fused 5- or 6-membered heterocycloalkyl ring and fused
C.sub.3-6 cycloalkyl ring are each optionally substituted with 1,
2, 3 or 4 substituents independently selected from R.sup.21; each
R.sup.21 is independently selected from C.sub.6-10 aryl, 5-10
membered heteroaryl, OR.sup.a4, and NR.sup.c4R.sup.d4; each
R.sup.22 is OR.sup.a6; each R.sup.c1 and R.sup.d1 is independently
selected from H, C.sub.1-6 alkyl, 4-10 membered heterocycloalkyl,
and C.sub.6-10 aryl; wherein said C.sub.1-6 alkyl, 4-10 membered
heterocycloalkyl and C.sub.6-10 aryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; or any R.sup.c1 and R.sup.d1 attached to the same N
atom, together with the N atom to which they are attached, form a
4-, 5-, 6- or 7-membered heterocycloalkyl group optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11; R.sup.b1 is 4-10 membered heterocycloalkyl
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.11; each R.sup.a2, R.sup.c2 and
R.sup.d2 is independently H or C.sub.1-6 alkyl; wherein said
C.sub.1-6 alkyl is optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.21; each R.sup.b2 is
C.sub.1-6 alkyl; each R.sup.b3 is C.sub.1-6 alkyl; each R.sup.a3 is
independently H or C.sub.1-6 alkyl; each R.sup.a4, R.sup.c4 and
R.sup.d4 is H or C.sub.1-6 alkyl; wherein said C.sub.1-6 alkyl is
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22; and R.sup.a6 is H.
42. The compound of claim 1 selected from:
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-phenyl-1H-pyrazolo[4,3-b]pyridine;
5-(2-Methoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3--
b]pyridine;
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-o-tolyl-1H-pyrazolo[4,3-b]pyridine-
;
5-(2-Fluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3--
b]pyridine;
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(2-(trifluoromethyl)phenyl)-1H-pyr-
azolo[4,3-b]pyridine;
2-Methyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)aniline;
5-(2-Fluoro-6-methylphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyraz-
olo[4,3-b]pyridine;
5-(2-Fluoro-6-methoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyra-
zolo[4,3-b]pyridine;
5-(2,3-Difluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4-
,3-b]pyridine;
5-(2,3-Difluoro-6-methoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H--
pyrazolo[4,3-b]pyridine;
(3-Fluoro-2-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyrid-
in-5-yl)phenyl)methanol; Ethyl
2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzoate;
N-(2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyr-
idin-5-yl)phenyl)methanesulfonamide;
2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)ph-
enol;
5-(2,3-Dihydrobenzofuran-7-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)--
1H-pyrazolo[4,3-b]pyridine;
5-(2,3-Dihydrobenzo[b][1,4]dioxin-5-yl)-3-(4-(4-methylpiperazin-1-yl)phen-
yl)-1H-pyrazolo[4,3-b]pyridine;
N-Methyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzamide;
N,N-Dimethyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]py-
ridin-5-yl)aniline;
2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)be-
nzonitrile; Methyl
2-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)be-
nzoate;
N-(2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyrid-
in-5-yl)phenyl)acetamide;
5-(Biphenyl-2-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]-
pyridine;
5-(1H-Indazol-4-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyra-
zolo[4,3-b]pyridine;
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyridin-3-yl)-1H-pyrazolo[4,3-b]p-
yridine;
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyridin-4-yl)-1H-pyrazolo-
[4,3-b]pyridine;
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyrimidin-5-yl)-1H-pyrazolo[4,3-b-
]pyridine;
5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyrid-
in-5-yl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one;
1'-Methyl-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H,
1'H-5,6'-bipyrazolo[4,3-b]pyridine;
2-(5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl-
)pyridin-3-yl)oxazole;
1-Methyl-5-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)pyridin-2(1H)-one;
5-(3-Methyl-3H-imidazo[4,5-b]pyridin-6-yl)-3-(4-(4-methylpiperazin-1-yl)p-
henyl)-1H-pyrazolo[4,3-b]pyridine;
7-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)py-
rido[3,2-b]pyrazine;
2-tert-Butyl-7-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]py-
ridin-5-yl)oxazolo[5,4-c]pyridine;
5-(3-Methyl-1H-pyrazol-4-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyra-
zolo[4,3-b]pyridine;
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-1H-p-
yrazolo[4,3-b]pyridine;
5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)qu-
inoline;
4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-
-5-yl)isoquinoline;
4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)in-
dolin-2-one;
5-(1-Methyl-1H-indol-4-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazo-
lo[4,3-b]pyridine;
2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzamide;
2-Fluoro-N-methyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-
-b]pyridin-5-yl)benzamide;
N-Benzyl-2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-
-b]pyridin-5-yl)benzamide;
2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)-N-(pyridin-4-ylmethyl)benzamide;
5-(Imidazo[1,2-a]pyridin-8-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-py-
razolo[4,3-b]pyridine;
5-(2-Ethylimidazo[1,2-a]pyridin-8-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl-
)-1H-pyrazolo[4,3-b]pyridine;
5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-1-
,2,3,4-tetrahydroisoquinoline;
4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-2-
,3-dihydro-1H-inden-1-amine;
N-Methyl-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)-2,3-dihydro-1H-inden-1-amine;
2-(4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl-
)-2,3-dihydro-1H-inden-1-ylamino)ethanol;
N-Benzyl-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)-2,3-dihydro-1H-inden-1-amine;
5-(2-Fluorophenyl)-3-phenyl-1H-pyrazolo[4,3-b]pyridine;
5-(2-Fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazolo[4,3-b]pyridine;
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N-methylbenzamide;
5-(2-Fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-
e;
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N-(1-methylpiperi-
din-4-yl)benzamide;
(4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)phenyl)(4-methylpip-
erazin-1-yl)methanone;
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N-phenylbenzamide;
5-(2-Fluorophenyl)-3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-
-b]pyridine;
5-(2-Fluorophenyl)-3-(1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-y-
l)-1H-pyrazolo[4,3-b]pyridine; and
1-(4-(4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-1H-pyrazol-1--
yl)piperidin-1-yl)ethanone; or a pharmaceutically acceptable salt
thereof.
43. The compound of claim 1 selected from:
1-(3,5-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b-
]pyridin-5-yl)phenyl)-N-methylmethanamine;
5-(2-Fluoro-6-methylphenyl)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-
-pyrazolo[4,3-b]pyridine-6-carbonitrile;
5-(2-Fluoro-6-methylphenyl)-3-(2-morpholinopyrimidin-5-yl)-1H-pyrazolo[4,-
3-b]pyridine-6-carbonitrile;
3-(4-(4-Ethylpiperazin-1-yl)phenyl)-5-(2-fluoro-6-methylphenyl)-1H-pyrazo-
lo[4,3-b]pyridine-6-carbonitrile;
5-(6-Cyano-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N--
methylpicolinamide;
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(1-methyl-1H-pyrazo-
l-4-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(6-(4-methylpiperaz-
in-1-yl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(2-(4-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
3-(4-(4-Ethylpiperazin-1-yl)phenyl)-5-(2-fluoro-6-methyl-4-((methylamino)-
methyl)phenyl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(2-morpholinopyrimi-
din-5-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(6-(2-hydroxypropan-
-2-yl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
5-(6-Cyano-5-(2-fluoro-6-methyl-4-((methylamino)methyl)phenyl)-1H-pyrazol-
o[4,3-b]pyridin-3-yl)-N-methylpicolinamide;
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(pyridin-3-yl)-1H-p-
yrazolo[4,3-b]pyridine-6-carbonitrile;
5-(6-Fluoro-1,2,3,4-tetrahydroisoquinolin-5-yl)-3-(1-methyl-1H-pyrazol-4--
yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
3-(4-(4-Ethylpiperazin-1-yl)phenyl)-5-(6-fluoro-1,2,3,4-tetrahydroisoquin-
olin-5-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile;
5-(6-Fluoro-1,2,3,4-tetrahydroisoquinolin-5-yl)-3-(6-(4-methylpiperazin-1-
-yl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile; and
5-(2-Fluoro-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3--
b]pyridine-6-carbonitrile; or a pharmaceutically acceptable salt
thereof.
44. A pharmaceutical composition comprising a compound of claim 1,
or a pharmaceutically acceptable salt thereof, and at least one
pharmaceutically acceptable carrier or excipient.
45. A method of inhibiting HPK1 activity, said method comprising
administering to a patient a compound of claim 1, or a
pharmaceutically acceptable salt thereof.
46. A method of treating a disease or disorder associated with
inhibition of HPK1 interaction, said method comprising
administering to a patient in need thereof a therapeutically
effective amount of a compound of claim 1, or a pharmaceutically
acceptable salt thereof.
47. A method for treating a cancer in a patient, said method
comprising administering to the patient a therapeutically effective
amount of the compound of claim 1, or a pharmaceutically acceptable
salt thereof.
48. The method of claim 47, wherein the cancer is selected from
breast cancer, colorectal cancer, lung cancer, ovarian cancer, and
pancreatic cancer.
Description
FIELD OF THE INVENTION
[0001] The disclosure provides compounds as well as their
compositions and methods of use. The compounds modulate
hematopoietic progenitor kinase 1 (HPK1) activity and are useful in
the treatment of various diseases including cancer.
BACKGROUND OF THE INVENTION
[0002] Hematopoietic progenitor kinase 1 (HPK1) originally cloned
from hematopoietic progenitor cells is a member of MAP kinase
kinase kinase kinases (MAP4Ks) family, which includes MAP4K1/HPK1,
MAP4K2/GCK, MAP4K3/GLK, MAP4K4/HGK, MAP4K5/KHS, and MAP4K6/MINK
(Hu, M. C., et al., Genes Dev, 1996. 10(18): p. 2251-64). HPK1 is
of particular interest because it is predominantly expressed in
hematopoietic cells such as T cells, B cells, macrophages,
dendritic cells, neutrophils, and mast cells (Hu, M. C., et al.,
Genes Dev, 1996. 10(18): p. 2251-64; Kiefer, F., et al., EMBO J,
1996. 15(24): p. 7013-25). HPK1 kinase activity has been shown to
be induced upon activation of T cell receptors (TCR) (Liou, J., et
al., Immunity, 2000. 12(4): p. 399-408), B cell receptors (BCR)
(Liou, J., et al., Immunity, 2000. 12(4): p. 399-408), transforming
growth factor receptor (TGF-.beta.R) (Wang, W., et al., J Biol
Chem, 1997. 272(36): p. 22771-5; Zhou, G., et al., J Biol Chem,
1999. 274(19): p. 13133-8), or G.sub.s-coupled PGE.sub.2 receptors
(EP2 and EP4) (Ikegami, R., et al., J Immunol, 2001. 166(7): p.
4689-96). As such, HPK1 regulates diverse functions of various
immune cells.
[0003] HPK1 is important in regulating the functions of various
immune cells and it has been implicated in autoimmune diseases and
anti-tumor immunity (Shui, J. W., et al., Nat Immunol, 2007. 8(1):
p. 84-91; Wang, X., et al., J Biol Chem, 2012. 287(14): p.
11037-48).
[0004] HPK1 knockout mice were more susceptible to the induction of
experimental autoimmune encephalomyelitis (EAE) (Shui, J. W., et
al., Nat Immunol, 2007. 8(1): p. 84-91). In human, HPK1 was
downregulated in peripheral blood mononuclear cells of psoriatic
arthritis patients or T cells of systemic lupus erythematosus (SLE)
patients (Batliwalla, F. M., et al., Mol Med, 2005. 11(1-12): p.
21-9). Those observations suggested that attenuation of HPK1
activity may contribute to autoimmunity in patients. Furthermore,
HPK1 may also control anti-tumor immunity via T cell-dependent
mechanisms. In the PGE2-producing Lewis lung carcinoma tumor model,
the tumors developed more slowly in HPK1 knockout mice as compared
to wild-type mice (see US 2007/0087988). In addition, it was shown
that adoptive transfer of HPK1 deficient T cells was more effective
in controlling tumor growth and metastasis than wild-type T cells
(Alzabin, S., et al., Cancer Immunol Immunother, 2010. 59(3): p.
419-29). Similarly, BMDCs from HPK1 knockout mice were more
efficient to mount a T cell response to eradicate Lewis lung
carcinoma as compared to wild-type BMDCs (Alzabin, S., et al., J
Immunol, 2009. 182(10): p. 6187-94). These data, in conjunction
with the restricted expression of HPK1 in hematopoietic cells and
lack of effect on the normal development of immune cells, suggest
that HPK1 may be an excellent drug target for enhancing antitumor
immunity. Accordingly, there is a need for new compounds that
modulate HPK1 activity.
SUMMARY
[0005] The present disclosure provides, inter alia, a compound of
Formula (I):
##STR00001##
or a pharmaceutically acceptable salt thereof, wherein constituent
variables are defined herein.
[0006] The present disclosure further provides a pharmaceutical
composition comprising a compound of the disclosure, or a
pharmaceutically acceptable salt thereof, and at least one
pharmaceutically acceptable carrier or excipient.
[0007] The present disclosure further provides methods of
inhibiting HPK1 activity, which comprises administering to an
individual a compound of the disclosure, or a pharmaceutically
acceptable salt thereof.
[0008] The present disclosure further provides methods of treating
a disease or disorder in a patient comprising administering to the
patient a therapeutically effective amount of a compound of the
disclosure, or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION
Compounds
[0009] The present disclosure provides, a compound of Formula
(I):
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein:
[0010] R.sup.1 is selected from Cy.sup.1, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo,
CN, NO.sub.2, OR.sup.a, SR.sup.a, C(O)R.sup.b, C(O)NR.sup.cR.sup.d,
C(O)OR.sup.a, OC(O)R.sup.b, OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d,
NR.sup.cC(O)R.sup.b, NR.sup.cC(O)OR.sup.a,
NR.sup.cC(O)NR.sup.cR.sup.d, C(.dbd.NR.sup.e)R.sup.b,
C(.dbd.NOR.sup.a)R.sup.b, C(.dbd.NR.sup.e)NR.sup.cR.sup.d,
NR.sup.cC(.dbd.NR.sup.e)NR.sup.cR.sup.d, NR.sup.cS(O)R.sup.b,
NR.sup.cS(O).sub.2R.sup.b, NR.sup.cS(O).sub.2NR.sup.cR.sup.d,
S(O)R.sup.b, S(O)NR.sup.cR.sup.d, S(O).sub.2R.sup.b, and
S(O).sub.2NR.sup.cR.sup.d; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.10;
[0011] Cy.sup.1 is selected from C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein each 4-10 membered heterocycloalkyl and 5-10
membered heteroaryl has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of 5-10 membered heteroaryl and 4-10
membered heterocycloalkyl is optionally substituted by oxo to form
a carbonyl group; and wherein the C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10;
[0012] Cy.sup.A is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-10 membered heteroaryl has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of the 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.20;
[0013] R.sup.2 is selected from H, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl, 5-10
membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10
membered heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10
aryl-C.sub.1-3 alkylene, 5-10 membered heteroaryl-C.sub.1-3
alkylene, halo, CN, OR.sup.a7, SR.sup.a7, C(O)R.sup.b7,
C(O)NR.sup.c7R.sup.d7, C(O)OR.sup.a7, NR.sup.c7R.sup.d7,
NR.sup.c7C(O)R.sup.b7, NR.sup.c7C(O)OR.sup.a7,
NR.sup.c7S(O)R.sup.b7, NR.sup.c7S(O).sub.2R.sup.b7,
NR.sup.c7S(O).sub.2NR.sup.c7R.sup.d7, S(O)R.sup.b7,
S(O)NR.sup.c7R.sup.d7, S(O).sub.2R.sup.b7, and
S(O).sub.2NR.sup.c7R.sup.d7; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.30;
[0014] each R.sup.10 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3
alkylene, 4-10 membered heterocycloalkyl-C.sub.1-3 alkylene,
C.sub.6-10 aryl-C.sub.1-3 alkylene, 5-10 membered
heteroaryl-C.sub.1-3 alkylene, halo, CN, NO.sub.2, OR.sup.a1,
SR.sup.a1, C(O)R.sup.b1, C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1,
OC(O)R.sup.b1, OC(O)NR.sup.c1R.sup.d1, NR.sup.c1R.sup.d1,
NR.sup.c1C(O)R.sup.b1, NR.sup.c1C(O)OR.sup.a1,
NR.sup.c1C(O)NR.sup.c1R.sup.d1, C(.dbd.NR.sup.e1)R.sup.b1,
C(.dbd.NOR.sup.a1)R.sup.b1, C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1,
NR.sup.c1C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1, NR.sup.c1S(O)R.sup.b1,
NR.sup.c1S(O).sub.2R.sup.b1, NR.sup.c1S(O).sub.2NR.sup.c1R.sup.d1,
S(O)R.sup.b1, S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.11;
[0015] or two R.sup.10 substituents taken together with the carbon
atom to which they are attached form a spiro 3-7-membered
heterocycloalkyl ring, or a spiro C.sub.3-6 cycloalkyl ring;
wherein each spiro 3-7-membered heterocycloalkyl ring has at least
one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each spiro 3-7-membered heterocycloalkyl ring is
optionally substituted by oxo to form a carbonyl group; and wherein
the spiro 3-7-membered heterocycloalkyl ring and spiro C.sub.3-6
cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.11;
[0016] each R.sup.11 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3
alkylene, 4-10 membered heterocycloalkyl-C.sub.1-3 alkylene,
C.sub.6-10 aryl-C.sub.1-3 alkylene, 5-10 membered
heteroaryl-C.sub.1-3 alkylene, halo, CN, OR.sup.a3, SR.sup.a3,
C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3, C(O)OR.sup.a3,
NR.sup.c3R.sup.d3, NR.sup.c3C(O)R.sup.b3, NR.sup.c3C(O)OR.sup.a3,
NR.sup.c3S(O)R.sup.b3, NR.sup.c3S(O).sub.2R.sup.b3,
NR.sup.c3S(O).sub.2NR.sup.c3R.sup.d3, S(O)R.sup.b3,
S(O)NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.12;
[0017] each R.sup.12 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl,
4-7 membered heterocycloalkyl, halo, CN, OR.sup.a5, SR.sup.a5,
C(O)R.sup.b5, C(O)NR.sup.c5R.sup.d5, C(O)OR.sup.a5,
NR.sup.c5R.sup.d5, NR.sup.c5C(O)R.sup.b5, NR.sup.c5C(O)OR.sup.a5,
NR.sup.c5S(O)R.sup.b5, NR.sup.c5S(O).sub.2R.sup.b5,
NR.sup.c5S(O).sub.2NR.sup.c5R.sup.d5, S(O)R.sup.b5
S(O)NR.sup.c5R.sup.d5, S(O).sub.2R.sup.b5, and
S(O).sub.2NR.sup.c5R.sup.d5; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl and 4-7 membered
heterocycloalkyl, are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g;
[0018] each R.sup.20 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3
alkylene, 4-10 membered heterocycloalkyl-C.sub.1-3 alkylene,
C.sub.6-10 aryl-C.sub.1-3 alkylene, 5-10 membered
heteroaryl-C.sub.1-3 alkylene, halo, CN, NO.sub.2, OR.sup.a2,
SR.sup.a2, C(O)R.sup.b2, C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2,
OC(O)R.sup.b2, OC(O)NR.sup.c2R.sup.d2, NR.sup.c2R.sup.d2,
NR.sup.c2C(O)R.sup.b2, NR.sup.c2C(O)OR.sup.a2,
NR.sup.c2C(O)NR.sup.c2R.sup.d2, C(.dbd.NR.sup.e2)R.sup.b2,
C(.dbd.NOR.sup.a2)R.sup.b2, C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2,
NR.sup.c2C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2, NR.sup.c2S(O)R.sup.b2,
NR.sup.c2S(O).sub.2R.sup.b2, NR.sup.c2S(O).sub.2NR.sup.c2R.sup.d2,
S(O)R.sup.b2, S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.21;
[0019] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused
C.sub.3-7 cycloalkyl ring; wherein each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring is optionally substituted by oxo to form a carbonyl group; and
wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
and fused C.sub.3-6 cycloalkyl ring are each optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.21;
[0020] each R.sup.21 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3
alkylene, 4-10 membered heterocycloalkyl-C.sub.1-3 alkylene,
C.sub.6-10 aryl-C.sub.1-3 alkylene, 5-10 membered
heteroaryl-C.sub.1-3 alkylene, halo, CN, OR.sup.a4, SR.sup.a4,
C(O)R.sup.b4, C(O)NR.sup.c4R.sup.d4, C(O)OR.sup.a4,
NR.sup.c4R.sup.d4, NR.sup.c4C(O)R.sup.b4, NR.sup.c4C(O)OR.sup.a4,
NR.sup.c4S(O)R.sup.b4, NR.sup.c4S(O).sub.2R.sup.b4,
NR.sup.c4S(O).sub.2NR.sup.c4R.sup.d4, S(O)R.sup.b4,
S(O)NR.sup.c4R.sup.d4, S(O).sub.2R.sup.b4, and
S(O).sub.2NR.sup.c4R.sup.d4; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22;
[0021] or two R.sup.21 substituents taken together with the carbon
atom to which they are attached form a spiro 3-7-membered
heterocycloalkyl ring, or a spiro C.sub.3-6 cycloalkyl ring;
wherein each spiro 3-7-membered heterocycloalkyl ring has at least
one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each spiro 3-7-membered heterocycloalkyl ring is
optionally substituted by oxo to form a carbonyl group; and wherein
the spiro 3-7 membered heterocycloalkyl ring and spiro C.sub.3-6
cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.22;
[0022] each R.sup.22 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered
heterocycloalkyl, halo, CN, OR.sup.a6, SR.sup.a6, C(O)R.sup.b6,
C(O)NR.sup.c6R.sup.d6, C(O)OR.sup.a6, NR.sup.c6R.sup.d6,
NR.sup.c6C(O)R.sup.b6, NR.sup.c6C(O)OR.sup.a6,
NR.sup.c6S(O)R.sup.b6, NR.sup.c6S(O).sub.2R.sup.b6,
NR.sup.c6S(O).sub.2NR.sup.c6R.sup.d6, S(O)R.sup.b6,
S(O)NR.sup.c6R.sup.d6, S(O).sub.2R.sup.b6, and
S(O).sub.2NR.sup.c6R.sup.d6; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g;
[0023] each R.sup.30 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered
heterocycloalkyl, halo, CN, OR.sup.a8, SR.sup.a8, C(O)R.sup.b8,
C(O)NR.sup.c8R.sup.d8, C(O)OR.sup.a8, NR.sup.c8R.sup.d8,
NR.sup.c8C(O)R.sup.b8, NR.sup.c8C(O)OR.sup.a8, NR.sup.c8
S(O)R.sup.b8, NR.sup.c8S(O).sub.2R.sup.b8,
NR.sup.c8S(O).sub.2NR.sup.c8R.sup.d8, S(O)R.sup.b8,
S(O)NR.sup.c8R.sup.d8, S(O).sub.2R.sup.b8, and
S(O).sub.2NR.sup.c8R.sup.d8; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g;
[0024] each R.sup.a and R.sup.c is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl, are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.10;
[0025] each R.sup.d is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10;
[0026] or any R.sup.c and R.sup.d attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.10;
[0027] each R.sup.b is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10;
[0028] each R.sup.e is independently selected from H, CN, C.sub.1-6
alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6
alkylsulfonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkylaminosulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl and
di(C.sub.1-6 alkyl)aminosulfonyl;
[0029] each R.sup.a1, R.sup.c1 and R.sup.d1 is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0030] or any R.sup.c1 and R.sup.d1 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0031] each R.sup.b1 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0032] each R.sup.e1 is independently selected from H, CN,
C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkylthio,
C.sub.1-6 alkylsulfonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkylaminosulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl and
di(C.sub.1-6 alkyl)aminosulfonyl;
[0033] each R.sup.a2, R.sup.c2 and R.sup.d2, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.21;
[0034] or any R.sup.c2 and R.sup.d2 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.21;
[0035] each R.sup.b2 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.21;
[0036] each R.sup.e2 is independently selected from H, CN,
C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkylthio,
C.sub.1-6 alkylsulfonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkylaminosulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl and
di(C.sub.1-6 alkyl)aminosulfonyl;
[0037] each R.sup.a3, R.sup.c3 and R.sup.d3, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.12;
[0038] or any R.sup.c3 and R.sup.d3 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.12;
[0039] each R.sup.b3 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.12;
[0040] each R.sup.a4, R.sup.c4 and R.sup.d4, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.22;
[0041] or any R.sup.c4 and R.sup.d4 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.22;
[0042] each R.sup.b4 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22;
[0043] each R.sup.a5, R.sup.c5 and R.sup.d5, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g;
[0044] each R.sup.b5 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g;
[0045] each R.sup.a6, R.sup.c6 and R.sup.d6, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g;
[0046] each R.sup.b6 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g;
[0047] each R.sup.a7, R.sup.c7, and R.sup.d7 is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.30;
[0048] or any R.sup.c7 and R.sup.d7 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.30;
[0049] each R.sup.b7 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.30;
[0050] each R.sup.as, R.sup.c8 and R.sup.d8, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.g;
[0051] or any R.sup.c8 and R.sup.d8 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.g;
[0052] each R.sup.b8 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; and
[0053] each R.sup.g is independently selected from OH, NO.sub.2,
CN, halo, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkyl-C.sub.1-2 alkylene, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-3 alkoxy-C.sub.1-3 alkyl, C.sub.1-3
alkoxy-C.sub.1-3 alkoxy, HO--C.sub.1-3 alkoxy, HO--C.sub.1-3 alkyl,
cyano-C.sub.1-3 alkyl, H.sub.2N--C.sub.1-3 alkyl, amino, C.sub.1-6
alkylamino, di(C.sub.1-6 alkyl)amino, thio, C.sub.1-6 alkylthio,
C.sub.1-6 alkylsulfinyl, C.sub.1-6 alkylsulfonyl, carbamyl,
C.sub.1-6 alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, carboxy,
C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkylcarbonylamino, C.sub.1-6 alkylsulfonylamino, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl, di(C.sub.1-6 alkyl)aminosulfonyl,
aminosulfonylamino, C.sub.1-6 alkylaminosulfonylamino, di(C.sub.1-6
alkyl)aminosulfonylamino, aminocarbonylamino, C.sub.1-6
alkylaminocarbonylamino, and di(C.sub.1-6
alkyl)aminocarbonylamino;
[0054] provided that:
[0055] 1) R.sup.1 is other than CH.sub.3;
[0056] 2) R.sup.1 is other than 2-morpholinopyridin-4-yl;
[0057] 3) when Cy.sup.A is phenyl, then R.sup.1 is other than
(2-chloropyridin-4-yloxy)methyl; and
[0058] 4) when R.sup.1 is halogen-substituted phenyl, then Cy.sup.A
is other than unsubstituted or substituted
4H-1,2,4-triazol-3-yl.
[0059] In some embodiments, R.sup.1 is selected from Cy.sup.1,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo,
CN, NO.sub.2, OR.sup.a, SR.sup.a, C(O)R.sup.b, C(O)NR.sup.cR.sup.d,
C(O)OR.sup.a, OC(O)R.sup.b, OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d,
NR.sup.cC(O)R.sup.b, and NR.sup.cC(O)OR.sup.a; wherein said
C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.10.
[0060] In some embodiments, R.sup.1 is selected from Cy.sup.1,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo,
and CN; wherein said C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are
each optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.10.
[0061] In some embodiments, R.sup.1 is selected from Cy.sup.1,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl; wherein said C.sub.2-6
alkenyl and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.10.
[0062] In some embodiments, R.sup.1 is Cy.sup.1.
[0063] In some embodiments, R.sup.1 is selected from Cy.sup.1,
C(O)NR.sup.cR.sup.d and NR.sup.cC(O)R.sup.b. In some embodiments,
R.sup.1 is selected from phenyl, pyridinyl, pyrazolyl, thiazolyl,
C(O)NR.sup.cR.sup.d and NR.sup.cC(O)R.sup.b; wherein the phenyl,
pyridinyl, pyrazolyl, and thiazolyl are each optionally substituted
with 1, 2 or 3 substituents independently selected from
R.sup.10.
[0064] In some embodiments, Cy.sup.1 is selected from C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein the 5-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of 5-10 membered heteroaryl is optionally
substituted by oxo to form a carbonyl group; and wherein the
C.sub.6-10 aryl and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.10.
[0065] In some embodiments, Cy.sup.1 is selected from phenyl and
5-6 membered heteroaryl; wherein the 5-6 membered heteroaryl has at
least one ring-forming carbon atom and 1, 2 or 3 ring-forming
heteroatoms independently selected from N, O, and S; wherein a
ring-forming carbon atom of 5-6 membered heteroaryl is optionally
substituted by oxo to form a carbonyl group; and wherein the phenyl
and 5-6 membered heteroaryl are each optionally substituted with 1,
2 or 3 substituents independently selected from R.sup.10.
[0066] In some embodiments, Cy.sup.1 is phenyl, pyridinyl,
pyrazolyl, or pyrimidinyl; wherein the phenyl, pyridinyl,
pyrazolyl, or pyrimidinyl are each optionally substituted with 1,
2, 3 or 4 substituents independently selected from R.sup.10.
[0067] In some embodiments, Cy.sup.1 is phenyl, pyridin-4-yl,
1H-pyrazol-4-yl, pyridin-3-yl, or pyrimidin-5-yl; wherein the
phenyl, pyridin-4-yl, 1H-pyrazol-4-yl, pyridin-3-yl, or
pyrimidin-5-yl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10.
[0068] In some embodiments, Cy.sup.1 is pyrazolyl (e.g.,
1H-pyrazol-4-yl) optionally substituted with 1 or 2 C.sub.1-6 alkyl
(e.g., methyl). In some embodiments, Cy.sup.1 is
1-methyl-1H-pyrazol-4-yl.
[0069] In some embodiments, Cy.sup.1 is phenyl, pyridin-4-yl, or
1H-pyrazol-4-yl; wherein the phenyl, pyridin-4-yl, and
1H-pyrazol-4-yl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10.
[0070] In some embodiments, each R.sup.10 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, halo,
CN, NO.sub.2, OR.sup.a1, SR.sup.a1, C(O)R.sup.b1,
C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1, OC(O)R.sup.b1,
OC(O)NR.sup.c1R.sup.d1, NR.sup.c1R.sup.d1, NR.sup.c1C(O)R.sup.b1,
NR.sup.c1C(O)OR.sup.a1, NR.sup.c1S(O)R.sup.b1,
NR.sup.c1S(O).sub.2R.sup.b1, NR.sup.c1S(O).sub.2NR.sup.c1R.sup.d1,
S(O)R.sup.b1, S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11.
[0071] In some embodiments, each R.sup.10 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, halo,
CN, OR.sup.a1, SR.sup.a1, C(O)R.sup.b1, C(O)NR.sup.c1R.sup.d1,
C(O)OR.sup.a1, NR.sup.c1R.sup.d1, and NR.sup.c1C(O)R.sup.b1;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, and 5-10 membered heteroaryl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.11.
[0072] In some embodiments, each R.sup.10 is independently selected
from C.sub.1-6 alkyl, 4-10 membered heterocycloalkyl, C(O)R.sup.b1,
and C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl and 4-10
membered heterocycloalkyl are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.11.
[0073] In some embodiments, each R.sup.10 is independently selected
from C.sub.1-6 alkyl, piperazinyl, piperidinyl, morpholinyl,
C(O)R.sup.b1, and C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6
alkyl, piperazinyl, and piperidinyl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.11.
[0074] In some embodiments, R.sup.10 is morpholinyl optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11. In some embodiments, R.sup.1 is
2-morpholinopyrimidin-5-yl.
[0075] In some embodiments, each R.sup.10 is independently selected
from C.sub.1-6 alkyl, piperazinyl, piperidinyl, C(O)R.sup.b1, and
C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl, piperazinyl,
and piperidinyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11.
[0076] In some embodiments, each R.sup.11 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, halo,
CN, OR.sup.a3, SR.sup.a3, C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3,
C(O)OR.sup.a3, S(O)R.sup.b3, S(O)NR.sup.c3R.sup.d3,
S(O).sub.2R.sup.b3, and S(O).sub.2NR.sup.c3R.sup.d3; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl, and
5-10 membered heteroaryl are each optionally substituted with 1, 2,
3, or 4 substituents independently selected from R.sup.12.
[0077] In some embodiments, each R.sup.11 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, halo, OR.sup.a3, C(O)R.sup.b3, and
S(O).sub.2R.sup.b3; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.12.
[0078] In some embodiments, each R.sup.11 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, halo, C(O)R.sup.b3, and S(O).sub.2R.sup.b3;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6
alkynyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.12.
[0079] In some embodiments, each R.sup.11 is independently selected
from C.sub.1-6 alkyl, OR.sup.a3, C(O)R.sup.b3, and
S(O).sub.2R.sup.b3.
[0080] In some embodiments, each R.sup.11 is independently selected
from C.sub.1-6 alkyl, C(O)R.sup.b3, and S(O).sub.2R.sup.b3.
[0081] In some embodiments, each R.sup.o1 is independently selected
from 4-methylpiperazin-1-yl, N-methylaminocarbonyl, methyl,
N-(1-methylpiperidin-4-yl)aminocarbonyl,
(4-methylpiperazin-1-yl)carbonyl, N-phenylaminocarbonyl,
piperidin-4-yl, 1-(methylsulfonyl)piperidin-4-yl,
1-acetyl-piperidin-4-yl, morpholinyl, 4-ethylpiperazin-1-yl, or
2-hydroxypropan-2-yl.
[0082] In some embodiments, each R.sup.10 is independently selected
from 4-methylpiperazin-1-yl, N-methylaminocarbonyl, methyl,
N-(1-methylpiperidin-4-yl)aminocarbonyl,
(4-methylpiperazin-1-yl)carbonyl, N-phenylaminocarbonyl,
piperidin-4-yl, 1-(methylsulfonyl)piperidin-4-yl, and
1-acetyl-piperidin-4-yl.
[0083] In some embodiments, Cy.sup.A is C.sub.6-10 aryl optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.20.
[0084] In some embodiments, Cy.sup.A is 5-10 membered heteroaryl;
wherein the 5-10 membered heteroaryl has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of the 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the 5-10 membered heteroaryl is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20.
[0085] In some embodiments, Cy.sup.A is phenyl, 1H-indazol-4-yl,
pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl,
1H-pyrazolo[4,3-b]pyridin-6-yl, pyridin-2(1H)-on-5-yl,
3H-imidazo[4,5-b]pyridin-6-yl, pyrido[3,2-b]pyrazin-7-yl,
oxazolo[5,4-c]pyridin-7-yl, 1H-pyrazol-4-yl,
pyrazolo[1,5-a]pyridin-3-yl, quinolin-5-yl, isoquinolin-4-yl,
1H-indol-4-yl, and imidazo[1,2-a]pyridin-8-yl, each of which is
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20.
[0086] In some embodiments, Cy.sup.A is phenyl optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.20; wherein optionally two adjacent R.sup.20
substituents on the Cy.sup.A ring, taken together with the atoms to
which they are attached, form a fused 5- or 6-membered
heterocycloalkyl ring, or a fused C.sub.4-6 cycloalkyl ring;
wherein the fused 5- or 6-membered heterocycloalkyl ring each has
at least one ring-forming carbon atom and 1, 2 or 3 ring-forming
heteroatoms independently selected from N, O, and S; wherein a
ring-forming carbon atom of each fused 5- or 6-membered
heterocycloalkyl ring is optionally substituted by oxo to form a
carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.4-6 cycloalkyl ring are each
optionally substituted with 1, 2 or 3 substituents independently
selected from R.sup.21.
[0087] In some embodiments, Cy.sup.A is phenyl optionally
substituted with 1, 2, 3 or 4 substituents independently selected
from R.sup.20. In some embodiments, Cy.sup.A is phenyl substituted
with 1, 2, or 3 substituents independently selected from C.sub.1-6
alkyl or halo, wherein said C.sub.1-6 alkyl is each optionally
substituted NR.sup.c4R.sup.d4. In some embodiments, Cy.sup.A is
phenyl substituted with methyl, fluoro, or methylaminomethyl.
[0088] In some embodiments, each R.sup.20 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, halo,
CN, NO.sub.2, OR.sup.a2, SR.sup.a2, C(O)R.sup.b2,
C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.2, OC(O)R.sup.b2,
OC(O)NR.sup.c2R.sup.d2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2,
NR.sup.c2C(O)OR.sup.a2, NR.sup.c2S(O)R.sup.b2,
NR.sup.c2S(O).sub.2R.sup.b2, S(O)R.sup.b2, S(O)NR.sup.c2R.sup.d2,
S(O).sub.2R.sup.b2, and S(O).sub.2NR.sup.c2R.sup.d2; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl, and
5-10 membered heteroaryl are each optionally substituted with 1, 2,
3, or 4 substituents independently selected from R.sup.21;
[0089] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused
C.sub.3-7 cycloalkyl ring; wherein each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring is optionally substituted by oxo to form a carbonyl group; and
wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
and fused C.sub.3-6 cycloalkyl ring are each optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.21.
[0090] In some embodiments, each R.sup.20 is independently selected
from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl,
halo, CN, OR.sup.a2, SR.sup.a2, C(O)R.sup.b2,
C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2, NR.sup.c2R.sup.d2,
NR.sup.c2C(O)R.sup.b2, NR.sup.c2C(O)OR.sup.a2,
NR.sup.c2S(O)R.sup.b2, NR.sup.c2S(O).sub.2R.sup.b2, S(O)R.sup.b2,
S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, and 5-10
membered heteroaryl are each optionally substituted with 1, 2, 3,
or 4 substituents independently selected from R.sup.21;
[0091] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused
C.sub.3-7 cycloalkyl ring; wherein each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring is optionally substituted by oxo to form a carbonyl group; and
wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
and fused C.sub.3-6 cycloalkyl ring are each optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.21.
[0092] In some embodiments, each R.sup.20 is independently selected
from C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.6-10 aryl, 5-10
membered heteroaryl, halo, CN, OR, C(O)NR.sup.c2R.sup.d2,
C(O)OR.sup.a2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, and
NR.sup.c2S(O).sub.2R.sup.b2; wherein said C.sub.1-6 alkyl,
C.sub.6-10 aryl, and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21;
[0093] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused
C.sub.3-7 cycloalkyl ring; wherein each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring is optionally substituted by oxo to form a carbonyl group; and
wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
and fused C.sub.3-6 cycloalkyl ring are each optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.21.
[0094] In some embodiments, each R.sup.20 is independently selected
from methoxy, methyl, fluoro, trifluoromethyl, amino, methoxy,
hydroxymethyl, ethoxycarbonyl, methanesulfonamino, hydroxyl,
N-methylaminocarbonyl, dimethylamino, cyano, methoxycarbonyl,
acetylamino, phenyl, 2-oxazolyl, tert-butyl, aminocarbonyl,
N-benzylaminocarbonyl, N-(pyridin-4-ylmethyl)aminocarbonyl, ethyl,
methylaminomethyl;
[0095] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 5- or 6-membered heterocycloalkyl ring, or a fused C.sub.5
cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1 or 2 ring-forming heteroatoms independently selected from N and
O; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.5 cycloalkyl ring are each
optionally substituted with 1 or 2 substituents independently
selected from amino, methylamino, 2-hydroxyethylamino, and
N-benzylamino.
[0096] In some embodiments, each R.sup.20 is independently selected
from methoxy, methyl, fluoro, trifluoromethyl, amino, methoxy,
hydroxymethyl, ethoxycarbonyl, methanesulfonamino, hydroxyl,
N-methylaminocarbonyl, dimethylamino, cyano, methoxycarbonyl,
acetylamino, phenyl, 2-oxazolyl, tert-butyl, aminocarbonyl,
N-benzylaminocarbonyl, N-(pyridin-4-ylmethyl)aminocarbonyl, and
ethyl;
[0097] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 5- or 6-membered heterocycloalkyl ring, or a fused C.sub.5
cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1 or 2 ring-forming heteroatoms independently selected from N and
O; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.5 cycloalkyl ring are each
optionally substituted with 1 or 2 substituents independently
selected from amino, methylamino, 2-hydroxyethylamino, and
N-benzylamino.
[0098] In some embodiments, R.sup.2 is selected from H, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
halo, CN, OR.sup.a7, SR.sup.a7, C(O)R.sup.b7,
C(O)NR.sup.c7R.sup.d7, C(O)OR.sup.a7, NR.sup.c7R.sup.d7,
NR.sup.c7C(O)R.sup.b7, S(O)R.sup.b7, S(O)NR.sup.c7R.sup.d7,
S(O).sub.2R.sup.b7, and S(O).sub.2NR.sup.c7R.sup.d7; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.30.
[0099] In some embodiments, R.sup.2 is selected from H, C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
halo, and CN; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.30.
[0100] In some embodiments, R.sup.2 is H, C.sub.1-6 alkyl, or
CN.
[0101] In some embodiments, R.sup.2 is H or C.sub.1-6 alkyl.
[0102] In some embodiments, R.sup.2 is H. In some embodiments,
R.sup.2 is CN.
[0103] In some embodiments, provided herein is a compound having
Formula IIa:
##STR00003##
or a pharmaceutically acceptable salt thereof, wherein n is 1, 2,
3, or 4.
[0104] In some embodiments, provided herein is a compound having
Formula IIb:
##STR00004##
or a pharmaceutically acceptable salt thereof, wherein m is 1, 2,
or 3.
[0105] In some embodiments, provided herein is a compound having
Formula IIIa:
##STR00005##
or a pharmaceutically acceptable salt thereof.
[0106] In some embodiments, provided herein is a compound having
Formula IIIb:
##STR00006##
or a pharmaceutically acceptable salt thereof.
[0107] In some embodiments, provided herein is a compound having
Formula IVa:
##STR00007##
or a pharmaceutically acceptable salt thereof, wherein n is 1, 2,
3, or 4 and y is 1, 2, 3, or 4.
[0108] In some embodiments, n is 1.
[0109] In some embodiments, n is 2.
[0110] In some embodiments, n is 3.
[0111] In some embodiments, m is 1.
[0112] In some embodiments, m is 2.
[0113] In some embodiments, y is 1.
[0114] In some embodiments, y is 2.
[0115] In some embodiments, y is 3.
[0116] In some embodiments:
[0117] Cy.sup.A is phenyl substituted with 1, 2, or 3 substitutents
selected from C.sub.1-6 alkyl and halo, wherein said C.sub.1-6
alkyl is optionally substituted with NR.sup.c4R.sup.d4;
[0118] R.sup.2 is H or CN;
[0119] Cy.sup.1 is 5-6 membered heteroaryl optionally substituted
with C.sub.1-6 alkyl or halo; and
[0120] each of R.sup.c4 and R.sup.d4 is H or C.sub.1-6 alkyl.
[0121] In some embodiments:
[0122] R.sup.1 is selected from Cy.sup.1, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, CN, NO.sub.2,
OR.sup.a, SR.sup.a, C(O)R.sup.b, C(O)NR.sup.cR.sup.d, C(O)OR.sup.a,
OC(O)R.sup.b, OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d,
NR.sup.cC(O)R.sup.b, NR.sup.cC(O)OR.sup.a,
NR.sup.cC(O)NR.sup.cR.sup.d, C(.dbd.NR.sup.e)R.sup.b,
C(.dbd.NOR.sup.a)R.sup.b, C(.dbd.NR.sup.e)NR.sup.cR.sup.d,
NR.sup.cC(.dbd.NR.sup.e)NR.sup.cR.sup.d, NR.sup.cS(O)R.sup.b,
NR.sup.cS(O).sub.2R.sup.b, NR.sup.cS(O).sub.2NR.sup.cR.sup.d,
S(O)R.sup.b, S(O)NR.sup.cR.sup.d, S(O).sub.2R.sup.b, and
S(O).sub.2NR.sup.cR.sup.d; wherein said C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.10;
[0123] Cy.sup.1 is selected from C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein each 4-10 membered heterocycloalkyl and 5-10
membered heteroaryl has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of 5-10 membered heteroaryl and 4-10
membered heterocycloalkyl is optionally substituted by oxo to form
a carbonyl group; and wherein the C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10;
[0124] Cy.sup.A is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-membered heteroaryl has at least one
ring-forming carbon atom and 1 or 2 ring-forming heteroatoms
independently selected from N, O, and S and the 6-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of the 5-10 membered heteroaryl is
optionally substituted by oxo to form a carbonyl group; and wherein
the C.sub.6-10 aryl and 5-10 membered heteroaryl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20;
[0125] R.sup.2 is selected from H, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl, 5-10
membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10
membered heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10
aryl-C.sub.1-3 alkylene, 5-10 membered heteroaryl-C.sub.1-3
alkylene, halo, CN, OR.sup.a7, SR.sup.a7, C(O)R.sup.b7,
C(O)NR.sup.c7R.sup.d7, C(O)OR.sup.a7, NR.sup.c7R.sup.d7,
NR.sup.c7C(O)R.sup.b7, NR.sup.c7C(O)OR.sup.a7,
NR.sup.c7S(O)R.sup.b7, NR.sup.c7S(O).sub.2R.sup.b7,
NR.sup.c7S(O).sub.2NR.sup.c7R.sup.d7, S(O)R.sup.b7,
S(O)NR.sup.c7R.sup.d7, S(O).sub.2R.sup.b7, and
S(O).sub.2NR.sup.c7R.sup.d7; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.30;
[0126] each R.sup.10 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, piperazinyl, piperidinyl, C.sub.6-10 aryl,
5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene,
4-10 membered heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10
aryl-C.sub.1-3 alkylene, 5-10 membered heteroaryl-C.sub.1-3
alkylene, halo, CN, NO.sub.2, OR.sup.a1, SR.sup.a1, C(O)R.sup.b1,
C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1, OC(O)R.sup.b1,
OC(O)NR.sup.c1R.sup.d1, NR.sup.c1R.sup.d1, NR.sup.c1C(O)R.sup.b1,
NR.sup.c1C(O)OR.sup.a1, NR.sup.c1C(O)NR.sup.c1R.sup.d1,
C(.dbd.NR.sup.e1)R.sup.b1, C(.dbd.NOR.sup.a1)R.sup.b1,
C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1,
NR.sup.c1C(.dbd.NR.sup.e1)NR.sup.c1R.sup.d1, NR.sup.c1S(O)R.sup.b1,
NR.sup.c1S(O).sub.2R.sup.b1, NR.sup.c1S(O).sub.2NR.sup.c1R.sup.d1,
S(O)R.sup.b1, S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
piperazinyl, piperidinyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.11;
[0127] or two R.sup.10 substituents taken together with the carbon
atom to which they are attached form a spiro 3-7-membered
heterocycloalkyl ring, or a spiro C.sub.3-6 cycloalkyl ring;
wherein each spiro 3-7-membered heterocycloalkyl ring has at least
one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each spiro 3-7-membered heterocycloalkyl ring is
optionally substituted by oxo to form a carbonyl group; and wherein
the spiro 3-7-membered heterocycloalkyl ring and spiro C.sub.3-6
cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.11;
[0128] each R.sup.11 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3
alkylene, 4-10 membered heterocycloalkyl-C.sub.1-3 alkylene,
C.sub.6-10 aryl-C.sub.1-3 alkylene, 5-10 membered
heteroaryl-C.sub.1-3 alkylene, halo, CN, OR.sup.a3, SR.sup.a3,
C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3, C(O)OR.sup.a3,
NR.sup.c3R.sup.d3, NR.sup.c3C(O)R.sup.b3, NR.sup.c3C(O)OR.sup.a3,
NR.sup.c3S(O)R.sup.b3, NR.sup.c3S(O).sub.2R.sup.b3,
NR.sup.c3S(O).sub.2NR.sup.c3R.sup.d3, S(O)R.sup.b3,
S(O)NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.12;
[0129] each R.sup.12 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl,
4-7 membered heterocycloalkyl, halo, CN, OR.sup.a5, SR.sup.a5,
C(O)R.sup.b5, C(O)NR.sup.c5R.sup.d5, C(O)OR.sup.a5,
NR.sup.c5R.sup.d5, NR.sup.c5C(O)R.sup.b5, NR.sup.c5C(O)OR.sup.a5,
NR.sup.c5S(O)R.sup.b5, NR.sup.c5S(O).sub.2R.sup.b5,
NR.sup.c5S(O).sub.2NR.sup.c5R.sup.d5, S(O)R.sup.b5
S(O)NR.sup.c5R.sup.d5, S(O).sub.2R.sup.b5, and
S(O).sub.2NR.sup.c5R.sup.d5; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl and 4-7 membered
heterocycloalkyl, are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g;
[0130] each R.sup.20 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3
alkylene, 4-10 membered heterocycloalkyl-C.sub.1-3 alkylene,
C.sub.6-10 aryl-C.sub.1-3 alkylene, 5-10 membered
heteroaryl-C.sub.1-3 alkylene, halo, CN, NO.sub.2, OR.sup.a2,
SR.sup.a2, C(O)R.sup.b2, C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2,
OC(O)R.sup.b2, OC(O)NR.sup.c2R.sup.d2, NR.sup.c2R.sup.d2,
NR.sup.c2C(O)R.sup.b2, NR.sup.c2C(O)OR.sup.a2,
NR.sup.c2C(O)NR.sup.c2R.sup.d2, C(.dbd.NR.sup.e2)R.sup.b2,
C(.dbd.NOR.sup.a2)R.sup.b2, C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2,
NR.sup.c2C(.dbd.NR.sup.e2)NR.sup.c2R.sup.d2, NR.sup.c2S(O)R.sup.b2,
NR.sup.c2S(O).sub.2R.sup.b2, NR.sup.c2S(O).sub.2NR.sup.c2R.sup.d2,
S(O)R.sup.b2 S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.21;
[0131] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring, or a fused
C.sub.3-7 cycloalkyl ring; wherein each fused 4-, 5-, 6- or
7-membered heterocycloalkyl ring has at least one ring-forming
carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each fused 4-, 5-, 6- or 7-membered heterocycloalkyl
ring is optionally substituted by oxo to form a carbonyl group; and
wherein the fused 4-, 5-, 6- or 7-membered heterocycloalkyl ring
and fused C.sub.3-6 cycloalkyl ring are each optionally substituted
with 1, 2, 3 or 4 substituents independently selected from
R.sup.21;
[0132] each R.sup.21 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3
alkylene, 4-10 membered heterocycloalkyl-C.sub.1-3 alkylene,
C.sub.6-10 aryl-C.sub.1-3 alkylene, 5-10 membered
heteroaryl-C.sub.1-3 alkylene, halo, CN, OR.sup.a4, SR.sup.a4,
C(O)R.sup.b4, C(O)NR.sup.c4R.sup.d4, C(O)OR.sup.a4,
NR.sup.c4R.sup.d4, NR.sup.c4C(O)R.sup.b4, NR.sup.c4C(O)OR.sup.a4,
NR.sup.c4S(O)R.sup.b4, NR.sup.c4S(O).sub.2R.sup.b4,
NR.sup.c4S(O).sub.2NR.sup.c4R.sup.d4, S(O)R.sup.b4,
S(O)NR.sup.c4R.sup.d4, S(O).sub.2R.sup.b4, and
S(O).sub.2NR.sup.c4R.sup.d4; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, C.sub.3-10 cycloalkyl-C.sub.1-3 alkylene, 4-10 membered
heterocycloalkyl-C.sub.1-3 alkylene, C.sub.6-10 aryl-C.sub.1-3
alkylene and 5-10 membered heteroaryl-C.sub.1-3 alkylene are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22;
[0133] or two R.sup.21 substituents taken together with the carbon
atom to which they are attached form a spiro 3-7-membered
heterocycloalkyl ring, or a spiro C.sub.3-6 cycloalkyl ring;
wherein each spiro 3-7-membered heterocycloalkyl ring has at least
one ring-forming carbon atom and 1, 2 or 3 ring-forming heteroatoms
independently selected from N, O, and S; wherein a ring-forming
carbon atom of each spiro 3-7-membered heterocycloalkyl ring is
optionally substituted by oxo to form a carbonyl group; and wherein
the spiro 3-7 membered heterocycloalkyl ring and spiro C.sub.3-6
cycloalkyl ring are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.22;
[0134] each R.sup.22 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered
heterocycloalkyl, halo, CN, OR.sup.a6, SR.sup.a6, C(O)R.sup.b6,
C(O)NR.sup.c6R.sup.d6, C(O)OR.sup.a6, NR.sup.c6R.sup.d6,
NR.sup.c6C(O)R.sup.b6, NR.sup.c6C(O)OR.sup.a6,
NR.sup.c6S(O)R.sup.b6, NR.sup.c6S(O).sub.2R.sup.b6,
NR.sup.c6S(O).sub.2NR.sup.c6R.sup.d6, S(O)R.sup.b6,
S(O)NR.sup.c6R.sup.d6, S(O).sub.2R.sup.b6, and
S(O).sub.2NR.sup.c6R.sup.d6; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g;
[0135] each R.sup.30 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered
heterocycloalkyl, halo, CN, OR.sup.a8, SR.sup.a8, C(O)R.sup.b8,
C(O)NR.sup.c8R.sup.d8, C(O)OR.sup.a8, NR.sup.c8R.sup.d8,
NR.sup.c8C(O)R.sup.b8, NR.sup.c8(O)OR.sup.a8,
NR.sup.c8S(O)R.sup.b8, NR.sup.c S(O).sub.2R.sup.b8,
NR.sup.c8S(O).sub.2NR.sup.c8R.sup.d8, S(O)R.sup.b8,
S(O)NR.sup.c8R.sup.d8, S(O).sub.2R.sup.b8, and
S(O).sub.2NR.sup.c8R.sup.d8; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl,
5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g;
[0136] each R.sup.a and R.sup.c is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl,
C.sub.6-10 aryl and 5-10 membered heteroaryl; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10 aryl and
5-10 membered heteroaryl, are each optionally substituted with 1,
2, 3, or 4 substituents independently selected from R.sup.10;
[0137] each R.sup.d is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10;
[0138] or any R.sup.c and R.sup.d attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.10;
[0139] each R.sup.b is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10;
[0140] each R.sup.e is independently selected from H, CN, C.sub.1-6
alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkylthio, C.sub.1-6
alkylsulfonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkylaminosulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl and
di(C.sub.1-6 alkyl)aminosulfonyl;
[0141] each R.sup.a1, R.sup.c1 and R.sup.d1 is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0142] or any R.sup.c1 and R.sup.d1 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0143] each R.sup.b1 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0144] each R.sup.e1 is independently selected from H, CN,
C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkylthio,
C.sub.1-6 alkylsulfonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkylaminosulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl and
di(C.sub.1-6 alkyl)aminosulfonyl;
[0145] each R.sup.a2, R.sup.c2 and R.sup.d2, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.21;
[0146] or any R.sup.c2 and R.sup.d2 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.21;
[0147] each R.sup.b2 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.21;
[0148] each R.sup.e2 is independently selected from H, CN,
C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, C.sub.1-6 alkylthio,
C.sub.1-6 alkylsulfonyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6
alkylaminosulfonyl, carbamyl, C.sub.1-6 alkylcarbamyl, di(C.sub.1-6
alkyl)carbamyl, aminosulfonyl, C.sub.1-6 alkylaminosulfonyl and
di(C.sub.1-6 alkyl)aminosulfonyl;
[0149] each R.sup.a3, R.sup.c3 and R.sup.d3, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.12;
[0150] or any R.sup.c3 and R.sup.d3 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.12;
[0151] each R.sup.b3 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl, are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.12;
[0152] each R.sup.a4, R.sup.c4 and R.sup.d4, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.22;
[0153] or any R.sup.c4 and R.sup.d4 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.22;
[0154] each R.sup.b4 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.22;
[0155] each R.sup.a5, R.sup.c5 and R.sup.d5, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g;
[0156] each R.sup.b5 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g;
[0157] each R.sup.a6, R.sup.c6 and R.sup.d6, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g;
[0158] each R.sup.b6 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.g;
[0159] each R.sup.a7, R.sup.c7, and R.sup.d7 is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-10 cycloalkyl, 4-10 membered
heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered heteroaryl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl, are each optionally substituted
with 1, 2, 3, or 4 substituents independently selected from
R.sup.30;
[0160] or any R.sup.c7 and R.sup.d7 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.30;
[0161] each R.sup.b7 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl and 5-10 membered heteroaryl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl and 5-10 membered
heteroaryl, are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.30;
[0162] each R.sup.a8, R.sup.c8 and R.sup.d8, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl; wherein said
C.sub.1-6 alkyl C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.g;
[0163] or any R.sup.c8 and R.sup.d8 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2 or 3 substituents independently selected from R.sup.g;
[0164] each R.sup.b8 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl and 4-7
membered heterocycloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, phenyl, 5-6
membered heteroaryl and 4-7 membered heterocycloalkyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g; and
[0165] each R.sup.g is independently selected from OH, NO.sub.2,
CN, halo, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.3-6 cycloalkyl, C.sub.3-6
cycloalkyl-C.sub.1-2 alkylene, C.sub.1-6 alkoxy, C.sub.1-6
haloalkoxy, C.sub.1-3 alkoxy-C.sub.1-3 alkyl, C.sub.1-3
alkoxy-C.sub.1-3 alkoxy, HO--C.sub.1-3 alkoxy, HO--C.sub.1-3 alkyl,
cyano-C.sub.1-3 alkyl, H.sub.2N--C.sub.1-3 alkyl, amino, C.sub.1-6
alkylamino, di(C.sub.1-6 alkyl)amino, thio, C.sub.1-6 alkylthio,
C.sub.1-6 alkylsulfinyl, C.sub.1-6 alkylsulfonyl, carbamyl,
C.sub.1-6 alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, carboxy,
C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkylcarbonylamino, C.sub.1-6 alkylsulfonylamino, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl, di(C.sub.1-6 alkyl)aminosulfonyl,
aminosulfonylamino, C.sub.1-6 alkylaminosulfonylamino, di(C.sub.1-6
alkyl)aminosulfonylamino, aminocarbonylamino, C.sub.1-6
alkylaminocarbonylamino, and di(C.sub.1-6
alkyl)aminocarbonylamino.
[0166] In some embodiments:
[0167] R.sup.1 is selected from Cy.sup.1, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, CN, NO.sub.2,
OR.sup.a, SR.sup.a, C(O)R.sup.b, C(O)NR.sup.cR.sup.d, C(O)OR.sup.a,
OC(O)R.sup.b, OC(O)NR.sup.cR.sup.d, NR.sup.cR.sup.d,
NR.sup.cC(O)R.sup.b, NR.sup.cC(O)OR.sup.a, NR.sup.cS(O)R.sup.b,
NR.sup.cS(O).sub.2R.sup.b, NR.sup.cS(O).sub.2NR.sup.cR.sup.d,
S(O)R.sup.b, S(O)NR.sup.cR.sup.d, S(O).sub.2R.sup.b, and
S(O).sub.2NR.sup.cR.sup.d; wherein said C.sub.2-6 alkenyl and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.10;
[0168] Cy.sup.1 is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-10 membered heteroaryl has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10;
[0169] Cy.sup.A is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-membered heteroaryl has at least one
ring-forming carbon atom and 1 or 2 ring-forming heteroatoms
independently selected from N, O, and S and the 6-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of the 5-10 membered heteroaryl is
optionally substituted by oxo to form a carbonyl group; and wherein
the C.sub.6-10 aryl and 5-10 membered heteroaryl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20;
[0170] R.sup.2 is selected from H, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, CN,
OR.sup.a7, SR.sup.a7, C(O)R.sup.b7, C(O)NR.sup.c7R.sup.d7,
C(O)OR.sup.a7, NR.sup.c7R.sup.d7, NR.sup.c7C(O)R.sup.b7, and
NR.sup.c7C(O)OR.sup.a7; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.30;
[0171] each R.sup.10 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, piperazinyl, piperidinyl, C.sub.6-10 aryl,
5-10 membered heteroaryl, halo, CN, NO.sub.2, OR.sup.a1, SR.sup.a1,
C(O)R.sup.b1, C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1,
NR.sup.c1R.sup.d1, NR.sup.c1C(O)R.sup.b1, NR.sup.c1C(O)OR.sup.a1,
S(O)R.sup.b1, S(O)NR.sup.c1R.sup.d1, S(O).sub.2R.sup.b1, and
S(O).sub.2NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
piperazinyl, piperidinyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0172] each R.sup.11 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
halo, CN, OR.sup.a3, SR.sup.a3, C(O)R.sup.b3,
C(O)NR.sup.c3R.sup.d3, C(O)OR.sup.a3, NR.sup.c3R.sup.d3,
NR.sup.c3C(O)R.sup.b3, NR.sup.c3C(O)OR.sup.a3, S(O)R.sup.b3,
S(O)NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.12;
[0173] each R.sup.12 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
CN, OR.sup.a5, SR.sup.a5, C(O)R.sup.b5, C(O)NR.sup.c5R.sup.d5,
C(O)OR.sup.a5, NR.sup.c5R.sup.d5,
NR.sup.c5C(O)R.sup.b5NR.sup.c5C(O)OR.sup.a5, S(O)R.sup.b5,
S(O)NR.sup.c5R.sup.d5, S(O).sub.2R.sup.b5, and
S(O).sub.2NR.sup.c5R.sup.d5; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.g;
[0174] each R.sup.20 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, halo, CN, NO.sub.2, OR.sup.a2,
SR.sup.a2, C(O)R.sup.b2, C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2,
OC(O)R.sup.b2, OC(O)NR.sup.c2R.sup.d2, NR.sup.c2R.sup.d2,
NR.sup.c2C(O)R.sup.b2, NR.sup.c2C(O)OR.sup.a2,
NR.sup.c2S(O)R.sup.b2, NR.sup.c2S(O).sub.2R.sup.b2,
NR.sup.c2S(O).sub.2NR.sup.c2R.sup.d2, S(O)R.sup.b2,
S(O)NR.sup.c2R.sup.d2, S(O).sub.2R.sup.b2, and
S(O).sub.2NR.sup.c2R.sup.d2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.21;
[0175] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 5- or 6-membered heterocycloalkyl ring, or a fused C.sub.3-7
cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl ring are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.21;
[0176] each R.sup.21 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.3-10 cycloalkyl, 4-10 membered heterocycloalkyl, C.sub.6-10
aryl, 5-10 membered heteroaryl, halo, CN, OR.sup.a4, SR.sup.a4,
C(O)R.sup.b4, C(O)NR.sup.c4R.sup.d4, C(O)OR.sup.a4,
NR.sup.c4R.sup.d4, NR.sup.c4C(O)R.sup.b4, NR.sup.c4C(O)OR.sup.a4,
S(O)R.sup.b4, S(O)NR.sup.c4R.sup.d4, S(O).sub.2R.sup.b4, and
S(O).sub.2NR.sup.c4R.sup.d4; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, 4-10
membered heterocycloalkyl, C.sub.6-10 aryl, and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.22;
[0177] each R.sup.22 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
CN, OR.sup.a6, SR.sup.a6, C(O)R.sup.b6, C(O)NR.sup.c6R.sup.d6,
C(O)OR.sup.a6, NR.sup.c6R.sup.d6, NR.sup.c6C(O)R.sup.b6,
NR.sup.c6C(O)OR.sup.a6, S(O)R.sup.b6, S(O)NR.sup.c6R.sup.d6,
S(O).sub.2R.sup.b6, and S(O).sub.2NR.sup.c6R.sup.d6; wherein said
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g;
[0178] each R.sup.30 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
phenyl, halo, CN, OR.sup.as, SR.sup.as, C(O)R.sup.b8,
C(O)NR.sup.c8R.sup.d8, C(O)OR.sup.as, NR.sup.c8R.sup.d8,
NR.sup.c8(O)R.sup.b8, NR.sup.c8C(O)OR.sup.as, S(O)R.sup.b8,
S(O)NR.sup.c8R.sup.d8, S(O).sub.2R.sup.b8, and
S(O).sub.2NR.sup.c8R.sup.d8; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and phenyl are each
optionally substituted with 1, 2, 3, or 4 substituents
independently selected from R.sup.g;
[0179] each R.sup.a and R.sup.c is independently selected from H,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and
C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6
alkenyl, and C.sub.2-6 alkynyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.10;
[0180] each R.sup.d is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6
alkynyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10;
[0181] each R.sup.b is independently selected from C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6 haloalkyl;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6
alkynyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.10;
[0182] each R.sup.a1, R.sup.c1 and R.sup.d1 is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, 4-10 membered heterocycloalkyl, and
C.sub.6-10 aryl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, 4-10 membered heterocycloalkyl and C.sub.6-10
aryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0183] or any R.sup.c1 and R.sup.d1 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0184] each R.sup.b1 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
and 4-10 membered heterocycloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0185] each R.sup.a2, R.sup.c2 and R.sup.d2, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21;
[0186] each R.sup.b2 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.21;
[0187] each R.sup.a3, R.sup.c3 and R.sup.d3, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.12;
[0188] each R.sup.b3 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl, and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.12;
[0189] each R.sup.a4, R.sup.c4 and R.sup.d4, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.22;
[0190] each R.sup.b4 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; wherein said C.sub.1-6 alkyl C.sub.2-6 alkenyl, and
C.sub.2-6 alkynyl are each optionally substituted with 1, 2, 3, or
4 substituents independently selected from R.sup.22;
[0191] each R.sup.a5, R.sup.c5 and R.sup.d5, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl;
[0192] each R.sup.b5 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl and C.sub.1-6
haloalkyl;
[0193] each R.sup.a6, R.sup.c6 and R.sup.d6, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl;
[0194] each R.sup.b6 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl;
[0195] each R.sup.a7, R.sup.c7, and R.sup.d7 is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl;
[0196] each R.sup.b7 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl;
[0197] each R.sup.a8, R.sup.c8 and R.sup.d8, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl;
[0198] each R.sup.b8 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl; and
[0199] each R.sup.g is independently selected from OH, NO.sub.2,
CN, halo, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.1-6 haloalkyl, C.sub.1-6 alkoxy, C.sub.1-6 haloalkoxy,
C.sub.1-3 alkoxy-C.sub.1-3 alkyl, C.sub.1-3 alkoxy-C.sub.1-3
alkoxy, HO--C.sub.1-3 alkoxy, HO--C.sub.1-3 alkyl, cyano-C.sub.1-3
alkyl, H.sub.2N--C.sub.1-3 alkyl, amino, C.sub.1-6 alkylamino,
di(C.sub.1-6 alkyl)amino, thio, C.sub.1-6 alkylthio, C.sub.1-6
alkylsulfinyl, C.sub.1-6 alkylsulfonyl, carbamyl, C.sub.1-6
alkylcarbamyl, di(C.sub.1-6 alkyl)carbamyl, carboxy, C.sub.1-6
alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkylcarbonylamino, C.sub.1-6 alkylsulfonylamino, aminosulfonyl,
C.sub.1-6 alkylaminosulfonyl, and di(C.sub.1-6
alkyl)aminosulfonyl.
[0200] In some embodiments:
[0201] R.sup.1 is selected from Cy.sup.1, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, and CN; wherein said
C.sub.2-6 alkenyl and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.10;
[0202] Cy.sup.1 is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-10 membered heteroaryl has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10;
[0203] Cy.sup.A is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-membered heteroaryl has at least one
ring-forming carbon atom and 1 or 2 ring-forming heteroatoms
independently selected from N, O, and S and the 6-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of the 5-10 membered heteroaryl is
optionally substituted by oxo to form a carbonyl group; and wherein
the C.sub.6-10 aryl and 5-10 membered heteroaryl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20;
[0204] R.sup.2 is selected from H, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl, halo, and CN;
[0205] each R.sup.10 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
piperazinyl, piperidinyl, halo, CN, OR.sup.a1, C(O)R.sup.b1,
C(O)NR.sup.c1R.sup.d1, C(O)OR.sup.a1, and NR.sup.c1R.sup.d1;
wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
piperazinyl, and piperidinyl are each optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0206] each R.sup.11 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
halo, OR.sup.a3, C(O)R.sup.b3, C(O)NR.sup.c3R.sup.d3,
C(O)OR.sup.a3, NR.sup.c3R.sup.d3, S(O).sub.2R.sup.b3, and
S(O).sub.2NR.sup.c3R.sup.d3;
[0207] each R.sup.20 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, CN, OR.sup.a2,
C(O)R.sup.b2, C(O)NR.sup.c2R.sup.d2, C(O)OR.sup.a2,
NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, and
NR.sup.c2S(O).sub.2R.sup.b2; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, and 5-10
membered heteroaryl are each optionally substituted with 1, 2, 3,
or 4 substituents independently selected from R.sup.21;
[0208] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 5- or 6-membered heterocycloalkyl ring, or a fused C.sub.3-7
cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl ring are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.21;
[0209] each R.sup.21 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
C.sub.6-10 aryl, 5-10 membered heteroaryl, halo, OR.sup.a4,
C(O)R.sup.b4, C(O)NR.sup.c4R.sup.d4, C(O)OR.sup.a4,
NR.sup.c4R.sup.d4, NR.sup.c4C(O)R.sup.b4, S(O).sub.2R.sup.b4, and
S(O).sub.2NR.sup.c4R.sup.d4; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.6-10 aryl, and 5-10
membered heteroaryl are each optionally substituted with 1, 2, 3,
or 4 substituents independently selected from R.sup.22;
[0210] each R.sup.22 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
OR.sup.a6, C(O)R.sup.b6, C(O)NR.sup.c6R.sup.d6, C(O)OR.sup.a6,
NR.sup.c6R.sup.d6, NR.sup.c6C(O)R.sup.b6, S(O).sub.2R.sup.b6, and
S(O).sub.2NR.sup.c6R.sup.d6;
[0211] each R.sup.a1, R.sup.c1 and R.sup.d1 is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.1-6 haloalkyl, 4-10 membered heterocycloalkyl, and
C.sub.6-10 aryl; wherein said C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, 4-10 membered heterocycloalkyl and C.sub.6-10
aryl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0212] or any R.sup.c1 and R.sup.d1 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0213] each R.sup.b1 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 haloalkyl,
and 4-10 membered heterocycloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0214] each R.sup.a2, R.sup.c2 and R.sup.d2, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21;
[0215] each R.sup.b2 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl;
[0216] each R.sup.a3, R.sup.c3 and R.sup.d3, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl;
[0217] each R.sup.b3 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl;
[0218] each R.sup.a4, R.sup.c4 and R.sup.d4, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, and C.sub.1-6 haloalkyl; wherein said C.sub.1-6 alkyl
C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.22;
[0219] each R.sup.b4 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl;
[0220] each R.sup.a6, R.sup.c6 and R.sup.d6, is independently
selected from H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl and C.sub.1-6 haloalkyl; and
[0221] each R.sup.b6 is independently selected from C.sub.1-6
alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, and C.sub.1-6
haloalkyl.
[0222] In some embodiments:
[0223] R.sup.1 is Cy.sup.1;
[0224] Cy.sup.1 is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-10 membered heteroaryl has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10;
[0225] Cy.sup.A is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-membered heteroaryl has at least one
ring-forming carbon atom and 1 or 2 ring-forming heteroatoms
independently selected from N, O, and S and the 6-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of the 5-10 membered heteroaryl is
optionally substituted by oxo to form a carbonyl group; and wherein
the C.sub.6-10 aryl and 5-10 membered heteroaryl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20;
[0226] R.sup.2 is H;
[0227] each R.sup.10 is independently selected from C.sub.1-6
alkyl, piperazinyl, piperidinyl, C(O)R.sup.b1 and
C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl, piperazinyl,
and piperidinyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0228] each R.sup.11 is independently selected from C.sub.1-6
alkyl, C(O)R.sup.b3, and S(O).sub.2R.sup.b3;
[0229] each R.sup.20 is independently selected from C.sub.1-6
alkyl, C.sub.1-6 haloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, halo, CN, OR.sup.a2, C(O)NR.sup.c2R.sup.d2,
C(O)OR.sup.a2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, and
NR.sup.c2S(O).sub.2R.sup.b2; wherein said C.sub.1-6 alkyl,
C.sub.6-10 aryl, and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21;
[0230] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 5- or 6-membered heterocycloalkyl ring, or a fused C.sub.3-7
cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl ring are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.21;
[0231] each R.sup.21 is independently selected from C.sub.6-10
aryl, 5-10 membered heteroaryl, OR.sup.a4, and
NR.sup.c4R.sup.d4;
[0232] each R.sup.22 is OR.sup.a6;
[0233] each R.sup.c1 and R.sup.d1 is independently selected from H,
C.sub.1-6 alkyl, 4-10 membered heterocycloalkyl, and C.sub.6-10
aryl; wherein said C.sub.1-6 alkyl, 4-10 membered heterocycloalkyl
and C.sub.6-10 aryl are each optionally substituted with 1, 2, 3,
or 4 substituents independently selected from R.sup.11;
[0234] or any R.sup.c1 and R.sup.d1 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0235] R.sup.b1 is 4-10 membered heterocycloalkyl optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11;
[0236] each R.sup.a2, R.sup.c2 and R.sup.d2 is independently H or
C.sub.1-6 alkyl; wherein said C.sub.1-6 alkyl is optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21;
[0237] each R.sup.b2 is C.sub.1-6 alkyl;
[0238] each R.sup.b3 is C.sub.1-6 alkyl;
[0239] each R.sup.a4, R.sup.c4 and R.sup.d4 is H or C.sub.1-6
alkyl; wherein said C.sub.1-6 alkyl is optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.22;
and
[0240] R.sup.a6 is H.
[0241] In some embodiments:
[0242] R.sup.1 is Cy.sup.1;
[0243] Cy.sup.1 is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-10 membered heteroaryl has at least one
ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms
independently selected from N, O, and S; wherein the N and S are
optionally oxidized; wherein a ring-forming carbon atom of 5-10
membered heteroaryl is optionally substituted by oxo to form a
carbonyl group; and wherein the C.sub.6-10 aryl and 5-10 membered
heteroaryl are each optionally substituted with 1, 2, 3 or 4
substituents independently selected from R.sup.10;
[0244] Cy.sup.A is selected from C.sub.6-10 aryl and 5-10 membered
heteroaryl; wherein the 5-membered heteroaryl has at least one
ring-forming carbon atom and 1 or 2 ring-forming heteroatoms
independently selected from N, O, and S and the 6-10 membered
heteroaryl has at least one ring-forming carbon atom and 1, 2, 3,
or 4 ring-forming heteroatoms independently selected from N, O, and
S; wherein the N and S are optionally oxidized; wherein a
ring-forming carbon atom of the 5-10 membered heteroaryl is
optionally substituted by oxo to form a carbonyl group; and wherein
the C.sub.6-10 aryl and 5-10 membered heteroaryl are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.20;
[0245] R.sup.2 is H or CN;
[0246] each R.sup.10 is independently selected from C.sub.1-6
alkyl, piperazinyl, piperidinyl, C(O)R.sup.b1 and
C(O)NR.sup.c1R.sup.d1; wherein said C.sub.1-6 alkyl, piperazinyl,
and piperidinyl are each optionally substituted with 1, 2, 3, or 4
substituents independently selected from R.sup.11;
[0247] each R.sup.11 is independently selected from C.sub.1-6
alkyl, OR.sup.a3, C(O)R.sup.b3, and S(O).sub.2R.sup.b3;
[0248] each R.sup.20 is independently selected from C.sub.1-6
alkyl, C.sub.1-6 haloalkyl, C.sub.6-10 aryl, 5-10 membered
heteroaryl, halo, CN, OR.sup.a2, C(O)NR.sup.c2R.sup.d2,
C(O)OR.sup.a2, NR.sup.c2R.sup.d2, NR.sup.c2C(O)R.sup.b2, and
NR.sup.c2S(O).sub.2R.sup.b2; wherein said C.sub.1-6 alkyl,
C.sub.6-10 aryl, and 5-10 membered heteroaryl are each optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21;
[0249] or two adjacent R.sup.20 substituents on the Cy.sup.A ring,
taken together with the atoms to which they are attached, form a
fused 5- or 6-membered heterocycloalkyl ring, or a fused C.sub.3-7
cycloalkyl ring; wherein each fused 5- or 6-membered
heterocycloalkyl ring has at least one ring-forming carbon atom and
1, 2, 3, or 4 ring-forming heteroatoms independently selected from
N, O, and S; wherein a ring-forming carbon atom of each fused 5- or
6-membered heterocycloalkyl ring is optionally substituted by oxo
to form a carbonyl group; and wherein the fused 5- or 6-membered
heterocycloalkyl ring and fused C.sub.3-6 cycloalkyl ring are each
optionally substituted with 1, 2, 3 or 4 substituents independently
selected from R.sup.21;
[0250] each R.sup.21 is independently selected from C.sub.6-10
aryl, 5-10 membered heteroaryl, OR.sup.a4, and
NR.sup.c4R.sup.d4;
[0251] each R.sup.22 is OR.sup.a6;
[0252] each R.sup.c1 and R.sup.d1 is independently selected from H,
C.sub.1-6 alkyl, 4-10 membered heterocycloalkyl, and C.sub.6-10
aryl; wherein said C.sub.1-6 alkyl, 4-10 membered heterocycloalkyl
and C.sub.6-10 aryl are each optionally substituted with 1, 2, 3,
or 4 substituents independently selected from R.sup.11;
[0253] or any R.sup.c1 and R.sup.d1 attached to the same N atom,
together with the N atom to which they are attached, form a 4-, 5-,
6- or 7-membered heterocycloalkyl group optionally substituted with
1, 2, 3, or 4 substituents independently selected from
R.sup.11;
[0254] R.sup.b1 is 4-10 membered heterocycloalkyl optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.11;
[0255] each R.sup.a2, R.sup.c2 and R.sup.d2 is independently H or
C.sub.1-6 alkyl; wherein said C.sub.1-6 alkyl is optionally
substituted with 1, 2, 3, or 4 substituents independently selected
from R.sup.21;
[0256] each R.sup.b2 is C.sub.1-6 alkyl;
[0257] each R.sup.b3 is C.sub.1-6 alkyl;
[0258] each R.sup.a3 is independently H or C.sub.1-6 alkyl;
[0259] each R.sup.a4, R.sup.c4 and R.sup.d4 is H or C.sub.1-6
alkyl; wherein said C.sub.1-6 alkyl is optionally substituted with
1, 2, 3, or 4 substituents independently selected from R.sup.22;
and
[0260] R.sup.a6 is H.
[0261] It is further appreciated that certain features of the
invention, which are, for clarity, described in the context of
separate embodiments, can also be provided in combination in a
single embodiment (while the embodiments are intended to be
combined as if written in multiply dependent form). Conversely,
various features of the invention which are, for brevity, described
in the context of a single embodiment, can also be provided
separately or in any suitable subcombination. Thus, it is
contemplated as features described as embodiments of the compounds
of Formula (I) can be combined in any suitable combination.
[0262] At various places in the present specification, certain
features of the compounds are disclosed in groups or in ranges. It
is specifically intended that such a disclosure include each and
every individual subcombination of the members of such groups and
ranges. For example, the term "C.sub.1-6 alkyl" is specifically
intended to individually disclose (without limitation) methyl,
ethyl, C.sub.3 alkyl, C.sub.4 alkyl, C.sub.5 alkyl and C.sub.6
alkyl.
[0263] The term "n-membered," where n is an integer, typically
describes the number of ring-forming atoms in a moiety where the
number of ring-forming atoms is n. For example, piperidinyl is an
example of a 6-membered heterocycloalkyl ring, pyrazolyl is an
example of a 5-membered heteroaryl ring, pyridyl is an example of a
6-membered heteroaryl ring and 1,2,3,4-tetrahydro-naphthalene is an
example of a 10-membered cycloalkyl group.
[0264] At various places in the present specification, variables
defining divalent linking groups may be described. It is
specifically intended that each linking substituent include both
the forward and backward forms of the linking substituent. For
example, --NR(CR'R'').sub.n-includes both --NR(CR'R'').sub.n-- and
--(CR'R'').sub.nNR-- and is intended to disclose each of the forms
individually. Where the structure requires a linking group, the
Markush variables listed for that group are understood to be
linking groups. For example, if the structure requires a linking
group and the Markush group definition for that variable lists
"alkyl" or "aryl" then it is understood that the "alkyl" or "aryl"
represents a linking alkylene group or arylene group,
respectively.
[0265] The term "substituted" means that an atom or group of atoms
formally replaces hydrogen as a "substituent" attached to another
group. The term "substituted", unless otherwise indicated, refers
to any level of substitution, e.g., mono-, di-, tri-, tetra- or
penta-substitution, where such substitution is permitted. The
substituents are independently selected, and substitution may be at
any chemically accessible position. It is to be understood that
substitution at a given atom is limited by valency. It is to be
understood that substitution at a given atom results in a
chemically stable molecule. The phrase "optionally substituted"
means unsubstituted or substituted. The term "substituted" means
that a hydrogen atom is removed and replaced by a substituent. A
single divalent substituent, e.g., oxo, can replace two hydrogen
atoms.
[0266] The term "C.sub.n-m" indicates a range which includes the
endpoints, wherein n and m are integers and indicate the number of
carbons. Examples include C.sub.1-4, C.sub.1-6 and the like.
[0267] The term "alkyl," employed alone or in combination with
other terms, refers to a saturated hydrocarbon group that may be
straight-chained or branched. The term "C.sub.n-m alkyl", refers to
an alkyl group having n to m carbon atoms. An alkyl group formally
corresponds to an alkane with one C--H bond replaced by the point
of attachment of the alkyl group to the remainder of the compound.
In some embodiments, the alkyl group contains from 1 to 6 carbon
atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to
2 carbon atoms. Examples of alkyl moieties include, but are not
limited to, chemical groups such as methyl, ethyl, n-propyl,
isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher
homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl,
1,2,2-trimethylpropyl and the like.
[0268] The term "alkenyl," employed alone or in combination with
other terms, refers to a straight-chain or branched hydrocarbon
group corresponding to an alkyl group having one or more double
carbon-carbon bonds. An alkenyl group formally corresponds to an
alkene with one C--H bond replaced by the point of attachment of
the alkenyl group to the remainder of the compound. The term
"C.sub.n-m alkenyl" refers to an alkenyl group having n to m
carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2
to 4, or 2 to 3 carbon atoms. Example alkenyl groups include, but
are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl,
sec-butenyl and the like.
[0269] The term "alkynyl," employed alone or in combination with
other terms, refers to a straight-chain or branched hydrocarbon
group corresponding to an alkyl group having one or more triple
carbon-carbon bonds. An alkynyl group formally corresponds to an
alkyne with one C--H bond replaced by the point of attachment of
the alkyl group to the remainder of the compound. The term
"C.sub.n-m alkynyl" refers to an alkynyl group having n to m
carbons. Example alkynyl groups include, but are not limited to,
ethynyl, propyn-1-yl, propyn-2-yl and the like. In some
embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3
carbon atoms.
[0270] The term "alkylene," employed alone or in combination with
other terms, refers to a divalent alkyl linking group. An alkylene
group formally corresponds to an alkane with two C--H bond replaced
by points of attachment of the alkylene group to the remainder of
the compound. The term "C.sub.n-m alkylene" refers to an alkylene
group having n to m carbon atoms. Examples of alkylene groups
include, but are not limited to, ethan-1,2-diyl, ethan-1,1-diyl,
propan-1,3-diyl, propan-1,2-diyl, propan-1,1-diyl, butan-1,4-diyl,
butan-1,3-diyl, butan-1,2-diyl, 2-methyl-propan-1,3-diyl and the
like.
[0271] The term "alkoxy," employed alone or in combination with
other terms, refers to a group of formula --O-alkyl, wherein the
alkyl group is as defined above. The term "C.sub.n-m alkoxy" refers
to an alkoxy group, the alkyl group of which has n to m carbons.
Example alkoxy groups include methoxy, ethoxy, propoxy (e.g.,
n-propoxy and isopropoxy), t-butoxy and the like. In some
embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon
atoms.
[0272] The term "amino" refers to a group of formula
--NH.sub.2.
[0273] The term "carbonyl," employed alone or in combination with
other terms, refers to a --C(.dbd.O)-- group, which also may be
written as C(O).
[0274] The term "cyano" or "nitrile" refers to a group of formula
--C.quadrature.N, which also may be written as --CN.
[0275] The terms "halo" or "halogen", used alone or in combination
with other terms, refers to fluoro, chloro, bromo and iodo. In some
embodiments, "halo" refers to a halogen atom selected from F, Cl,
or Br. In some embodiments, halo groups are F.
[0276] The term "haloalkyl" as used herein refers to an alkyl group
in which one or more of the hydrogen atoms has been replaced by a
halogen atom. The term "C.sub.n-m haloalkyl" refers to a C.sub.n-m
alkyl group having n to m carbon atoms and from a at least one up
to {2(n to m)+1}halogen atoms, which may either be the same or
different. In some embodiments, the halogen atoms are fluoro atoms.
In some embodiments, the haloalkyl group has 1 to 6 or 1 to 4
carbon atoms. Example haloalkyl groups include CF.sub.3,
C.sub.2F.sub.5, CHF.sub.2, CH.sub.2F, CCl.sub.3, CHCl.sub.2,
C.sub.2Cl.sub.5 and the like. In some embodiments, the haloalkyl
group is a fluoroalkyl group.
[0277] The term "haloalkoxy," employed alone or in combination with
other terms, refers to a group of formula --O-haloalkyl, wherein
the haloalkyl group is as defined above. The term "C.sub.n-m
haloalkoxy" refers to a haloalkoxy group, the haloalkyl group of
which has n to m carbons. Example haloalkoxy groups include
trifluoromethoxy and the like. In some embodiments, the haloalkoxy
group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0278] The term "oxo" refers to an oxygen atom as a divalent
substituent, forming a carbonyl group when attached to carbon, or
attached to a heteroatom forming a sulfoxide or sulfone group, or
an N-oxide group. In some embodiments, heterocyclic groups may be
optionally substituted by 1 or 2 oxo (.dbd.O) substituents.
[0279] The term "sulfido" refers to a sulfur atom as a divalent
substituent, forming a thiocarbonyl group (C.dbd.S) when attached
to carbon.
[0280] The term "aromatic" refers to a carbocycle or heterocycle
having one or more polyunsaturated rings having aromatic character
(i.e., having (4n+2) delocalized .pi. (pi) electrons where n is an
integer).
[0281] The term "aryl," employed alone or in combination with other
terms, refers to an aromatic hydrocarbon group, which may be
monocyclic or polycyclic (e.g., having 2 fused rings). The term
"C.sub.n-m aryl" refers to an aryl group having from n to m ring
carbon atoms.
[0282] Aryl groups include, e.g., phenyl, naphthyl, and the like.
In some embodiments, aryl groups have from 6 to about 10 carbon
atoms. In some embodiments aryl groups have 6 carbon atoms. In some
embodiments aryl groups have 10 carbon atoms. In some embodiments,
the aryl group is phenyl. In some embodiments, the aryl group is
naphthyl.
[0283] The term "heteroaryl" or "heteroaromatic," employed alone or
in combination with other terms, refers to a monocyclic or
polycyclic aromatic heterocycle having at least one heteroatom ring
member selected from sulfur, oxygen and nitrogen. In some
embodiments, the heteroaryl ring has 1, 2, 3 or 4 heteroatom ring
members independently selected from nitrogen, sulfur and oxygen. In
some embodiments, any ring-forming N in a heteroaryl moiety can be
an N-oxide. In some embodiments, the heteroaryl has 5-14 ring atoms
including carbon atoms and 1, 2, 3 or 4 heteroatom ring members
independently selected from nitrogen, sulfur and oxygen. In some
embodiments, the heteroaryl has 5-10 ring atoms including carbon
atoms and 1, 2, 3 or 4 heteroatom ring members independently
selected from nitrogen, sulfur and oxygen. In some embodiments, the
heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members
independently selected from nitrogen, sulfur and oxygen. In some
embodiments, the heteroaryl is a five-membered or six-membered
heteroaryl ring. In other embodiments, the heteroaryl is an
eight-membered, nine-membered or ten-membered fused bicyclic
heteroaryl ring. Example heteroaryl groups include, but are not
limited to, pyridinyl (pyridyl), pyrimidinyl, pyrazinyl,
pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, isoxazolyl,
thiazolyl, imidazolyl, furanyl, thiophenyl, quinolinyl,
isoquinolinyl, naphthyridinyl (including 1,2-, 1,3-, 1,4-, 1,5-,
1,6-, 1,7-, 1,8-, 2,3- and 2,6-naphthyridine), indolyl, indazolyl,
benzothiophenyl, benzofuranyl, benzisoxazolyl,
imidazo[1,2-b]thiazolyl, purinyl, pyrrolopyridinyl,
pyrazolopyridinyl, imidazopyridinyl, pyridopyridinyl,
pyridopyrazinyl, oxazolopyridinyl and the like. In some
embodiments, the heteroaryl group is pyridone (e.g.,
2-pyridone).
[0284] A five-membered heteroaryl ring is a heteroaryl group having
five ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms
are independently selected from N, O and S. Exemplary five-membered
ring heteroaryls include thienyl, furyl, pyrrolyl, imidazolyl,
thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl,
1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl,
1,3,4-triazolyl, 1,3,4-thiadiazolyl and 1,3,4-oxadiazolyl.
[0285] A six-membered heteroaryl ring is a heteroaryl group having
six ring atoms wherein one or more (e.g., 1, 2 or 3) ring atoms are
independently selected from N, O and S. Exemplary six-membered ring
heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and
pyridazinyl.
[0286] The term "cycloalkyl," employed alone or in combination with
other terms, refers to a non-aromatic hydrocarbon ring system
(monocyclic, bicyclic or polycyclic), including cyclized alkyl and
alkenyl groups. The term "C.sub.n-m cycloalkyl" refers to a
cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl
groups can include mono- or polycyclic (e.g., having 2, 3 or 4
fused rings) groups and spirocycles. Cycloalkyl groups can have 3,
4, 5, 6 or 7 ring-forming carbons (C.sub.3-7). In some embodiments,
the cycloalkyl group has 3 to 6 ring members, 3 to 5 ring members,
or 3 to 4 ring members. In some embodiments, the cycloalkyl group
is monocyclic. In some embodiments, the cycloalkyl group is
monocyclic or bicyclic. In some embodiments, the cycloalkyl group
is a C.sub.3-6 monocyclic cycloalkyl group. Ring-forming carbon
atoms of a cycloalkyl group can be optionally oxidized to form an
oxo or sulfido group. Cycloalkyl groups also include
cycloalkylidenes. In some embodiments, cycloalkyl is cyclopropyl,
cyclobutyl, cyclopentyl or cyclohexyl. Also included in the
definition of cycloalkyl are moieties that have one or more
aromatic rings fused (i.e., having a bond in common with) to the
cycloalkyl ring, e.g., benzo or thienyl derivatives of
cyclopentane, cyclohexane and the like. A cycloalkyl group
containing a fused aromatic ring can be attached through any
ring-forming atom including a ring-forming atom of the fused
aromatic ring. Examples of cycloalkyl groups include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl,
cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl,
norpinyl, norcarnyl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl,
and the like. In some embodiments, the cycloalkyl group is
cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0287] The term "heterocycloalkyl," employed alone or in
combination with other terms, refers to a non-aromatic ring or ring
system, which may optionally contain one or more alkenylene groups
as part of the ring structure, which has at least one heteroatom
ring member independently selected from nitrogen, sulfur oxygen and
phosphorus, and which has 4-10 ring members, 4-7 ring members, or
4-6 ring members. Included within the term "heterocycloalkyl" are
monocyclic 4-, 5-, 6- and 7-membered heterocycloalkyl groups.
Heterocycloalkyl groups can include mono- or bicyclic (e.g., having
two fused or bridged rings) or spirocyclic ring systems. In some
embodiments, the heterocycloalkyl group is a monocyclic group
having 1, 2 or 3 heteroatoms independently selected from nitrogen,
sulfur and oxygen. Ring-forming carbon atoms and heteroatoms of a
heterocycloalkyl group can be optionally oxidized to form an oxo or
sulfido group or other oxidized linkage (e.g., C(O), S(O), C(S) or
S(O).sub.2, N-oxide etc.) or a nitrogen atom can be quaternized.
The heterocycloalkyl group can be attached through a ring-forming
carbon atom or a ring-forming heteroatom. In some embodiments, the
heterocycloalkyl group contains 0 to 3 double bonds. In some
embodiments, the heterocycloalkyl group contains 0 to 2 double
bonds. Also included in the definition of heterocycloalkyl are
moieties that have one or more aromatic rings fused (i.e., having a
bond in common with) to the heterocycloalkyl ring, e.g., benzo or
thienyl derivatives of piperidine, morpholine, azepine, etc. A
heterocycloalkyl group containing a fused aromatic ring can be
attached through any ring-forming atom including a ring-forming
atom of the fused aromatic ring. Examples of heterocycloalkyl
groups include azetidinyl, azepanyl, dihydrobenzofuranyl,
dihydrobenzodioxine, dihydrofuranyl, dihydropyranyl,
dihydropyrolopyridinyl, morpholino, 3-oxa-9-azaspiro[5.5]undecanyl,
1-oxa-8-azaspiro[4.5]decanyl, piperidinyl, piperazinyl,
oxopiperazinyl, pyranyl, pyrrolidinyl, quinuclidinyl,
tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl,
1,2,3,4-tetrahydroisoquinolinyl, tropanyl, and thiomorpholino.
[0288] At certain places, the definitions or embodiments refer to
specific rings (e.g., an azetidine ring, a pyridine ring, etc.).
Unless otherwise indicated, these rings can be attached to any ring
member provided that the valency of the atom is not exceeded. For
example, an azetidine ring may be attached at any position of the
ring, whereas an azetidin-3-yl ring is attached at the
3-position.
[0289] The compounds described herein can be asymmetric (e.g.,
having one or more stereocenters). All stereoisomers, such as
enantiomers and diastereomers, are intended unless otherwise
indicated. Compounds of the present invention that contain
asymmetrically substituted carbon atoms can be isolated in
optically active or racemic forms. Methods on how to prepare
optically active forms from optically inactive starting materials
are known in the art, such as by resolution of racemic mixtures or
by stereoselective synthesis. Many geometric isomers of olefins,
C.dbd.N double bonds and the like can also be present in the
compounds described herein, and all such stable isomers are
contemplated in the present invention. Cis and trans geometric
isomers of the compounds of the present invention are described and
may be isolated as a mixture of isomers or as separated isomeric
forms.
[0290] Resolution of racemic mixtures of compounds can be carried
out by any of numerous methods known in the art. One method
includes fractional recrystallization using a chiral resolving acid
which is an optically active, salt-forming organic acid. Suitable
resolving agents for fractional recrystallization methods are,
e.g., optically active acids, such as the D and L forms of tartaric
acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid,
malic acid, lactic acid or the various optically active
camphorsulfonic acids such as 3-camphorsulfonic acid. Other
resolving agents suitable for fractional crystallization methods
include stereoisomerically pure forms of .alpha.-methylbenzylamine
(e.g., S and R forms, or diastereomerically pure forms),
2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine,
cyclohexylethylamine, 1,2-diaminocyclohexane and the like.
[0291] Resolution of racemic mixtures can also be carried out by
elution on a column packed with an optically active resolving agent
(e.g., dinitrobenzoylphenylglycine). Suitable elution solvent
composition can be determined by one skilled in the art.
[0292] In some embodiments, the compounds of the invention have the
(R)-configuration. In other embodiments, the compounds have the
(S)-configuration. In compounds with more than one chiral centers,
each of the chiral centers in the compound may be independently (R)
or (S), unless otherwise indicated.
[0293] Compounds of the invention also include tautomeric forms.
Tautomeric forms result from the swapping of a single bond with an
adjacent double bond together with the concomitant migration of a
proton. Tautomeric forms include prototropic tautomers which are
isomeric protonation states having the same empirical formula and
total charge. Example prototropic tautomers include ketone-enol
pairs, amide-imidic acid pairs, lactam-lactim pairs, enamine-imine
pairs, and annular forms where a proton can occupy two or more
positions of a heterocyclic system, e.g., 1H- and 3H-imidazole,
1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole and 1H- and
2H-pyrazole. Tautomeric forms can be in equilibrium or sterically
locked into one form by appropriate substitution.
[0294] Compounds of the invention can also include all isotopes of
atoms occurring in the intermediates or final compounds. Isotopes
include those atoms having the same atomic number but different
mass numbers. For example, isotopes of hydrogen include tritium and
deuterium. One or more constituent atoms of the compounds of the
invention can be replaced or substituted with isotopes of the atoms
in natural or non-natural abundance. In some embodiments, the
compound includes at least one deuterium atom. For example, one or
more hydrogen atoms in a compound of the present disclosure can be
replaced or substituted by deuterium. In some embodiments, the
compound includes two or more deuterium atoms. In some embodiments,
the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12
deuterium atoms. Synthetic methods for including isotopes into
organic compounds are known in the art (Deuterium Labeling in
Organic Chemistry by Alan F. Thomas (New York, N.Y.,
Appleton-Century-Crofts, 1971; The Renaissance of H/D Exchange by
Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann,
Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of
Isotopic Labelling by James R. Hanson, Royal Society of Chemistry,
2011). Isotopically labeled compounds can used in various studies
such as NMR spectroscopy, metabolism experiments, and/or
assays.
[0295] Substitution with heavier isotopes such as deuterium, may
afford certain therapeutic advantages resulting from greater
metabolic stability, for example, increased in vivo half-life or
reduced dosage requirements, and hence may be preferred in some
circumstances. (A. Kerekes et. al. J. Med. Chem. 2011, 54, 201-210;
R. Xu et. al. J. Label Compd. Radiopharm. 2015, 58, 308-312).
[0296] The term, "compound," as used herein is meant to include all
stereoisomers, geometric isomers, tautomers and isotopes of the
structures depicted. The term is also meant to refer to compounds
of the inventions, regardless of how they are prepared, e.g.,
synthetically, through biological process (e.g., metabolism or
enzyme conversion), or a combination thereof.
[0297] All compounds, and pharmaceutically acceptable salts
thereof, can be found together with other substances such as water
and solvents (e.g., hydrates and solvates) or can be isolated. When
in the solid state, the compounds described herein and salts
thereof may occur in various forms and may, e.g., take the form of
solvates, including hydrates. The compounds may be in any solid
state form, such as a polymorph or solvate, so unless clearly
indicated otherwise, reference in the specification to compounds
and salts thereof should be understood as encompassing any solid
state form of the compound.
[0298] In some embodiments, the compounds of the invention, or
salts thereof, are substantially isolated. By "substantially
isolated" is meant that the compound is at least partially or
substantially separated from the environment in which it was formed
or detected. Partial separation can include, e.g., a composition
enriched in the compounds of the invention. Substantial separation
can include compositions containing at least about 50%, at least
about 60%, at least about 70%, at least about 80%, at least about
90%, at least about 95%, at least about 97%, or at least about 99%
by weight of the compounds of the invention, or salt thereof.
[0299] The phrase "pharmaceutically acceptable" is employed herein
to refer to those compounds, materials, compositions and/or dosage
forms which are, within the scope of sound medical judgment,
suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response,
or other problem or complication, commensurate with a reasonable
benefit/risk ratio.
[0300] The expressions, "ambient temperature" and "room
temperature," as used herein, are understood in the art, and refer
generally to a temperature, e.g., a reaction temperature, that is
about the temperature of the room in which the reaction is carried
out, e.g., a temperature from about 20.degree. C. to about
30.degree. C.
[0301] The present invention also includes pharmaceutically
acceptable salts of the compounds described herein. The term
"pharmaceutically acceptable salts" refers to derivatives of the
disclosed compounds wherein the parent compound is modified by
converting an existing acid or base moiety to its salt form.
Examples of pharmaceutically acceptable salts include, but are not
limited to, mineral or organic acid salts of basic residues such as
amines; alkali or organic salts of acidic residues such as
carboxylic acids; and the like. The pharmaceutically acceptable
salts of the present invention include the non-toxic salts of the
parent compound formed, e.g., from non-toxic inorganic or organic
acids. The pharmaceutically acceptable salts of the present
invention can be synthesized from the parent compound which
contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or
base forms of these compounds with a stoichiometric amount of the
appropriate base or acid in water or in an organic solvent, or in a
mixture of the two; generally, non-aqueous media like ether, ethyl
acetate, alcohols (e.g., methanol, ethanol, iso-propanol or
butanol) or acetonitrile (MeCN) are preferred. Lists of suitable
salts are found in Remington's Pharmaceutical Sciences, 17.sup.th
Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et
al., J. Pharm. Sci., 1977, 66(1), 1-19 and in Stahl et al.,
Handbook of Pharmaceutical Salts: Properties, Selection, and Use,
(Wiley, 2002). In some embodiments, the compounds described herein
include the N-oxide forms.
Synthesis
[0302] Compounds of the invention, including salts thereof, can be
prepared using known organic synthesis techniques and can be
synthesized according to any of numerous possible synthetic routes,
such as those in the Schemes below.
[0303] The reactions for preparing compounds of the invention can
be carried out in suitable solvents which can be readily selected
by one of skill in the art of organic synthesis. Suitable solvents
can be substantially non-reactive with the starting materials
(reactants), the intermediates or products at the temperatures at
which the reactions are carried out, e.g., temperatures which can
range from the solvent's freezing temperature to the solvent's
boiling temperature. A given reaction can be carried out in one
solvent or a mixture of more than one solvent. Depending on the
particular reaction step, suitable solvents for a particular
reaction step can be selected by the skilled artisan.
[0304] Preparation of compounds of the invention can involve the
protection and deprotection of various chemical groups. The need
for protection and deprotection, and the selection of appropriate
protecting groups, can be readily determined by one skilled in the
art. The chemistry of protecting groups is described, e.g., in
Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting
Group Chemistry, (Oxford University Press, 2000); Smith et al.,
March's Advanced Organic Chemistry: Reactions, Mechanisms, and
Structure, 6.sup.th Ed. (Wiley, 2007); Peturssion et al.,
"Protecting Groups in Carbohydrate Chemistry," J. Chem. Educ.,
1997, 74(11), 1297; and Wuts et al., Protective Groups in Organic
Synthesis, 4th Ed., (Wiley, 2006).
[0305] Reactions can be monitored according to any suitable method
known in the art. For example, product formation can be monitored
by spectroscopic means, such as nuclear magnetic resonance
spectroscopy (e.g., .sup.1H or .sup.13C), infrared spectroscopy,
spectrophotometry (e.g., UV-visible), mass spectrometry or by
chromatographic methods such as high performance liquid
chromatography (HPLC) or thin layer chromatography (TLC).
[0306] The Schemes below provide general guidance in connection
with preparing the compounds of the invention. One skilled in the
art would understand that the preparations shown in the Schemes can
be modified or optimized using general knowledge of organic
chemistry to prepare various compounds of the invention.
[0307] Compounds of Formula (I) can be prepared, e.g., using a
process as illustrated in the schemes below. Compounds of Formula
(I) with a various substitutions at position R.sup.1 such as those
described herein can be prepared, using a process as illustrated in
Scheme 1. In the process depicted in Scheme 1, the halo substituent
in compounds of Formula 1-1 can be converted into Cy.sup.A via a
number of different cross-coupling reactions, including Suzuki
(e.g., in the presence of a palladium catalyst, such as Xphos Pd
G2, and a base, such as potassium phosphate), Negishi and Stille
(e.g., in the presence of a palladium(0) catalyst, such as
tetrakis(triphenylphosphine)palladium(0)), Cu-catalyzed amination
(e.g., in the presence of Cu catalyst and a ligand, such as CuI and
phenanthroline, and a base, such as cesium carbonate or potassium
carbonate), and others, to give compounds of Formula 1-2. These
compounds can be further halogenated with a halogenation agent
(e.g., NIS or iodine) to form compounds of Formula 1-3. The halogen
substituent in the compounds of Formula 1-3 can be converted into
R.sup.1 via a number of different cross-coupling reactions,
including Stille (ACS Catalysis 2015, 5, 3040-3053) Suzuki
(Tetrahedron 2002, 58, 9633-9695), Sonogashira (Chem. Soc. Rev.
2011, 40, 5084-5121), Negishi (ACS Catalysis 2016, 6, 1540-1552),
Buchwald-Hartwig amination (Chem. Sci. 2011, 2, 27-50),
Cu-catalyzed amination (Org. React. 2014, 85, 1-688) and others, to
give the desired compounds of Formula (I).
##STR00008##
[0308] Alternatively, for the exploration of the substitution at
position Cy.sup.A, compounds of Formula (I) can be prepared, using
a process as illustrated in Scheme 2. Iodination of the compounds
of Formula 1-1 with an iodination agent, such as iodine or NIS,
forms compounds of Formula 2-2. The iodo substituent in the
compounds of Formula 2-2 can be converted into R.sup.1 via a number
of different cross-coupling reactions, including Suzuki,
Sonogashira, Negishi, Buchwald-Hartwig amination, Cu-catalyzed
amination and others, to give the compounds of Formula 2-3. The
chloro substituent in the compounds of Formula 2-3 can be further
converted into Cy.sup.A via a number of different cross-coupling
reactions, including Suzuki, Stille, Negishi, Cu-catalyzed
amination and others, to give the desired compounds of Formula
(I).
##STR00009##
[0309] Compounds of Formula (Ia) (compounds of Formula I wherein
R.sup.1 is NR.sup.cC(O)R.sup.b) can be prepared, using a process as
illustrated in Scheme 3. In the process depicted in Scheme 3,
compounds of Formula 3-1 react which hydroxylamine hydrochloride to
form oxime intermediates, which are further converted to compounds
of Formula 3-2 under the standard conditions (e.g. under treatment
with cyanuric chloride). Cyclization upon treatment of the
compounds of Formula 3-2 with hydrazine hydrate results in
compounds of Formula 3-3. The NH group of the pyrazole ring of the
compounds of Formula 3-3 is protected with a suitable protecting
group (e.g., Boc) to form compounds of Formula 3-4. The halo
substituent in the compounds of Formula 3-4 can be further
converted into Cy.sup.A via a number of different cross-coupling
reactions, including Suzuki, Stille, Negishi, Cu-catalyzed
amination, and others, to give the compounds of Formula 3-5.
Compounds of Formula 3-5 react with different acid chlorides in a
presence of base, such as triethylamine or DIPEA, to form compounds
of Formula 3-6. Finally, deprotection of the protecting group, e.g.
under acidic conditions, such as treatment with HCl or TFA, results
in the formation of the desired compounds of Formula (Ia).
Alternatively compounds of Formula 3-6 can be alkylated or arylated
and then deprotected to prepare amides wherein R.sup.c is other
than hydrogen.
##STR00010##
[0310] Compounds of Formula (Ib) (compounds of Formula I wherein
R.sup.1 is C(O)NR.sup.cR.sup.d) can be prepared, using a process as
illustrated in Scheme 4. In the process depicted in Scheme 4,
compounds of Formula 4-2 are formed after protection of the NH
group of the compounds of Formula 1-3 with a suitable protecting
group (e.g. SEM or Boc). The compounds of Formula 4-2 are converted
into compounds of Formula 4-3 under Pd-catalyzed carbonylation
conditions, such as in a presence of Pd catalyst (e.g.,
Pd(dppf)Cl.sub.2*DCM) and base (e.g., triethylamine) under carbon
monoxide atmosphere. Hydrolysis of the ester group under basic
conditions, such as LiOH or NaOH, forms the compounds of Formula
4-4. Compounds of the Formula 4-4 can be coupled to an amine,
HNR.sup.cR.sup.d, using standard amide coupling agents (e.g., HBTU,
HATU or EDC) to give compounds of Formula 4-5. Finally,
deprotection of the protecting group, e.g. under acidic conditions,
such as treatment with HCl or TFA, results in the formation of the
desired compounds of Formula (Ib).
##STR00011##
[0311] Compounds of Formula (I) with various substitutions at
position R.sup.2 such as those described herein can be prepared,
using a process as illustrated in Scheme 5. In the process depicted
in Scheme 5, bromination of 5-chloro-2-methylpyridin-3-amine 5-1
with a brominating agent (e.g., bromine or NBS) forms compounds of
Formula 5-2. Acylation of the NH.sub.2 group in the compounds of
Formula 5-2 with acylating agents (e.g., Ac.sub.2O or AcCl)
followed by the treatment with amyl nitrite forms compounds of
Formula 5-3. These compounds can be further iodinated with an
iodinating agent (e.g., NIS or iodine) to form compounds of Formula
5-4. The NH group of the pyrazole ring in the compounds of Formula
5-4 is protected with a suitable protecting group, such as Boc or
SEM, to form compounds of Formula 5-5. The iodo substituent in the
compounds of Formula 5-5 can be converted into R via a number of
different cross-coupling reactions, including Suzuki, Stille,
Negishi, Cu-catalyzed amination, and others, to give the compounds
of Formula 5-6. The bromo substituent in the compounds of Formula
5-6 can be further converted into Cy.sup.A via a number of
different cross-coupling reactions, including Suzuki, Stille,
Negishi, and others, to give the compounds of Formula 5-7. The
chloro substituent in the compounds of Formula 5-7 can be further
converted into R.sup.2 via a number of different cross-coupling
reactions, including Suzuki, Stille, Negishi, and others, to give
the compounds of Formula 5-8. Finally, deprotection of the
protecting group, e.g. under acidic conditions, such as treatment
with HCl or TFA, results in the formation of the desired compounds
of Formula (I).
##STR00012##
[0312] Compounds of Formula (Ic) with the cyano group at position
R.sup.2 such as those described herein can be prepared, using a
process as illustrated in Scheme 6. In the process depicted in
Scheme 6, protection of 6-bromo-1H-pyrazolo[4,3-b]pyridine 6-1 with
a suitable protecting group (e.g., trityl, SEM, boc and others)
forms compounds of Formula 6-2. Treating the compounds of Formula
6-2 with m-CPBA forms compounds of Formula 6-3 which could be
further converted into compounds of Formula 6-4 via Pd-catalyzed
cyanation. Upon treating with base (eg. Et.sub.3N or
.sup.1Pr.sub.2EtN) and oxalyl dichloride, the compounds of Formula
6-4 are converted into compounds of Formula 6-5. The chloro
substituent in the compounds of Formula 6-5 can be converted into
Cy.sup.A via a number of different cross-coupling reactions,
including Suzuki, Stille, Negishi, and others, to give the
compounds of Formula 6-6. Removal of the protecting group in the
compounds of Formula 6-6 (e.g. under acidic conditions, such as
treatment with HCl or TFA) gives compounds of Formula 6-7. These
compounds can be further halogenated with one of the halogenation
agents (e.g., NIS or iodine) to form compounds of formula 6-8. Upon
protection with a suitable protecting group (e.g., Boc, SEM and
others), the compounds of Formula 6-8 are converted into compounds
of Formula 6-9. The iodo substituent in the compounds of Formula
6-9 can be further converted into R.sup.1 via a number of different
cross-coupling reactions, including Suzuki, Stille, Sonogashira,
Negishi, Buchwald-Hartwig amination, Cu-catalyzed amination and
others, to give the compounds of Formula 6-10. Finally,
deprotection of the protecting group, e.g. under acidic conditions,
such as treatment with HCl or TFA, results in the formation of the
desired compounds of Formula (Ic).
##STR00013##
HPK1 Kinase
[0313] Extensive studies have established that HPK1 is a negative
regulator of T cell and B cell activation (Hu, M. C., et al., Genes
Dev, 1996. 10(18): p. 2251-64; Kiefer, F., et al., EMBO J, 1996.
15(24): p. 7013-25). HPK1-deficient mouse T cells showed
dramatically increased activation of TCR proximal signaling,
enhanced IL-2 production, and hyper-proliferation in vitro upon
anti-CD3 stimulation (Shui, J. W., et al., Nat Immunol, 2007. 8(1):
p. 84-91). Similar to T cells, HPK1 knockout B cells produced much
higher levels of IgM and IgG isoforms after KLH immunization and
displayed hyper-proliferation potentially as a result of enhanced
BCR signaling. Wang, X., et al., J Biol Chem, 2012. 287(14): p.
11037-48. Mechanistically, during TCR or BCR signaling, HPK1 is
activated by LCK/ZAP70 (T cells) or SYK/LYN (B cells)
mediated-Tyr379 phosphorylation and its subsequent binding to
adaptor protein SLP-76 (T cells) or BLNK (B cells) (Wang, X., et
al., J Biol Chem, 2012. 287(14): p. 11037-48). Activated HPK1
phosphorylates SLP-76 on Ser376 or BLNK on Thr152, leading to the
recruitment of signaling molecule 14-3-3 and ultimate
ubiquitination-mediated degradation of SLP-76 or BLNK (Liou, J., et
al., Immunity, 2000. 12(4): p. 399-408; Di Bartolo, V., et al., J
Exp Med, 2007. 204(3): p. 681-91). As SLP-76 and BLNK are essential
for TCR/BCR-mediated signaling activation (e.g. ERK, phospholipase
C.gamma.1, calcium flux, and NFAT activation), HPK1-mediated
downregulation of these adaptor proteins provide a negative
feedback mechanism to attenuate signaling intensity during T cell
or B cell activation (Wang, X., et al., J Biol Chem, 2012. 287(14):
p. 11037-48).
[0314] The bone marrow-derived dendritic cells (BDMCs) from HPK1
knockout mice showed higher expression of co-stimulatory molecules
(e.g. CD80/CD86) and enhanced production of proinflammatory
cytokines (IL-12, TNF-.alpha.t etc), and demonstrated superior
ability to stimulate T cell proliferation in vitro and in vivo as
compared to wild-type DCs (Alzabin, S., et al., J Immunol, 2009.
182(10): p. 6187-94). These data suggest that HPK1 is also an
important negative regulator of dendritic cell activation (Alzabin,
S., et al., J Immunol, 2009. 182(10): p. 6187-94). However, the
signaling mechanisms underlying HPK-1 mediated negative regulation
of DC activation remains to be elucidated.
[0315] In contrast, HPK1 appears to be a positive regulator of
suppressive functions of regulatory T cells (Treg) (Sawasdikosol,
S. et al., The journal of immunology, 2012. 188 (supplement 1): p.
163). HPK1 deficient mouse Foxp3+Tregs were defective in
suppressing TCR-induced effector T cell proliferation, and
paradoxically gained the ability to produce IL-2 following TCR
engagement (Sawasdikosol, S. et al., The Journal of Immunology,
2012. 188 (supplement 1): p. 163). These data suggest that HPK1 is
an important regulator of Treg functions and peripheral
self-tolerance.
[0316] HPK1 was also involved in PGE2-mediated inhibition of CD4+ T
cell activation (Ikegami, R., et al., J Immunol, 2001. 166(7): p.
4689-96). Studies published in US 2007/0087988 indicated that HPK1
kinase activity was increased by exposure to physiological
concentrations of PGE2 in CD4+ T cells and this effect was mediated
by PEG2-induced PKA activation. The proliferation of HPK1 deficient
T cells was resistant to the suppressive effects of PGE2 (see US
2007/0087988). Therefore, PGE2-mediated activation of HPK1 may
represent a novel regulatory pathway of modulating immune
response.
Uses of the Compounds
[0317] The present disclosure provides methods of modulating (e.g.,
inhibiting) HPK1 activity, said method comprising administering to
a patient a compound provided herein, or a pharmaceutically
acceptable salt thereof. In certain embodiments, the compounds of
the present disclosure, or pharmaceutically acceptable salts
thereof, are useful for therapeutic administration to enhance,
stimulate and/or increase immunity in cancer. For example, a method
of treating a disease or disorder associated with inhibition of
HPK1 interaction can include administering to a patient in need
thereof a therapeutically effective amount of a compound provided
herein, or a pharmaceutically acceptable salt thereof. The
compounds of the present disclosure can be used alone, in
combination with other agents or therapies or as an adjuvant or
neoadjuvant for the treatment of diseases or disorders, including
cancers. For the uses described herein, any of the compounds of the
disclosure, including any of the embodiments thereof, may be
used.
[0318] Examples of cancers that are treatable using the compounds
of the present disclosure include, but are not limited to, bone
cancer, pancreatic cancer, skin cancer, cancer of the head or neck,
cutaneous or intraocular malignant melanoma, uterine cancer,
ovarian cancer, rectal cancer, cancer of the anal region, stomach
cancer, testicular cancer, uterine cancer, carcinoma of the
fallopian tubes, carcinoma of the endometrium, endometrial cancer,
carcinoma of the cervix, carcinoma of the vagina, carcinoma of the
vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the
esophagus, cancer of the small intestine, cancer of the endocrine
system, cancer of the thyroid gland, cancer of the parathyroid
gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer
of the urethra, cancer of the penis, chronic or acute leukemias
including acute myeloid leukemia, chronic myeloid leukemia, acute
lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors
of childhood, lymphocytic lymphoma, cancer of the bladder, cancer
of the kidney or urethra, carcinoma of the renal pelvis, neoplasm
of the central nervous system (CNS), primary CNS lymphoma, tumor
angiogenesis, spinal axis tumor, brain stem glioma, pituitary
adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer,
T-cell lymphoma, environmentally induced cancers including those
induced by asbestos, and combinations of said cancers.
[0319] In some embodiments, cancers treatable with compounds of the
present disclosure include melanoma (e.g., metastatic malignant
melanoma), renal cancer (e.g. clear cell carcinoma), prostate
cancer (e.g. hormone refractory prostate adenocarcinoma), breast
cancer, triple-negative breast cancer, colon cancer and lung cancer
(e.g. non-small cell lung cancer and small cell lung cancer).
Additionally, the disclosure includes refractory or recurrent
malignancies whose growth may be inhibited using the compounds of
the disclosure.
[0320] In some embodiments, cancers that are treatable using the
compounds of the present disclosure include, but are not limited
to, solid tumors (e.g., prostate cancer, colon cancer, esophageal
cancer, endometrial cancer, ovarian cancer, uterine cancer, renal
cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast
cancer, lung cancer, cancers of the head and neck, thyroid cancer,
glioblastoma, sarcoma, bladder cancer, etc.), hematological cancers
(e.g., lymphoma, leukemia such as acute lymphoblastic leukemia
(ALL), acute myelogenous leukemia (AML), chronic lymphocytic
leukemia (CLL), chronic myelogenous leukemia (CML), DLBCL, mantle
cell lymphoma, Non-Hodgkin lymphoma (including relapsed or
refractory NHL and recurrent follicular), Hodgkin lymphoma or
multiple myeloma) and combinations of said cancers.
[0321] In some embodiments, diseases and indications that are
treatable using the compounds of the present disclosure include,
but are not limited to hematological cancers, sarcomas, lung
cancers, gastrointestinal cancers, genitourinary tract cancers,
liver cancers, bone cancers, nervous system cancers, gynecological
cancers, and skin cancers.
[0322] Exemplary hematological cancers include lymphomas and
leukemias such as acute lymphoblastic leukemia (ALL), acute
myelogenous leukemia (AML), acute promyelocytic leukemia (APL),
chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia
(CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma,
Non-Hodgkin lymphoma (including relapsed or refractory NHL and
recurrent follicular), Hodgkin lymphoma, myeloproliferative
diseases (e.g., primary myelofibrosis (PMF), polycythemia vera
(PV), essential thrombocytosis (ET)), myelodysplasia syndrome
(MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple
myeloma, cutaneous T-cell lymphoma, Waldenstrom's
Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma
and Burkitt's lymphoma.
[0323] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma,
osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma,
liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma,
harmatoma, and teratoma.
[0324] Exemplary lung cancers include non-small cell lung cancer
(NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous
cell, undifferentiated small cell, undifferentiated large cell,
adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
adenoma, chondromatous hamartoma, and mesothelioma.
[0325] Exemplary gastrointestinal cancers include cancers of the
esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma,
lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas
(ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma,
carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma,
carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma,
neurofibroma, fibroma), large bowel (adenocarcinoma, tubular
adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal
cancer.
[0326] Exemplary genitourinary tract cancers include cancers of the
kidney (adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and
urethra (squamous cell carcinoma, transitional cell carcinoma,
adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis
(seminoma, teratoma, embryonal carcinoma, teratocarcinoma,
choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma,
fibroadenoma, adenomatoid tumors, lipoma).
[0327] Exemplary liver cancers include hepatoma (hepatocellular
carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma,
hepatocellular adenoma, and hemangioma.
[0328] Exemplary bone cancers include, for example, osteogenic
sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous
histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma
(reticulum cell sarcoma), multiple myeloma, malignant giant cell
tumor chordoma, osteochronfroma (osteocartilaginous exostoses),
benign chondroma, chondroblastoma, chondromyxofibroma, osteoid
osteoma, and giant cell tumors
[0329] Exemplary nervous system cancers include cancers of the
skull (osteoma, hemangioma, granuloma, xanthoma, osteitis
deformans), meninges (meningioma, meningiosarcoma, gliomatosis),
brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma
(pinealoma), glioblastoma, glioblastoma multiform,
oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),
and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as
well as neuroblastoma and Lhermitte-Duclos disease.
[0330] Exemplary gynecological cancers include cancers of the
uterus (endometrial carcinoma), cervix (cervical carcinoma,
pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous
cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified
carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell
tumors, dysgerminoma, malignant teratoma), vulva (squamous cell
carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma,
melanoma), vagina (clear cell carcinoma, squamous cell carcinoma,
botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes
(carcinoma).
[0331] Exemplary skin cancers include melanoma, basal cell
carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell
skin cancer, moles dysplastic nevi, lipoma, angioma,
dermatofibroma, and keloids. In some embodiments, diseases and
indications that are treatable using the compounds of the present
disclosure include, but are not limited to, sickle cell disease
(e.g., sickle cell anemia), triple-negative breast cancer (TNBC),
myelodysplastic syndromes, testicular cancer, bile duct cancer,
esophageal cancer, and urothelial carcinoma.
[0332] Exemplary head and neck cancers include glioblastoma,
melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell
carcinomas, adenocarcinomas, oral cancer, laryngeal cancer,
nasopharyngeal cancer, nasal and paranasal cancers, thyroid and
parathyroid cancers.
[0333] In some embodiments, HPK1 inhibitors may be used to treat
tumors producing PGE2 (e.g. Cox-2 overexpressing tumors) and/or
adenosine (CD73 and CD39 over-expressing tumors). Overexpression of
Cox-2 has been detected in a number of tumors, such as colorectal,
breast, pancreatic and lung cancers, where it correlates with a
poor prognosis. Overexpression of COX-2 has been reported in
hematological cancer models such as RAJI (Burkitt's lymphoma) and
U937 (acute promonocytic leukemia) as well as in patient's blast
cells. CD73 is up-regulated in various human carcinomas including
those of colon, lung, pancreas and ovary. Importantly, higher
expression levels of CD73 are associated with tumor
neovascularization, invasiveness, and metastasis and with shorter
patient survival time in breast cancer.
[0334] The terms "individual" or "patient," used interchangeably,
refer to any animal, including mammals, preferably mice, rats,
other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses,
or primates, and most preferably humans.
[0335] The phrase "therapeutically effective amount" refers to the
amount of active compound or pharmaceutical agent that elicits the
biological or medicinal response in a tissue, system, animal,
individual or human that is being sought by a researcher,
veterinarian, medical doctor or other clinician.
[0336] As used herein, the term "treating" or "treatment" refers to
one or more of (1) inhibiting the disease; e.g., inhibiting a
disease, condition or disorder in an individual who is experiencing
or displaying the pathology or symptomatology of the disease,
condition or disorder (i.e., arresting further development of the
pathology and/or symptomatology); and (2) ameliorating the disease;
e.g., ameliorating a disease, condition or disorder in an
individual who is experiencing or displaying the pathology or
symptomatology of the disease, condition or disorder (i.e.,
reversing the pathology and/or symptomatology) such as decreasing
the severity of disease.
[0337] In some embodiments, the compounds of the invention are
useful in preventing or reducing the risk of developing any of the
diseases referred to herein; e.g., preventing or reducing the risk
of developing a disease, condition or disorder in an individual who
may be predisposed to the disease, condition or disorder but does
not yet experience or display the pathology or symptomatology of
the disease.
Combination Therapies
[0338] Cancer cell growth and survival can be impacted by multiple
signaling pathways. Thus, it is useful to combine different
enzyme/protein/receptor inhibitors, exhibiting different
preferences in the targets which they modulate the activities of,
to treat such conditions. Examples of agents that may be combined
with compounds of the present disclosure include inhibitors of the
PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway,
inhibitors of JAK-STAT pathway, inhibitors of beta catenin pathway,
inhibitors of notch pathway, inhibitors of hedgehog pathway,
inhibitors of Pim kinases, and inhibitors of protein chaperones and
cell cycle progression. Targeting more than one signaling pathway
(or more than one biological molecule involved in a given signaling
pathway) may reduce the likelihood of drug-resistance arising in a
cell population, and/or reduce the toxicity of treatment.
[0339] The compounds of the present disclosure can be used in
combination with one or more other enzyme/protein/receptor
inhibitors for the treatment of diseases, such as cancer. Examples
of cancers include solid tumors and liquid tumors, such as blood
cancers. For example, the compounds of the present disclosure can
be combined with one or more inhibitors of the following kinases
for the treatment of cancer: Akt1, Akt2, Akt3, TGF-.beta.R, PKA,
PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR,
EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGF.alpha.R,
PDGF.beta.R, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, fit-1, FGFR1,
FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3,
VEGFR/Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src,
Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In some
embodiments, the compounds of the present disclosure can be
combined with one or more of the following inhibitors for the
treatment of cancer. Non-limiting examples of inhibitors that can
be combined with the compounds of the present disclosure for
treatment of cancers include an FGFR inhibitor (FGFR1, FGFR2, FGFR3
or FGFR4, e.g., AZD4547, BAY1187982, ARQ087, BGJ398, BIBF1120,
TKI258, lucitanib, dovitinib, TAS-120, JNJ-42756493, Debio1347,
INCB54828, INCB62079 and INCB63904), a JAK inhibitor (JAK1 and/or
JAK2, e.g., ruxolitinib, baricitinib or INCB39110), an IDO
inhibitor (e.g., epacadostat and NLG919), an LSD1 inhibitor (e.g.,
GSK2979552, INCB59872 and INCB60003), a TDO inhibitor, a PI3K-delta
inhibitor (e.g., INCB50797 and INCB50465), a PI3K-gamma inhibitor
such as a PI3K-gamma selective inhibitor, a CSF1R inhibitor (e.g.,
PLX3397 and LY3022855), a TAM receptor tyrosine kinases (Tyro-3,
Ax1, and Mer), an angiogenesis inhibitor, an interleukin receptor
inhibitor, bromo and extra terminal family members inhibitors (for
example, bromodomain inhibitors or BET inhibitors such as OTX015,
CPI-0610, INCB54329 and INCB57643) and an adenosine receptor
antagonist or combinations thereof. Inhibitors of HDAC such as
panobinostat and vorinostat. Inhibitors of c-Met such as
onartumzumab, tivantnib, and INC-280. Inhibitors of BTK such as
ibrutinib. Inhibitors of mTOR such as rapamycin, sirolimus,
temsirolimus, and everolimus. Inhibitors of Raf, such as
vemurafenib and dabrafenib. Inhibitors of MEK such as trametinib,
selumetinib and GDC-0973. Inhibitors of Hsp90 (e.g., tanespimycin),
cyclin dependent kinases (e.g., palbociclib), PARP (e.g., olaparib)
and Pim kinases (LGH447, INCB053914 and SGI-1776) can also be
combined with compounds of the present disclosure.
[0340] Compounds of the present disclosure can be used in
combination with one or more immune checkpoint inhibitors.
Exemplary immune checkpoint inhibitors include inhibitors against
immune checkpoint molecules such as CD20, CD27, CD28, CD39, CD40,
CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K
gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR,
B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1 and
PD-L2. In some embodiments, the immune checkpoint molecule is a
stimulatory checkpoint molecule selected from CD27, CD28, CD40,
ICOS, OX40, GITR and CD137. In some embodiments, the immune
checkpoint molecule is an inhibitory checkpoint molecule selected
from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3,
and VISTA. In some embodiments, the compounds provided herein can
be used in combination with one or more agents selected from KIR
inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors,
2B4 inhibitors and TGFR beta inhibitors.
[0341] In some embodiments, the inhibitor of an immune checkpoint
molecule is anti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4
antibody.
[0342] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal
antibody. In some embodiments, the anti-PD-1 monoclonal antibody is
nivolumab, pembrolizumab (also known as MK-3475), pidilizumab,
SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1
monoclonal antibody is nivolumab or pembrolizumab. In some
embodiments, the anti-PD1 antibody is pembrolizumab. In some
embodiments, the anti PD-1 antibody is SHR-1210.
[0343] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal
antibody. In some embodiments, the anti-PD-L1 monoclonal antibody
is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or
MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal
antibody is MPDL3280A or MEDI4736.
[0344] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
In some embodiments, the anti-CTLA-4 antibody is ipilimumab.
[0345] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of CSF1R, e.g., an anti-CSF1R antibody. In
some embodiments, the anti-CSF1R antibody is IMC-CS4 or RG7155.
[0346] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In
some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525,
IMP321 or GSK2831781.
[0347] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In
some embodiments, the anti-GITR antibody is TRX518, MK-4166,
MK1248, BMS-986156, MEDI1873 or GWN323.
[0348] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or
OX40L fusion protein. In some embodiments, the anti-OX40 antibody
is MEDI0562, MEDI6469, MOXR0916, PF-04518600 or GSK3174998. In some
embodiments, the OX40L fusion protein is MEDI6383.
[0349] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of TIM3, e.g., an anti-TIM3 antibody. In
some embodiments, the anti-TIM3 antibody is MBG-453.
[0350] In some embodiments, the inhibitor of an immune checkpoint
molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody. In
some embodiments, the anti-CD20 antibody is obinutuzumab or
rituximab.
[0351] In some embodiments, the compounds of the invention can be
used in combination with one or more metabolic enzyme inhibitors.
In some embodiments, the metabolic enzyme inhibitor is an inhibitor
of IDO1, TDO, or arginase. Examples of IDO1 inhibitors include
epacadostat and NGL919. An example of an arginase inhibitor is
CB-1158.
[0352] The compounds of the present disclosure can be used in
combination with bispecific antibodies. In some embodiments, one of
the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4,
GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGF.beta. receptor.
[0353] Compounds of the present disclosure can be used in
combination with one or more agents for the treatment of diseases
such as cancer. In some embodiments, the agent is an alkylating
agent, a proteasome inhibitor, a corticosteroid, or an
immunomodulatory agent. Examples of an alkylating agent include
bendamustine, nitrogen mustards, ethylenimine derivatives, alkyl
sulfonates, nitrosoureas and triazenes, uracil mustard,
chlormethine, cyclophosphamide (Cytoxan.TM.), ifosfamide,
melphalan, chlorambucil, pipobroman, triethylene-melamine,
triethylenethiophosphoramine, busulfan, carmustine, lomustine,
streptozocin, dacarbazine, and temozolomide. In some embodiments,
the proteasome inhibitor is carfilzomib. In some embodiments, the
corticosteroid is dexamethasone (DEX). In some embodiments, the
immunomodulatory agent is lenalidomide (LEN) or pomalidomide
(POM).
[0354] The compounds of the present disclosure can further be used
in combination with other methods of treating cancers, for example
by chemotherapy, irradiation therapy, tumor-targeted therapy,
adjuvant therapy, immunotherapy or surgery. Examples of
immunotherapy include cytokine treatment (e.g., interferons,
GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccine,
monoclonal antibody, adoptive T cell transfer, oncolytic
virotherapy and immunomodulating small molecules, including
thalidomide or JAK1/2 inhibitor and the like. The compounds can be
administered in combination with one or more anti-cancer drugs,
such as a chemotherapeutics. Example chemotherapeutics include any
of: abarelix, abiraterone, afatinib, aflibercept, aldesleukin,
alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole,
arsenic trioxide, asparaginase, axitinib, azacitidine, bevacizumab,
bexarotene, baricitinib, bicalutamide, bleomycin, bortezombi,
bortezomib, brivanib, buparlisib, busulfan intravenous, busulfan
oral, calusterone, capecitabine, carboplatin, carmustine,
cediranib, cetuximab, chlorambucil, cisplatin, cladribine,
clofarabine, crizotinib, cyclophosphamide, cytarabine, dacarbazine,
dacomitinib, dactinomycin, dalteparin sodium, dasatinib,
dactinomycin, daunorubicin, decitabine, degarelix, denileukin,
denileukin diftitox, deoxycoformycin, dexrazoxane, docetaxel,
doxorubicin, droloxafine, dromostanolone propionate, eculizumab,
enzalutamide, epidophyllotoxin, epirubicin, erlotinib,
estramustine, etoposide phosphate, etoposide, exemestane, fentanyl
citrate, filgrastim, floxuridine, fludarabine, fluorouracil,
flutamide, fulvestrant, gefitinib, gemcitabine, gemtuzumab
ozogamicin, goserelin acetate, histrelin acetate, ibritumomab
tiuxetan, idarubicin, idelalisib, ifosfamide, imatinib mesylate,
interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide,
letrozole, leucovorin, leuprolide acetate, levamisole, lomustine,
meclorethamine, megestrol acetate, melphalan, mercaptopurine,
methotrexate, methoxsalen, mithramycin, mitomycin C, mitotane,
mitoxantrone, nandrolone phenpropionate, navelbene, necitumumab,
nelarabine, neratinib, nilotinib, nilutamide, nofetumomab,
oserelin, oxaliplatin, paclitaxel, pamidronate, panitumumab,
pazopanib, pegaspargase, pegfilgrastim, pemetrexed disodium,
pentostatin, pilaralisib, pipobroman, plicamycin, ponatinib,
prednisone, procarbazine, quinacrine, rasburicase, regorafenib,
reloxafine, rituximab, ruxolitinib, sorafenib, streptozocin,
sunitinib, sunitinib maleate, tamoxifen, tegafur, temozolomide,
teniposide, testolactone, thalidomide, thioguanine, thiotepa,
topotecan, toremifene, tositumomab, trastuzumab, tretinoin,
triptorelin, uracil mustard, valrubicin, vandetanib, vinblastine,
vincristine, vinorelbine, vorinostat and zoledronate.
[0355] Other anti-cancer agent(s) include antibody therapeutics
such as trastuzumab (Herceptin), antibodies to costimulatory
molecules such as CTLA-4 (e.g., ipilimumab or tremelimumab), 4-1BB,
antibodies to PD-1 and PD-L1, or antibodies to cytokines (IL-10,
TGF-.beta., etc.). Examples of antibodies to PD-1 and/or PD-L1 that
can be combined with compounds of the present disclosure for the
treatment of cancer or infections such as viral, bacteria, fungus
and parasite infections include, but are not limited to, nivolumab,
pembrolizumab, MPDL3280A, MEDI-4736 and SHR-1210.
[0356] Other anti-cancer agents include inhibitors of kinases
associated cell proliferative disorder. These kinases include but
not limited to Aurora-A, CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9,
ephrin receptor kinases, CHK1, CHK2, SRC, Yes, Fyn, Lck, Fer, Fes,
Syk, Itk, Bmx, GSK3, JNK, PAK1, PAK2, PAK3, PAK4, PDK1, PKA, PKC,
Rsk and SGK.
[0357] Other anti-cancer agents also include those that block
immune cell migration such as antagonists to chemokine receptors,
including CCR2 and CCR4.
[0358] The compounds of the present disclosure can further be used
in combination with one or more anti-inflammatory agents, steroids,
immunosuppressants or therapeutic antibodies.
[0359] The compounds of Formula (I) or any of the formulas as
described herein, a compound as recited in any of the claims and
described herein, or salts thereof can be combined with another
immunogenic agent, such as cancerous cells, purified tumor antigens
(including recombinant proteins, peptides, and carbohydrate
molecules), cells, and cells transfected with genes encoding immune
stimulating cytokines. Non-limiting examples of tumor vaccines that
can be used include peptides of melanoma antigens, such as peptides
of gp100, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor
cells transfected to express the cytokine GM-CSF.
[0360] The compounds of Formula (I) or any of the formulas as
described herein, a compound as recited in any of the claims and
described herein, or salts thereof can be used in combination with
a vaccination protocol for the treatment of cancer. In some
embodiments, the tumor cells are transduced to express GM-CSF. In
some embodiments, tumor vaccines include the proteins from viruses
implicated in human cancers such as Human Papilloma Viruses (HPV),
Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus
(KHSV). In some embodiments, the compounds of the present
disclosure can be used in combination with tumor specific antigen
such as heat shock proteins isolated from tumor tissue itself. In
some embodiments, the compounds of Formula (I) or any of the
formulas as described herein, a compound as recited in any of the
claims and described herein, or salts thereof can be combined with
dendritic cells immunization to activate potent anti-tumor
responses.
[0361] The compounds of the present disclosure can be used in
combination with bispecific macrocyclic peptides that target Fe
alpha or Fe gamma receptor-expressing effectors cells to tumor
cells. The compounds of the present disclosure can also be combined
with macrocyclic peptides that activate host immune
responsiveness.
[0362] The compounds of the present disclosure can be used in
combination with bone marrow transplant for the treatment of a
variety of tumors of hematopoietic origin.
[0363] Suitable antiviral agents contemplated for use in
combination with the compounds of the present disclosure can
comprise nucleoside and nucleotide reverse transcriptase inhibitors
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs),
protease inhibitors and other antiviral drugs.
[0364] Example suitable NRTIs include zidovudine (AZT); didanosine
(ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC);
abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir
(BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L-FD4 (also
called beta-L-D4C and named
beta-L-2',3'-dicleoxy-5-fluoro-cytidene); DAPD,
((-)-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA).
Typical suitable NNRTIs include nevirapine (BI-RG-587);
delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721;
AG-1549; MKC-442
(1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimid-
inedione); and (+)-calanolide A (NSC-675451) and B. Typical
suitable protease inhibitors include saquinavir (Ro 31-8959);
ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343);
amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623;
ABT-378; and AG-1 549. Other antiviral agents include hydroxyurea,
ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.
11607.
[0365] When more than one pharmaceutical agent is administered to a
patient, they can be administered simultaneously, separately,
sequentially, or in combination (e.g., for more than two
agents).
Formulation, Dosage Forms and Administration
[0366] When employed as pharmaceuticals, the compounds of the
present disclosure can be administered in the form of
pharmaceutical compositions. Thus the present disclosure provides a
composition comprising a compound of Formula (I) or any of the
formulas as described herein, a compound as recited in any of the
claims and described herein, or a pharmaceutically acceptable salt
thereof, or any of the embodiments thereof, and at least one
pharmaceutically acceptable carrier or excipient. These
compositions can be prepared in a manner well known in the
pharmaceutical art, and can be administered by a variety of routes,
depending upon whether local or systemic treatment is indicated and
upon the area to be treated. Administration may be topical
(including transdermal, epidermal, ophthalmic and to mucous
membranes including intranasal, vaginal and rectal delivery),
pulmonary (e.g., by inhalation or insufflation of powders or
aerosols, including by nebulizer; intratracheal or intranasal),
oral or parenteral. Parenteral administration includes intravenous,
intraarterial, subcutaneous, intraperitoneal intramuscular or
injection or infusion; or intracranial, e.g., intrathecal or
intraventricular, administration. Parenteral administration can be
in the form of a single bolus dose, or may be, e.g., by a
continuous perfusion pump. Pharmaceutical compositions and
formulations for topical administration may include transdermal
patches, ointments, lotions, creams, gels, drops, suppositories,
sprays, liquids and powders. Conventional pharmaceutical carriers,
aqueous, powder or oily bases, thickeners and the like may be
necessary or desirable.
[0367] This invention also includes pharmaceutical compositions
which contain, as the active ingredient, the compound of the
present disclosure or a pharmaceutically acceptable salt thereof,
in combination with one or more pharmaceutically acceptable
carriers or excipients. In some embodiments, the composition is
suitable for topical administration. In making the compositions of
the invention, the active ingredient is typically mixed with an
excipient, diluted by an excipient or enclosed within such a
carrier in the form of, e.g., a capsule, sachet, paper, or other
container. When the excipient serves as a diluent, it can be a
solid, semi-solid, or liquid material, which acts as a vehicle,
carrier or medium for the active ingredient. Thus, the compositions
can be in the form of tablets, pills, powders, lozenges, sachets,
cachets, elixirs, suspensions, emulsions, solutions, syrups,
aerosols (as a solid or in a liquid medium), ointments containing,
e.g., up to 10% by weight of the active compound, soft and hard
gelatin capsules, suppositories, sterile injectable solutions and
sterile packaged powders.
[0368] In preparing a formulation, the active compound can be
milled to provide the appropriate particle size prior to combining
with the other ingredients. If the active compound is substantially
insoluble, it can be milled to a particle size of less than 200
mesh. If the active compound is substantially water soluble, the
particle size can be adjusted by milling to provide a substantially
uniform distribution in the formulation, e.g., about 40 mesh.
[0369] The compounds of the invention may be milled using known
milling procedures such as wet milling to obtain a particle size
appropriate for tablet formation and for other formulation types.
Finely divided (nanoparticulate) preparations of the compounds of
the invention can be prepared by processes known in the art see,
e.g., WO 2002/000196.
[0370] Some examples of suitable excipients include lactose,
dextrose, sucrose, sorbitol, mannitol, starches, gum acacia,
calcium phosphate, alginates, tragacanth, gelatin, calcium
silicate, microcrystalline cellulose, polyvinylpyrrolidone,
cellulose, water, syrup and methyl cellulose. The formulations can
additionally include: lubricating agents such as talc, magnesium
stearate and mineral oil; wetting agents; emulsifying and
suspending agents; preserving agents such as methyl- and
propylhydroxy-benzoates; sweetening agents; and flavoring agents.
The compositions of the invention can be formulated so as to
provide quick, sustained or delayed release of the active
ingredient after administration to the patient by employing
procedures known in the art.
[0371] In some embodiments, the pharmaceutical composition
comprises silicified microcrystalline cellulose (SMCC) and at least
one compound described herein, or a pharmaceutically acceptable
salt thereof. In some embodiments, the silicified microcrystalline
cellulose comprises about 98% microcrystalline cellulose and about
2% silicon dioxide w/w.
[0372] In some embodiments, the composition is a sustained release
composition comprising at least one compound described herein, or a
pharmaceutically acceptable salt thereof, and at least one
pharmaceutically acceptable carrier or excipient. In some
embodiments, the composition comprises at least one compound
described herein, or a pharmaceutically acceptable salt thereof,
and at least one component selected from microcrystalline
cellulose, lactose monohydrate, hydroxypropyl methylcellulose and
polyethylene oxide. In some embodiments, the composition comprises
at least one compound described herein, or a pharmaceutically
acceptable salt thereof, and microcrystalline cellulose, lactose
monohydrate and hydroxypropyl methylcellulose. In some embodiments,
the composition comprises at least one compound described herein,
or a pharmaceutically acceptable salt thereof, and microcrystalline
cellulose, lactose monohydrate and polyethylene oxide. In some
embodiments, the composition further comprises magnesium stearate
or silicon dioxide. In some embodiments, the microcrystalline
cellulose is Avicel PH102.TM.. In some embodiments, the lactose
monohydrate is Fast-flo 316.TM.. In some embodiments, the
hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208
K4M (e.g., Methocel K4 M Premier.TM.) and/or hydroxypropyl
methylcellulose 2208 K100LV (e.g., Methocel K00LV.TM.). In some
embodiments, the polyethylene oxide is polyethylene oxide WSR 1105
(e.g., Polyox WSR 1105.TM.).
[0373] In some embodiments, a wet granulation process is used to
produce the composition. In some embodiments, a dry granulation
process is used to produce the composition.
[0374] The compositions can be formulated in a unit dosage form,
each dosage containing from about 5 to about 1,000 mg (1 g), more
usually about 100 mg to about 500 mg, of the active ingredient. In
some embodiments, each dosage contains about 10 mg of the active
ingredient. In some embodiments, each dosage contains about 50 mg
of the active ingredient. In some embodiments, each dosage contains
about 25 mg of the active ingredient. The term "unit dosage forms"
refers to physically discrete units suitable as unitary dosages for
human subjects and other mammals, each unit containing a
predetermined quantity of active material calculated to produce the
desired therapeutic effect, in association with a suitable
pharmaceutical excipient.
[0375] The components used to formulate the pharmaceutical
compositions are of high purity and are substantially free of
potentially harmful contaminants (e.g., at least National Food
grade, generally at least analytical grade, and more typically at
least pharmaceutical grade). Particularly for human consumption,
the composition is preferably manufactured or formulated under Good
Manufacturing Practice standards as defined in the applicable
regulations of the U.S. Food and Drug Administration. For example,
suitable formulations may be sterile and/or substantially isotonic
and/or in full compliance with all Good Manufacturing Practice
regulations of the U.S. Food and Drug Administration.
[0376] The active compound may be effective over a wide dosage
range and is generally administered in a therapeutically effective
amount. It will be understood, however, that the amount of the
compound actually administered will usually be determined by a
physician, according to the relevant circumstances, including the
condition to be treated, the chosen route of administration, the
actual compound administered, the age, weight, and response of the
individual patient, the severity of the patient's symptoms and the
like.
[0377] The therapeutic dosage of a compound of the present
invention can vary according to, e.g., the particular use for which
the treatment is made, the manner of administration of the
compound, the health and condition of the patient, and the judgment
of the prescribing physician. The proportion or concentration of a
compound of the invention in a pharmaceutical composition can vary
depending upon a number of factors including dosage, chemical
characteristics (e.g., hydrophobicity), and the route of
administration. For example, the compounds of the invention can be
provided in an aqueous physiological buffer solution containing
about 0.1 to about 10% w/v of the compound for parenteral
administration. Some typical dose ranges are from about 1 .mu.g/kg
to about 1 g/kg of body weight per day. In some embodiments, the
dose range is from about 0.01 mg/kg to about 100 mg/kg of body
weight per day. The dosage is likely to depend on such variables as
the type and extent of progression of the disease or disorder, the
overall health status of the particular patient, the relative
biological efficacy of the compound selected, formulation of the
excipient, and its route of administration. Effective doses can be
extrapolated from dose-response curves derived from in vitro or
animal model test systems.
[0378] For preparing solid compositions such as tablets, the
principal active ingredient is mixed with a pharmaceutical
excipient to form a solid preformulation composition containing a
homogeneous mixture of a compound of the present invention. When
referring to these preformulation compositions as homogeneous, the
active ingredient is typically dispersed evenly throughout the
composition so that the composition can be readily subdivided into
equally effective unit dosage forms such as tablets, pills and
capsules. This solid preformulation is then subdivided into unit
dosage forms of the type described above containing from, e.g.,
about 0.1 to about 1000 mg of the active ingredient of the present
invention.
[0379] The tablets or pills of the present invention can be coated
or otherwise compounded to provide a dosage form affording the
advantage of prolonged action. For example, the tablet or pill can
comprise an inner dosage and an outer dosage component, the latter
being in the form of an envelope over the former. The two
components can be separated by an enteric layer which serves to
resist disintegration in the stomach and permit the inner component
to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or
coatings, such materials including a number of polymeric acids and
mixtures of polymeric acids with such materials as shellac, cetyl
alcohol and cellulose acetate.
[0380] The liquid forms in which the compounds and compositions of
the present invention can be incorporated for administration orally
or by injection include aqueous solutions, suitably flavored
syrups, aqueous or oil suspensions, and flavored emulsions with
edible oils such as cottonseed oil, sesame oil, coconut oil, or
peanut oil, as well as elixirs and similar pharmaceutical
vehicles.
[0381] Compositions for inhalation or insufflation include
solutions and suspensions in pharmaceutically acceptable, aqueous
or organic solvents, or mixtures thereof, and powders. The liquid
or solid compositions may contain suitable pharmaceutically
acceptable excipients as described supra. In some embodiments, the
compositions are administered by the oral or nasal respiratory
route for local or systemic effect. Compositions can be nebulized
by use of inert gases. Nebulized solutions may be breathed directly
from the nebulizing device or the nebulizing device can be attached
to a face mask, tent, or intermittent positive pressure breathing
machine. Solution, suspension, or powder compositions can be
administered orally or nasally from devices which deliver the
formulation in an appropriate manner.
[0382] Topical formulations can contain one or more conventional
carriers. In some embodiments, ointments can contain water and one
or more hydrophobic carriers selected from, e.g., liquid paraffin,
polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and
the like. Carrier compositions of creams can be based on water in
combination with glycerol and one or more other components, e.g.,
glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl
alcohol. Gels can be formulated using isopropyl alcohol and water,
suitably in combination with other components such as, e.g.,
glycerol, hydroxyethyl cellulose, and the like. In some
embodiments, topical formulations contain at least about 0.1, at
least about 0.25, at least about 0.5, at least about 1, at least
about 2 or at least about 5 wt % of the compound of the invention.
The topical formulations can be suitably packaged in tubes of,
e.g., 100 g which are optionally associated with instructions for
the treatment of the select indication, e.g., psoriasis or other
skin condition.
[0383] The amount of compound or composition administered to a
patient will vary depending upon what is being administered, the
purpose of the administration, such as prophylaxis or therapy, the
state of the patient, the manner of administration and the like. In
therapeutic applications, compositions can be administered to a
patient already suffering from a disease in an amount sufficient to
cure or at least partially arrest the symptoms of the disease and
its complications. Effective doses will depend on the disease
condition being treated as well as by the judgment of the attending
clinician depending upon factors such as the severity of the
disease, the age, weight and general condition of the patient and
the like.
[0384] The compositions administered to a patient can be in the
form of pharmaceutical compositions described above. These
compositions can be sterilized by conventional sterilization
techniques, or may be sterile filtered. Aqueous solutions can be
packaged for use as is, or lyophilized, the lyophilized preparation
being combined with a sterile aqueous carrier prior to
administration. The pH of the compound preparations typically will
be between 3 and 11, more preferably from 5 to 9 and most
preferably from 7 to 8. It will be understood that use of certain
of the foregoing excipients, carriers or stabilizers will result in
the formation of pharmaceutical salts.
[0385] The therapeutic dosage of a compound of the present
invention can vary according to, e.g., the particular use for which
the treatment is made, the manner of administration of the
compound, the health and condition of the patient, and the judgment
of the prescribing physician. The proportion or concentration of a
compound of the invention in a pharmaceutical composition can vary
depending upon a number of factors including dosage, chemical
characteristics (e.g., hydrophobicity), and the route of
administration. For example, the compounds of the invention can be
provided in an aqueous physiological buffer solution containing
about 0.1 to about 10% w/v of the compound for parenteral
administration. Some typical dose ranges are from about 1 .mu.g/kg
to about 1 g/kg of body weight per day. In some embodiments, the
dose range is from about 0.01 mg/kg to about 100 mg/kg of body
weight per day. The dosage is likely to depend on such variables as
the type and extent of progression of the disease or disorder, the
overall health status of the particular patient, the relative
biological efficacy of the compound selected, formulation of the
excipient, and its route of administration. Effective doses can be
extrapolated from dose-response curves derived from in vitro or
animal model test systems.
Labeled Compounds and Assay Methods
[0386] The compounds of the present disclosure can further be
useful in investigations of biological processes in normal and
abnormal tissues. Thus, another aspect of the present invention
relates to fluorescent dye, spin label, heavy metal or
radio-labeled compounds provided herein that would be useful not
only in imaging techniques but also in assays, both in vitro and in
vivo, for localizing and quantitating HPK1 protein in tissue
samples, including human, and for identifying HPK1 ligands by
inhibition binding of a labeled compound. Accordingly, the present
invention includes HPK1 binding assays that contain such labeled
compounds.
[0387] The present invention further includes
isotopically-substituted compounds of the disclosure. An
"isotopically-substituted" compound is a compound of the invention
where one or more atoms are replaced or substituted by an atom
having the same atomic number but a different atomic mass or mass
number. Compounds of the invention may contain isotopes in a
natural abundance as found in nature. Compounds of the invention
may also have isotopes in amounts greater to that found in nature,
e.g., synthetically incorporating low natural abundance isotopes
into the compounds of the invention so they are enriched in a
particularly useful isotope (e.g., .sup.2H and .sup.13C). It is to
be understood that a "radio-labeled" compound is a compound that
has incorporated at least one isotope that is radioactive (e.g.,
radionuclide), e.g., .sup.3H and .sup.14C. Suitable radionuclides
that may be incorporated in compounds of the present invention
include but are not limited to .sup.3H (also written as T for
tritium), .sup.11C, .sup.13C, .sup.14C, .sup.13N, .sup.15N,
.sup.15O, .sup.17O, .sup.18O, .sup.18F, .sup.35S, .sup.36Cl,
.sup.82Br, .sup.75Br, .sup.76Br, .sup.77Br, .sup.123I, .sup.124I,
.sup.125I and .sup.131I. The radionuclide that is incorporated in
the instant radio-labeled compounds will depend on the specific
application of that radio-labeled compound. In some embodiments the
radionuclide is selected from the group consisting of .sup.3H,
.sup.14C, .sup.125I, .sup.35S and .sup.82Br. For in vitro HPK1
labeling and competition assays, compounds that incorporate
.sup.3H, .sup.14C, .sup.82Br, .sup.125I, .sup.131I, or .sup.35S
will generally be most useful. For radio-imaging applications C,
.sup.18F, .sup.125I, .sup.123I, .sup.124I, .sup.131I, .sup.75Br,
.sup.76Br or .sup.77Br will generally be most useful. Synthetic
methods for incorporating radio-isotopes into organic compounds are
known in the art.
[0388] Specifically, a labeled compound of the invention can be
used in a screening assay to identify and/or evaluate compounds.
For example, a newly synthesized or identified compound (i.e., test
compound) which is labeled can be evaluated for its ability to bind
a HPK1 protein by monitoring its concentration variation when
contacting with the HPK1, through tracking of the labeling. For
example, a test compound (labeled) can be evaluated for its ability
to reduce binding of another compound which is known to bind to a
HPK1 protein (i.e., standard compound). Accordingly, the ability of
a test compound to compete with the standard compound for binding
to the HPK1 protein directly correlates to its binding affinity.
Conversely, in some other screening assays, the standard compound
is labeled and test compounds are unlabeled. Accordingly, the
concentration of the labeled standard compound is monitored in
order to evaluate the competition between the standard compound and
the test compound, and the relative binding affinity of the test
compound is thus ascertained.
Kits
[0389] The present disclosure also includes pharmaceutical kits
useful, e.g., in the treatment or prevention of diseases or
disorders associated with the activity of HPK1, such as cancer or
infections, which include one or more containers containing a
pharmaceutical composition comprising a therapeutically effective
amount of a compound of Formula (I), or any of the embodiments
thereof. Such kits can further include one or more of various
conventional pharmaceutical kit components, such as, e.g.,
containers with one or more pharmaceutically acceptable carriers,
additional containers, etc., as will be readily apparent to those
skilled in the art. Instructions, either as inserts or as labels,
indicating quantities of the components to be administered,
guidelines for administration, and/or guidelines for mixing the
components, can also be included in the kit.
[0390] The invention will be described in greater detail by way of
specific examples. The following examples are offered for
illustrative purposes, and are not intended to limit the invention
in any manner. Those of skill in the art will readily recognize a
variety of non-critical parameters which can be changed or modified
to yield essentially the same results. The compounds of the
Examples have been found to inhibit the activity of HPK1 according
to at least one assay described herein.
EXAMPLES
[0391] Experimental procedures for compounds of the invention are
provided below. Preparatory LC-MS purifications of some of the
compounds prepared were performed on Waters mass directed
fractionation systems. The basic equipment setup, protocols, and
control software for the operation of these systems have been
described in detail in the literature. See e.g. "Two-Pump At Column
Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi.
Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations
and Methods for Parallel Synthesis Purification", K. Blom, R.
Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J Combi. Chem.,
5, 670 (2003); and "Preparative LC-MS Purification: Improved
Compound Specific Method Optimization", K. Blom, B. Glass, R.
Sparks, A.
[0392] Combs, J Combi. Chem., 6, 874-883 (2004). The separated
compounds were typically subjected to analytical liquid
chromatography mass spectrometry (LCMS) for purity check under the
following conditions: Instrument; Agilent 1100 series, LC/MSD,
Column: Waters Sunfire.TM. C.sub.18 5 .mu.m particle size,
2.1.times.5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and
mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes
with flow rate 2.0 mL/minute.
[0393] Some of the compounds prepared were also separated on a
preparative scale by reverse-phase high performance liquid
chromatography (RP-HPLC) with MS detector or flash chromatography
(silica gel) as indicated in the Examples. Typical preparative
reverse-phase high performance liquid chromatography (RP-HPLC)
column conditions are as follows:
[0394] pH=2 purifications: Waters Sunfire.TM. C.sub.18 5 m particle
size, 19.times.100 mm column, eluting with mobile phase A: 0.1% TFA
(trifluoroacetic acid) in water and mobile phase B: acetonitrile;
the flow rate was 30 mL/minute, the separating gradient was
optimized for each compound using the Compound Specific Method
Optimization protocol as described in the literature (see
"Preparative LCMS Purification: Improved Compound Specific Method
Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb.
Chem., 6, 874-883 (2004)). Typically, the flow rate used with the
30.times.100 mm column was 60 mL/minute.
[0395] pH=10 purifications: Waters XBridge C.sub.18 5 m particle
size, 19.times.100 mm column, eluting with mobile phase A: 0.15%
NH.sub.4OH in water and mobile phase B: acetonitrile; the flow rate
was 30 mL/minute, the separating gradient was optimized for each
compound using the Compound Specific Method Optimization protocol
as described in the literature (See "Preparative LCMS Purification:
Improved Compound Specific Method Optimization", K. Blom, B. Glass,
R. Sparks, A. Combs, J Comb. Chem., 6, 874-883 (2004)). Typically,
the flow rate used with 30.times.100 mm column was 60
mL/minute.
Example 1.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-phenyl-1H-pyrazolo[4,3-b-
]pyridine
##STR00014##
[0396] Step 1. 5-Chloro-3-iodo-1H-pyrazolo[4,3-b]pyridine
##STR00015##
[0398] To a solution of 5-chloro-1H-pyrazolo[4,3-b]pyridine (1.0 g,
6.5 mmol) in 1,4-dioxane (60 mL) was added potassium hydroxide (1.5
g, 26 mmol) and iodine (3.3 g, 13 mmol). The reaction was warmed up
to 50.degree. C. and stirred at that temperature for 4 hours. After
this time the reaction mixture was cooled to r.t. and then poured
into saturated sodium thiosulfate solution (100 mL) and stirred for
another 10 mins. The resulting mixture was extracted with ethyl
acetate (2.times.50 mL). The combined organic layers were dried
over MgSO.sub.4, filtered and concentrated to dryness. The residue
was used in the next step without further purification. LC-MS
calculated for C.sub.6H4ClIN.sub.3 (M+H)+: m/z=279.9; found
279.9.
Step 2.
5-Chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]py-
ridine
##STR00016##
[0400] To a solution of the above intermediate in 1,4-dioxane (60
mL) and water (20 mL) was added potassium phosphate (2.76 g, 13.0
mmol), (4-(4-methylpiperazin-1-yl)phenyl)boronic acid (1.4 g, 6.5
mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (50 mg,
0.061 mmol). The reaction mixture was degassed and backfilled with
N.sub.2 and then stirred at 90.degree. C. for 15 hours. The
reaction mixture was cooled to r.t., filtered and concentrated to
dryness. The residue was purified by silica gel chromatography
using 0-15% methanol in DCM to afford the desired product as
brownish solid (630 mg, 30% over two steps). LC-MS calculated for
C.sub.17H.sub.19ClN.sub.5 (M+H).sup.+: m/z=328.1; found 328.1.
Step 3.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-phenyl-1H-pyrazolo[4,3-b]py-
ridine
[0401] To a solution of
5-chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridine
(20 mg, 0.061 mmol) in 1,4-dioxane (1 mL) and water (0.25 mL) was
added (2-fluoro-6-methylphenyl)boronic acid (14 mg, 0.092 mmol),
potassium phosphate (26 mg, 0.12 mmol) and
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopropylbipheny-
l-2-yl)phosphoranylidene)palladium (10 mg, 0.013 mmol). The
reaction was degassed and backfilled with N.sub.2 and warmed up to
90.degree. C. The reaction mixture was stirred at 90.degree. C. for
15 hours. The reaction mixture was cooled to r.t., diluted with
methanol, filtered and purified by prep-LCMS (XBridge C18 column,
eluting with a gradient of acetonitrile/water containing 0.1% TFA,
at flow rate of 60 mL/min). LCMS calculated for
C.sub.23H.sub.24N.sub.5(M+H).sup.+: m/z=370.2; found 370.2.
Example 2.
5-(2-Methoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyr-
azolo[4,3-b]pyridine
##STR00017##
[0403] This compound was prepared according to the procedures
described in Example 1, using 2-methoxyphenylboronic acid instead
of phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.26N.sub.5O (M+H).sup.+: m/z=400.2; found 400.2.
Example 3.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-o-tolyl-1H-pyrazolo[4,3--
b]pyridine
##STR00018##
[0405] This compound was prepared according to the procedures
described in Example 1, using 2-methylphenylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.26N.sub.5(M+H).sup.+: m/z=384.2; found 384.2.
Example 4.
5-(2-Fluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyra-
zolo[4,3-b]pyridine
##STR00019##
[0407] This compound was prepared according to the procedures
described in Example 1, using 2-fluorophenylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.23H.sub.23FN.sub.5 (M+H).sup.+: m/z=388.2; found 388.2.
Example 5.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(2-(trifluoromethyl)phen-
yl)-1H-pyrazolo[4,3-b]pyridine
##STR00020##
[0409] This compound was prepared according to the procedures
described in Example 1, using 2-(trifluoromethyl)phenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.24H.sub.23F.sub.3N.sub.5 (M+H).sup.+:
m/z=438.2; found 438.2.
Example 6.
2-Methyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,-
3-b]pyridin-5-yl)aniline
##STR00021##
[0411] This compound was prepared according to the procedures
described in Example 1, using 3-amino-2-methylphenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.24H.sub.27N.sub.6(M+H).sup.+: m/z=399.2; found
399.2.
Example 7.
5-(2-Fluoro-6-methylphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl-
)-1H-pyrazolo[4,3-b]pyridine
##STR00022##
[0413] This compound was prepared according to the procedures
described in Example 1, using 2-fluoro-6-methylphenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.24H.sub.25FN.sub.5 (M+H).sup.+: m/z=402.2;
found 402.2.
Example 8.
5-(2-Fluoro-6-methoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)pheny-
l)-1H-pyrazolo[4,3-b]pyridine
##STR00023##
[0415] This compound was prepared according to the procedures
described in Example 1, using 2-fluoro-6-methoxyphenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.24H.sub.25FN.sub.5O (M+H).sup.+: m/z=418.2;
found 418.2. .sup.1H NMR (400 MHz, DMSO) .delta. 8.43-8.31 (m, 2H),
8.11-8.02 (d, J=8.6 Hz, 1H), 7.53-7.44 (td, J=8.4, 6.7 Hz, 1H),
7.44-7.37 (d, J=8.7 Hz, 1H), 7.16-7.13 (d, J=8.9 Hz, 2H), 7.06-7.02
(d, J=8.3 Hz, 1H), 7.00-6.93 (t, J=8.8 Hz, 1H), 4.02-3.87 (m, 2H),
3.83-3.70 (s, 3H), 3.61-3.48 (d, J=11.7 Hz, 2H), 3.27-3.10 (m, 2H),
3.11-2.97 (m, 2H), 2.93-2.80 (s, 3H).
Example 9.
5-(2,3-Difluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H--
pyrazolo[4,3-b]pyridine
##STR00024##
[0417] This compound was prepared according to the procedures
described in Example 1, using 2,3-difluorophenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.23H.sub.22F.sub.2N.sub.5 (M+H).sup.+:
m/z=406.2; found 406.2.
Example 10.
5-(2,3-Difluoro-6-methoxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H--
pyrazolo[4,3-b]pyridine
##STR00025##
[0419] This compound was prepared according to the procedures
described in Example 1, using 2,3-difluoro-6-methoxyphenylboronic
acid instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.24H.sub.24F.sub.2N.sub.5O (M+H).sup.+:
m/z=436.2; found 436.2.
Example 11.
(3-Fluoro-2-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyrid-
in-5-yl)phenyl)methanol
##STR00026##
[0421] This compound was prepared according to the procedures
described in Example 1, using
2-fluoro-6-(hydroxymethyl)phenylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.25FN.sub.5O (M+H): m/z=418.2; found 418.2.
Example 12. Ethyl
2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzoate
##STR00027##
[0423] This compound was prepared according to the procedures
described in Example 1, using
3-(ethoxycarbonyl)-2-fluorophenylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.26H.sub.27FN.sub.5O.sub.2(M+H).sup.+: m/z=460.2; found
460.2.
Example 13.
N-(2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyr-
idin-5-yl)phenyl)methanesulfonamide
##STR00028##
[0425] To a solution of
2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)aniline (Example 6, 20 mg, 0.050 mmol) in tetrahydrofuran (1
mL) was added N,N-diisopropylethylamine (20 mg, 0.15 mmol) followed
by methanesulfonyl chloride (12 mg, 0.1 mmol) and the reaction was
stirred at r.t. for 1 hour. After this time the reaction mixture
was diluted with methanol, filtered and purified by prep-LCMS
(XBridge C18 column, eluting with a gradient of acetonitrile/water
containing 0.1% TFA, at flow rate of 60 mL/min). LC-MS calculated
for C.sub.24H.sub.26FN.sub.6O.sub.2S (M+H).sup.+: m/z=481.2; found
481.2.
Example 14.
2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)ph-
enol
##STR00029##
[0427] This compound was prepared according to the procedures
described in Example 1, using 2-hydroxyphenylboronic acid instead
of phenylboronic acid as starting material. LC-MS calculated for
C.sub.23H.sub.24N.sub.5O (M+H).sup.+: m/z=386.2; found 386.2.
Example 15.
5-(2,3-Dihydrobenzofuran-7-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-py-
razolo[4,3-b]pyridine
##STR00030##
[0429] This compound was prepared according to the procedures
described in Example 1, using 2,3-dihydrobenzofuran-7-ylboronic
acid instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.25H.sub.26N.sub.5O (M+H).sup.+: m/z=412.2;
found 412.2.
Example 16.
5-(2,3-Dihydrobenzo[b][1,4]dioxin-5-yl)-3-(4-(4-methylpiperazin-1-yl)phen-
yl)-1H-pyrazolo[4,3-b]pyridine
##STR00031##
[0431] This compound was prepared according to the procedures
described in Example 1, using
2,3-dihydrobenzo[b][1,4]dioxin-5-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.25H.sub.26N.sub.5O.sub.2 (M+H).sup.+: m/z=428.2; found
428.2.
Example 17.
N-Methyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzamide
##STR00032##
[0433] This compound was prepared according to the procedures
described in Example 1, using 3-(methylcarbamoyl)phenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.25H.sub.27N.sub.6O (M+H).sup.+: m/z=427.2;
found 427.2.
Example 18.
N,N-Dimethyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]py-
ridin-5-yl)aniline
##STR00033##
[0435] This compound was prepared according to the procedures
described in Example 1, using 3-(dimethylamino)phenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.25H.sub.29N.sub.6(M+H).sup.+: m/z=413.2; found
413.2.
Example 19.
2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)be-
nzonitrile
##STR00034##
[0437] This compound was prepared according to the procedures
described in Example 1, using 2-cyanophenylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.23N.sub.6(M+H).sup.+: m/z=395.2; found 395.2.
Example 20. Methyl
2-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)be-
nzoate
##STR00035##
[0439] This compound was prepared according to the procedures
described in Example 1, using 2-(methoxycarbonyl)phenylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.25H.sub.26N.sub.5O.sub.2 (M+H).sup.+:
m/z=428.2; found 428.2.
Example 21.
N-(2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl-
)phenyl)acetamide
##STR00036##
[0441] This compound was prepared according to the procedures
described in Example 1, using 2-acetamidophenylboronic acid instead
of phenylboronic acid as starting material. LC-MS calculated for
C.sub.25H.sub.27N.sub.6O (M+H).sup.+: m/z=427.2; found 427.2.
Example 22.
5-(Biphenyl-2-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]-
pyridine
##STR00037##
[0443] This compound was prepared according to the procedures
described in Example 1, using biphenyl-2-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.29H.sub.28N.sub.5(M+H).sup.+: m/z=446.2; found 446.2.
Example 23.
5-(1H-Indazol-4-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3--
b]pyridine
##STR00038##
[0445] This compound was prepared according to the procedures
described in Example 1, using 1H-indazol-4-ylboronic acid instead
of phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.24N.sub.7(M+H).sup.+: m/z=410.2; found 410.2.
Example 24.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyridin-3-yl)-1H-pyrazolo[4,3-b]p-
yridine
##STR00039##
[0447] This compound was prepared according to the procedures
described in Example 1, using pyridin-3-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.22H.sub.23N.sub.6(M+H).sup.+: m/z=371.2; found 371.2. .sup.1H
NMR (400 MHz, DMSO) .delta. 9.50 (d, J=2.2 Hz, 1H), 8.82-8.72 (m,
2H), 8.55-8.45 (m, 2H), 8.24-8.09 (m, 2H), 7.81-7.71 (dd, J=8.0,
5.0 Hz, 1H), 7.26-7.16 (m, 2H), 4.07-3.89 (m, 2H), 3.65-3.47 (m,
2H), 3.30-3.03 (m, 4H), 2.95-2.80 (s, 3H).
Example 25.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyridin-4-yl)-1H-pyrazolo[4,3-b]p-
yridine
##STR00040##
[0449] This compound was prepared according to the procedures
described in Example 1, using pyridin-4-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.22H.sub.23N.sub.6(M+H).sup.+: m/z=371.2; found 371.2.
Example 26.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyrimidin-5-yl)-1H-pyrazolo[4,3-b-
]pyridine
##STR00041##
[0451] This compound was prepared according to the procedures
described in Example 1, using pyrimidin-5-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.21H.sub.22N.sub.7(M+H).sup.+: m/z=372.2; found 372.2.
Example 27.
5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-1-
H-pyrrolo[2,3-b]pyridin-2(3H)-one
##STR00042##
[0453] This compound was prepared according to the procedures
described in Example 1, using
2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-ylboronic acid instead
of phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.24N.sub.7O (M+H).sup.+: m/z=426.2; found 426.2.
Example 28.
1'-Methyl-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H,1'H-5,6'-bipyrazolo[4,3-
-b]pyridine
##STR00043##
[0455] This compound was prepared according to the procedures
described in Example 1, using
1-methyl-1H-pyrazolo[4,3-b]pyridin-6-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.25N.sub.8(M+H).sup.+: m/z=425.2; found 425.2.
Example 29.
2-(5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl-
)pyridin-3-yl)oxazole
##STR00044##
[0457] This compound was prepared according to the procedures
described in Example 1, using 5-(oxazol-2-yl)pyridin-3-ylboronic
acid instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.25H.sub.24N.sub.7O (M+H).sup.+: m/z=438.2;
found 438.2.
Example 30.
1-Methyl-5-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)pyridin-2(1H)-one
##STR00045##
[0459] This compound was prepared according to the procedures
described in Example 1, using
1-methyl-6-oxo-1,6-dihydropyridin-3-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.23H.sub.25N.sub.6O (M+H).sup.+: m/z=401.2; found 401.2.
Example 31.
5-(3-Methyl-3H-imidazo[4,5-b]pyridin-6-yl)-3-(4-(4-methylpiperazin-1-yl)p-
henyl)-1H-pyrazolo[4,3-b]pyridine
##STR00046##
[0461] This compound was prepared according to the procedures
described in Example 1, using
3-methyl-3H-imidazo[4,5-b]pyridin-6-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.24H.sub.25N.sub.8(M+H).sup.+: m/z=425.2; found 425.2.
Example 32.
7-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)py-
rido[3,2-b]pyrazine
##STR00047##
[0463] This compound was prepared according to the procedures
described in Example 1, using pyrido[3,2-b]pyrazin-7-ylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.24H.sub.23N.sub.8(M+H).sup.+: m/z=423.2; found
423.2.
Example 33.
2-tert-Butyl-7-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]py-
ridin-5-yl)oxazolo[5,4-c]pyridine
##STR00048##
[0465] This compound was prepared according to the procedures
described in Example 1, using
2-tert-butyloxazolo[5,4-c]pyridin-7-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.27H3.sub.0N.sub.7O (M+H).sup.+: m/z=468.2; found 468.2.
Example 34.
5-(3-Methyl-1H-pyrazol-4-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyra-
zolo[4,3-b]pyridine
##STR00049##
[0467] This compound was prepared according to the procedures
described in Example 1, using 3-methyl-1H-pyrazol-4-ylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.21H.sub.24N.sub.7(M+H).sup.+: m/z=374.2; found
374.2. .sup.1H NMR (400 MHz, DMSO) .delta. 9.50 (d, J=2.2 Hz, 1H),
8.82-8.72 (m, 2H), 8.55-8.45 (m, 2H), 8.24-8.09 (m, 2H), 7.81-7.71
(dd, J=8.0, 5.0 Hz, 1H), 7.26-7.16 (m, 2H), 4.07-3.89 (m, 2H),
3.65-3.47 (m, 2H), 3.30-3.03 (m, 4H), 2.95-2.80 (s, 3H).
Example 35.
3-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-1H-p-
yrazolo[4,3-b]pyridine
##STR00050##
[0469] This compound was prepared according to the procedures
described in Example 1, using pyrazolo[1,5-a]pyridin-3-ylboronic
acid instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.24H.sub.24N.sub.7(M+H).sup.+: m/z=410.2; found
410.2.
Example 36.
5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)qu-
inoline
##STR00051##
[0471] This compound was prepared according to the procedures
described in Example 1, using quinolin-5-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.26H.sub.25N.sub.6(M+H).sup.+: m/z=421.2; found 421.2.
Example 37.
4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)is-
oquinoline
##STR00052##
[0473] This compound was prepared according to the procedures
described in Example 1, using isoquinolin-4-ylboronic acid instead
of phenylboronic acid as starting material. LC-MS calculated for
C.sub.26H.sub.25N.sub.6(M+H).sup.+: m/z=421.2; found 421.2.
Example 38.
4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)in-
dolin-2-one
##STR00053##
[0475] This compound was prepared according to the procedures
described in Example 1, using 2-oxoindolin-4-ylboronic acid instead
of phenylboronic acid as starting material. LC-MS calculated for
C.sub.25H.sub.25N.sub.6O (M+H).sup.+: m/z=425.2; found 425.2.
Example 39.
5-(1-Methyl-1H-indol-4-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazo-
lo[4,3-b]pyridine
##STR00054##
[0477] This compound was prepared according to the procedures
described in Example 1, using 1-methyl-1H-indol-4-ylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.26H.sub.27N.sub.6(M+H).sup.+: m/z=423.2; found
423.2.
Example 40.
2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzamide
##STR00055##
[0478] Step 1. Ethyl
2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzoate
##STR00056##
[0480] To a solution of
5-chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridine
(Example 1, Step 2, 200 mg, 0.61 mmol) in 1,4-dioxane (4 mL) and
water (1 mL) was added ethyl
2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
(380 mg, 1.29 mmol) and potassium phosphate (280 mg, 1.32 mmol),
followed by
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopropylbipheny-
l-2-yl)phosphoranylidene)palladium (50 mg, 0.064 mmol), and the
reaction vial was purged with nitrogen for 5 mins. After this time
the reaction mixture was stirred at 90.degree. C. for 15 hours. It
was then cooled to r.t., filtered and concentrated to dryness. The
residue was purified by silica gel chromatography using 0-10%
methanol in DCM to afford desired product as yellowish solid (151
mg, 55%). LC-MS calculated for
C.sub.26H.sub.27FN.sub.5O.sub.2(M+H).sup.+: m/z=460.2; found
460.2.
Step 2.
2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b-
]pyridin-5-yl)benzoic acid
##STR00057##
[0482] To a solution of ethyl
2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzoate (151 mg, 0.329 mmol) in methanol (4 mL) was added
potassium hydroxide (185 mg, 3.30 mmol) and the reaction mixture
was stirred at r.t. for 1 hour. After this time the reaction was
filtered and concentrated to dryness. To the residue was added 1N
HCl solution in water (10 mL) and the product was extracted with
ethyl acetate (2.times.10 mL). The combined organic layers were
washed with brine, dried over MgSO.sub.4, filtered and concentrated
to dryness to afford the crude desired product as yellowish solid
which was used for next step without purification. LC-MS calculated
for C.sub.24H.sub.23FN.sub.5O.sub.2(M+H).sup.+: m/z=432.2; found
432.2.
Step 3.
2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b-
]pyridin-5-yl)benzamide
[0483] To a solution of
2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)benzoic acid (20 mg, 0.046 mmol) in N,N-dimethylformamide (1
mL) were added ammonia in dioxane (0.5 M in dioxane, 1 mL, 0.5
mmol), N,N-diisopropylethylamine (0.4 mL, 0.9 mmol) and
N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium
hexafluorophosphate (53 mg, 0.14 mmol). The reaction was stirred at
r.t. for 30 mins, then diluted with acetonitrile, filtered and
purified by prep-LCMS (XBridge C18 column, eluting with a gradient
of acetonitrile/water containing 0.1% TFA, at flow rate of 60
mL/min). LC-MS calculated for C.sub.24H.sub.24FN.sub.6O
(M+H).sup.+: m/z=431.2; found 431.2.
Example 41.
2-Fluoro-N-methyl-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-
-b]pyridin-5-yl)benzamide
##STR00058##
[0485] This compound was prepared according to the procedures
described in example 40, using methylamine solution instead of
ammonia solution as starting material. LC-MS calculated for
C.sub.25H.sub.26FN.sub.6O (M+H).sup.+: m/z=445.2; found 445.2.
Example 42.
N-Benzyl-2-fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-
-b]pyridin-5-yl)benzamide
##STR00059##
[0487] This compound was prepared according to the procedures
described in example 40, using benzylamine instead of ammonia
solution as starting material. LC-MS calculated for
C.sub.31H3.sub.0FN.sub.6O (M+H).sup.+: m/z=521.2; found 521.2.
Example 43.
2-Fluoro-3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)-N-(pyridin-4-ylmethyl)benzamide
##STR00060##
[0489] This compound was prepared according to the procedures
described in Example 40, using pyridin-4-ylmethanamine instead of
ammonia solution as starting material. LC-MS calculated for
C.sub.30H.sub.29FN.sub.7O (M+H).sup.+: m/z=522.2; found 522.2.
Example 44.
5-(Imidazo[1,2-a]pyridin-8-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-py-
razolo[4,3-b]pyridine
##STR00061##
[0490] Step 1.
3-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)py-
ridin-2-amine
##STR00062##
[0492] To a solution of
5-chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridine
(Example 1, Step 2, 150 mg, 0.456 mmol) in 1,4-dioxane (4 mL) and
water (1 mL) were added
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (100
mg, 0.455 mmol), potassium phosphate (190 mg, 0.896 mmol) and
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopropylbipheny-
l-2-yl)phosphoranylidene)palladium (40 mg, 0.051 mmol). The
reaction was degassed and backfilled with N.sub.2 and stirred at
90.degree. C. for 15 hours. The reaction mixture was cooled to
r.t., diluted with ethyl acetate and washed with water and brine.
The organic layer was dried over MgSO.sub.4, filtered and
concentrated to dryness. The residue was used in the next step
without purification. LC-MS calculated for
C.sub.22H.sub.24N.sub.7(M+H).sup.+: m/z=386.2; found 386.2.
Step 2.
5-(Imidazo[1,2-a]pyridin-8-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl-
)-1H-pyrazolo[4,3-b]pyridine
[0493] To a solution of
3-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)py-
ridin-2-amine (20 mg, 0.052 mmol) in isopropyl alcohol (1 mL) was
added N,N-diisopropylethylamine (20 mg, 0.16 mmol) and
chloroacetaldehyde (40 mg, 0.51 mmol) then it was stirred at
90.degree. C. for 15 hours. After this time the reaction mixture
was cooled to r.t., diluted with methanol, filtered and purified by
prep-LCMS (XBridge C18 column, eluting with a gradient of
acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min)
to afford desired product. LC-MS calculated for
C.sub.24H.sub.24N.sub.7(M+H).sup.+: m/z=410.2; found 410.2.
Example 45.
5-(2-Ethylimidazo[1,2-a]pyridin-8-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl-
)-1H-pyrazolo[4,3-b]pyridine
##STR00063##
[0495] This compound was prepared according to the procedures
described in Example 44, using 1-chlorobutan-2-one instead of
chloroacetaldehyde as starting material. LC-MS calculated for
C.sub.26H.sub.28N.sub.7(M+H).sup.+: m/z=438.2; found 438.2.
Example 46.
5-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-1-
,2,3,4-tetrahydroisoquinoline
##STR00064##
[0497] To a solution of
5-chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridine
(Example 1, Step 2, 30 mg, 0.091 mmol) in 1,4-dioxane (1 mL) and
water (0.25 mL) were added tert-butyl
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2-
(1H)-carboxylate (66 mg, 0.18 mmol), potassium phosphate (39 mg,
0.18 mmol) and
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopro-
pylbiphenyl-2-yl)phosphoranylidene)palladium (7 mg, 0.01 mmol). The
reaction was degassed and backfilled with N.sub.2 and stirred at
90.degree. C. for 15 hours. The reaction mixture was cooled to
r.t., filtered and concentrated to dryness. 1 mL of 1:1 mixture of
TFA and DCM was added to the obtained residue and the reaction was
stirred for another 1 hour. The solution was concentrated to
dryness, diluted with methanol, filtered and purified by prep-LCMS
(XBridge C18 column, eluting with a gradient of acetonitrile/water
containing 0.1% TFA, at flow rate of 60 mL/min). LC-MS calculated
for C.sub.26H.sub.29N.sub.6(M+H).sup.+: m/z=425.2; found 425.2.
Example 47.
4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-2-
,3-dihydro-1H-inden-1-amine
##STR00065##
[0498] Step 1.
4-(3-(4-(4(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-
-2,3-dihydro-1H-inden-1-one
##STR00066##
[0500] To a solution of 4-bromoindan-1-one (200 mg, 0.952 mmol) in
1,4-dioxane (4 mL) were added bis(pinacolato)diboron (0.48 g, 1.9
mmol), potassium acetate (0.19 g, 1.9 mmol) and
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopropylbipheny-
l-2-yl)phosphoranylidene)palladium (100 mg, 0.127 mmol). The
reaction was stirred at 100.degree. C. for 4 hours. After this time
it was cooled to r.t., and then water (0.8 mL),
5-chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridine
(Example 1, Step 2, 200 mg, 0.608 mmol) and potassium phosphate
(200 mg, 0.943 mmol) were added and the reaction was stirred for
another 4 hours at 90.degree. C. The reaction mixture was cooled to
r.t., diluted with DCM (20 mL) filtered and concentrated to
dryness. The residue was used in the next step without
purification. LC-MS calculated for C.sub.26H.sub.26N.sub.5O
(M+H).sup.+: m/z=424.2; found 424.2.
Step 2.
4-(3-(4-(4(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)-2,3-dihydro-1H-inden-1-amine
[0501] To a solution of
4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl)in-
dan-1-one (20 mg, 0.047 mmol) in methanol (20 mmol) was added
ammonium acetate (40 mg, 0.526 mmol) and sodium cyanoborohydride
(10 mg, 0.16 mmol). The reaction was stirred at 60.degree. C. for 2
hours. After this time it was diluted with methanol, filtered and
purified by prep-LCMS (XBridge C18 column, eluting with a gradient
of acetonitrile/water containing 0.1% TFA, at flow rate of 60
mL/min). LC-MS calculated for C.sub.26H.sub.29N.sub.6(M+H).sup.+:
m/z=425.2; found 425.2.
Example 48.
N-Methyl-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridi-
n-5-yl)-2,3-dihydro-1H-inden-1-amine
##STR00067##
[0503] To a solution of
4-{3-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrazolo[4,3-b]pyridin-5-yl}in-
dan-1-one (Example 47, step 1, 20 mg, 0.047 mmol) in
tetrahydrofuran (1 mL) was added sodium cyanoborohydride (10 mg,
0.16 mmol) and methyl amine (HCl salt, 30 mg, 0.44 mmol). The
reaction was stirred at 80.degree. C. for 4 hours. After this time
it was cooled to r.t., diluted with methanol, filtered and purified
by prep-LCMS (XBridge C18 column, eluting with a gradient of
acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min).
LC-MS calculated for C.sub.27H3.sub.1N.sub.6(M+H).sup.+: m/z=439.2;
found 439.2.
Example 49.
2-(4-(3-(4-(4-Methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-5-yl-
)-2,3-dihydro-1H-inden-1-ylamino)ethanol
##STR00068##
[0505] This compound was prepared according to the procedures
described in example 48, using 2-aminoethanol instead of
methylamine as starting material. LC-MS calculated for
C.sub.28H3.sub.3N.sub.6O (M+H).sup.+: m/z=469.2; found 469.2.
Example 50.
N-Benzyl-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-H-pyrazolo[4,3-b]pyridin-
-5-yl)-2,3-dihydro-1H-inden-1-amine
##STR00069##
[0507] This compound was prepared according to the procedures
described in example 48, using benzylamine instead of methylamine
as starting material. LC-MS calculated for
C.sub.33H.sub.35N.sub.6(M+H).sup.+: m/z=515.2; found 515.2.
Example 51.
5-(2-Fluorophenyl)-3-phenyl-1H-pyrazolo[4,3-b]pyridine
##STR00070##
[0508] Step 1. 5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridine
##STR00071##
[0510] To a solution of 5-chloro-1H-pyrazolo[4,3-b]pyridine (500
mg, 3.29 mmol) in 1,4-dioxane (20 mL) and water (5 mL) were added
(2-fluorophenyl)boronic acid (500 mg, 3.57 mmol), potassium
phosphate (1.4 g, 6.5 mmol) and
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopropylbipheny-
l-2-yl)phosphoranylidene)palladium (100 mg, 0.127 mmol). The
reaction was degassed and backfilled with N.sub.2 and stirred at
90.degree. C. for 15 hours. After this time it was cooled to r.t.,
filtered and concentrated to dryness. The residue was purified by
silica gel chromatography using 0-100% ethyl acetate in hexanes to
afford desired product as yellowish oil (620 mg, 98%). LC-MS
calculated for C.sub.12H.sub.9FN.sub.3 (M+H).sup.+: m/z=214.2;
found 214.2.
Step 2. 5-(2-Fluorophenyl)-3-iodo-1H-pyrazolo[4,3-b]pyridine
##STR00072##
[0512] To a solution of
5-(2-fluorophenyl)-1H-pyrazolo[4,3-b]pyridine (750 mg, 3.50 mmol)
in 1,4-dioxane (20 mL) were added iodine (1.8 g, 7.0 mmol) and
potassium hydroxide (590 mg, 10.5 mmol) and the reaction was
stirred at 50.degree. C. for 15 hours. The resulting slurry was
poured into an aq. solution of sodium thiosulfate and stirred for
15 mins. After this time the product was extracted with ethyl
acetate. The organic layer was washed with brine, dried with
MgSO.sub.4, filtered and concentrated to dryness to afford the
crude product as brownish solid which was used in the next step
without purification. LC-MS calculated for C.sub.12H.sub.8FIN.sub.3
(M+H).sup.+: m/z=340.2; found 340.2.
Step 3. 5-(2-Fluorophenyl)-3-phenyl-1H-pyrazolo[4,3-b]pyridine
[0513] To a solution of
5-(3-fluorophenyl)-3-iodo-1H-pyrazolo[4,3-b]pyridine (30 mg, 0.09
mmol) in 1,4-dioxane (1 mL) and water (0.25 mL) were added
phenylboronic acid (16 mg, 0.13 mmol), potassium phosphate (38 mg,
0.18 mmol) and
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopropylbipheny-
l-2-yl)phosphoranylidene)palladium (20 mg, 0.013 mmol). The
reaction was degassed and stirred at 100.degree. C. for 3 hours.
The reaction mixture was then cooled to r.t., diluted with
methanol, filtered and purified by prep-LCMS (XBridge C18 column,
eluting with a gradient of acetonitrile/water containing 0.1% TFA,
at flow rate of 60 mL/min). LC-MS calculated for
C.sub.18H.sub.13FN.sub.3 (M+H).sup.+: m/z=290.2; found 290.2.
Example 52.
5-(2-Fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazolo[4,3-b]pyridine
##STR00073##
[0515] This compound was prepared according to the procedures
described in Example 51, using pyridin-4-ylboronic acid instead of
phenylboronic acid as starting material. LC-MS calculated for
C.sub.17H1.sub.2FN.sub.4 (M+H).sup.+: m/z=291.2; found 291.2.
Example 53.
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N-methylbenzamide
##STR00074##
[0517] This compound was prepared according to the procedures
described in Example 51, using 4-(methylcarbamoyl)phenylboronic
acid instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.20H.sub.16FN.sub.4O (M+H).sup.+: m/z=347.2;
found 347.2.
Example 54.
5-(2-Fluorophenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridin-
e
##STR00075##
[0519] This compound was prepared according to the procedures
described in Example 51, using 1-methyl-1H-pyrazol-4-ylboronic acid
instead of phenylboronic acid as starting material. LC-MS
calculated for C.sub.16H1.sub.3FN.sub.5 (M+H).sup.+: m/z=294.2;
found 294.2.
Example 55.
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N-(1-methylpiperidi-
n-4-yl)benzamide
##STR00076##
[0520] Step 1.
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic
acid
##STR00077##
[0522] To a solution of
5-(3-fluorophenyl)-3-iodo-1H-pyrazolo[4,3-b]pyridine (Example 51,
Step 2, 300 mg, 0.882 mmol) in 1,4-dioxane (10 mL) and water (2 mL)
were added (4-(methoxycarbonyl)phenyl)boronic acid (240 mg, 1.33
mmol), potassium phosphate (380 mg, 1.79 mmol) and
(2'-aminobiphenyl-2-yl)(chloro)(dicyclohexyl(2',4',6'-triisopropylbipheny-
l-2-yl)phosphoranylidene)palladium (70 mg, 0.089 mmol). The
reaction was degassed and stirred at 100.degree. C. for 15 hours.
The reaction mixture was cooled to r.t., filtered and concentrated
to dryness. The residue was dissolved in methanol (10 mL) and
potassium hydroxide (500 mg, 8.93 mmol) was added. The reaction was
stirred at r.t. for 1 hour. After this time the reaction mixture
was concentrated to dryness, diluted with water, acidified with 1N
HCl and the product extracted with ethyl acetate. The organic layer
was dried over MgSO.sub.4, filtered and concentrated to dryness to
afford a crude product as white solid. It was used in the next step
without further purification. LC-MS calculated for
C.sub.19H1.sub.3FN.sub.3O.sub.2(M+H).sup.+: m/z=334.2; found
334.2.
Step 2.
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N-(1-methylp-
iperidin-4-yl)benzamide
[0523] To a solution of
4-(5-(2-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid
(30 mg, 0.090 mmol) in N,N-dimethylformamide (1 mL) were added
N,N-diisopropylethylamine (40 mg, 0.31 mmol),
1-methylpiperidin-4-amine (50 mg, 0.44 mmol) and
N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium
hexafluorophosphate (HATU, 100 mg, 0.263 mmol). The reaction was
stirred for 30 mins at r.t., then it was diluted with methanol,
filtered and purified by prep-LCMS (XBridge C18 column, eluting
with a gradient of acetonitrile/water containing 0.1% TFA, at flow
rate of 60 mL/min). LC-MS calculated for C.sub.25H.sub.25FN.sub.5O
(M+H).sup.+: m/z=430.2; found 430.2.
Example 56.
(4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)phenyl)(4-methylpip-
erazin-1-yl)methanone
##STR00078##
[0525] This compound was prepared according to the procedures
described in Example 55, using 1-methylpiperazine instead of
1-methylpiperidin-4-amine as starting material. LC-MS calculated
for C.sub.24H.sub.23FN.sub.5O (M+H).sup.+: m/z=416.2; found
416.2.
Example 57.
4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N-phenylbenzamide
##STR00079##
[0527] This compound was prepared according to the procedures
described in Example 55, using aniline instead of
1-methylpiperidin-4-amine as starting material. LC-MS calculated
for C.sub.25H1.sub.8FN.sub.4O (M+H).sup.+: m/z=409.2; found
409.2.
Example 58.
5-(2-Fluorophenyl)-3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-
-b]pyridine
##STR00080##
[0529] To a solution of
5-(3-fluorophenyl)-3-iodo-1H-pyrazolo[4,3-b]pyridine (30 mg, 0.090
mmol) in 1,4-dioxane (1 mL) and water (0.25 mL) were added
(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)boronic
acid (39 mg, 0.13 mmol), potassium phosphate (38 mg, 0.18 mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (20 mg,
0.027 mmol). The reaction was degassed and was stirred at
100.degree. C. for 3 hours. The reaction mixture was then cooled to
r.t., filtered and concentrated to dryness. It was dissolved in
dioxane (1 mL) and 1N HCl solution in water was added. The reaction
mixture was stirred at r.t. for 1 hour. After this time the
solution was diluted with methanol, filtered and purified by
prep-LCMS (XBridge C18 column, eluting with a gradient of
acetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min).
LC-MS calculated for C.sub.20H.sub.20FN.sub.6 (M+H).sup.+:
m/z=363.2; found 363.2.
Example 59.
5-(2-Fluorophenyl)-3-(1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-y-
l)-1H-pyrazolo[4,3-b]pyridine
##STR00081##
[0531] To a solution of
5-(2-fluorophenyl)-3-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-b-
]pyridine (20 mg, 0.055 mmol) in 1,4-dioxane (1 mL) were added
N,N-diisopropylethylamine (20 mg, 0.16 mmol) and methanesulfonyl
chloride (20 mg, 0.18 mmol). The reaction was stirred at r.t. for 1
hour. The resulting solution was diluted with methanol, filtered
and purified by prep-LCMS (XBridge C18 column, eluting with a
gradient of acetonitrile/water containing 0.1% TFA, at flow rate of
60 mL/min). LC-MS calculated for C.sub.21H.sub.22FN.sub.6O.sub.2S
(M+H).sup.+: m/z=441.2; found 441.2.
Example 60.
1-(4-(4-(5-(2-Fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-1H-pyrazol-1--
yl)piperidin-1-yl)ethanone
##STR00082##
[0533] This compound was prepared according to the procedures
described in Example 59, using acetyl chloride instead of
methanesulfonyl chloride as starting material. LC-MS calculated for
C.sub.22H.sub.22FN.sub.6O (M+H).sup.+: m/z=405.2; found 405.2.
Intermediate 1.
5-Chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1-((2-(trimethylsilyl)ethox-
y)methyl)-1H-pyrazolo[4,3-b]pyridine
##STR00083##
[0534] Step 1.
5-Chloro-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-H-pyrazolo[4,3-b]pyr-
idine
##STR00084##
[0536] To a solution of 5-chloro-1H-pyrazolo[4,3-b]pyridine (1.0 g,
6.5 mmol) in acetonitrile (32.6 ml) was added N-iodosuccinimide
(1.61 g, 7.16 mmol) and the reaction mixture was stirred at
50.degree. C. for 2 hours. The reaction mixture was cooled to room
temperature and DIPEA (1.25 ml, 7.16 mmol) was added followed by
the addition of SEM-Cl (1.27 ml, 7.16 mmol). The resulting solution
was stirred for another 1 hour at room temperature and then
concentrated to dryness. The residue was purified by silica gel
chromatography using 0-100% ethyl acetate in hexanes to afford
desired product as yellowish solid (2.2 g, 82%). LC-MS calculated
for C.sub.12H.sub.18ClIN.sub.3OSi (M+H).sup.+: m/z=410.0; found
410.0.
Step 2.
5-Chloro-3-(4-(4-methylpiperazin-1-yl)phenyl)-1-((2-(trimethylsily-
l)ethoxy)methyl)-1H-pyrazolo[4,3-b]pyridine
##STR00085##
[0538] To a solution of
5-chloro-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[4,3-b]py-
ridine (2.2 g, 5.4 mmol) in dioxane (43.0 ml) and water (10.7 ml)
was added potassium phosphate (2.28 g, 10.7 mmol),
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperaz-
ine (1.623 g, 5.37 mmol) followed by Pd-dppf (4.38 g, 5.37 mmol).
The reaction mixture was degassed by bubbling nitrogen through the
mixture for 10 minutes and was then stirred at 90.degree. C. for 15
hours. After cooling to room temperature it was concentrated to
dryness. The residue was purified by silica gel chromatography
using 0-10% methanol in DCM to afford Intermediate 1 as brownish
oil (1.8 g, 73%). LC-MS calculated for C.sub.23H.sub.33ClN.sub.5OSi
(M+H).sup.+: m/z=458.0; found 458.0.
Intermediate 2. tert-Butyl
3-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl(m-
ethyl)carbamate
##STR00086##
[0539] Step 1. 4-Bromo-3-fluoro-5-methylaniline
##STR00087##
[0541] N-Bromosuccinimide (15.8 g, 89 mmol) was added to a solution
of 3-fluoro-5-methylaniline (Combi-Blocks, 11 g, 88 mmol) in DMF
(80 mL) cooled to 0.degree. C. in an ice bath. The reaction mixture
was stirred at 0.degree. C. for 30 minutes. After warming to room
temperature, the reaction was stirred for an additional 1 hour.
Water and EtOAc were then added, and the separated organic phase
was washed with saturated aqueous NaHCO.sub.3 and brine. The
organic phase was dried over magnesium sulfate and concentrated
under reduced pressure. The crude product was purified by Biotage
Isolera.TM. (17.2 g, 96%). LCMS calculated for C.sub.7H.sub.8BrFN
(M+H).sup.+ m/z=203.9; found 204.0.
Step 2. 2-Bromo-1-fluoro-5-iodo-3-methylbenzene
##STR00088##
[0543] To a solution of 4-bromo-3-fluoro-5-methylaniline (7.28 g,
36 mmol) in acetonitrile (190 mL) cooled to 0.degree. C. was added
aqueous sulfuric acid (4.75 mL, 89 mmol in 10 mL H.sub.2O). After
stirring for 5 minutes, a solution of sodium nitrite (4.92 g, 71.4
mmol) in water (10 mL) was added dropwise and the reaction mixture
was stirred for an additional 15 minutes at 0.degree. C. Potassium
iodide (23.7 g, 143 mmol) in water (20 mL) was then added, and the
ice-bath was removed. After warming to room temperature the
reaction was stirred for an additional 20 minutes before the
reaction was treated with aqueous Na.sub.2S.sub.2O.sub.3. The
mixture was extracted with ethyl acetate and the combined organic
phases were washed with brine, dried over magnesium sulfate, and
concentrated under reduced pressure. The crude product was purified
by Biotage Isolera.TM. (10.3 g, 94%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.39 (br s, 1H), 7.29 (m, 1H), 2.38 (s, 3H)
ppm.
Step 3. 2-Bromo-1-fluoro-3-methyl-5-vinylbenzene
##STR00089##
[0545] To a solution of 2-bromo-1-fluoro-5-iodo-3-methylbenzene
(10.3 g, 32.8 mmol) in 1,4-dioxane (80 mL) and water (13.3 mL) was
added 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (Aldrich,
6.16 mL, 34.5 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II)
(Pd(dppf)Cl.sub.2) (2.40 g, 3.3 mmol), and potassium phosphate
tribasic (13.9 g, 65.7 mmol). The reaction mixture was degassed by
bubbling nitrogen through the mixture for 10 minutes and then
heated to 70.degree. C. for 1 h. After cooling to room temperature
the reaction mixture was filtered over a pad of Celite, diluted
with water, and extracted with ethyl acetate. The combined organic
phases were washed with brine, dried over magnesium sulfate, and
concentrated under reduced pressure. The crude product was purified
by Biotage Isolera.TM. (5.46 g, 77%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.05 (br s, 1H), 7.01 (dd, J=2.0, 9.4 Hz, 1H),
6.60 (dd, J=10.9, 17.5 Hz, 1H), 5.75 (d, J=17.5 Hz, 1H), 5.31 (d,
J=10.9 Hz, 1H), 2.42 (s, 3H) ppm.
Step 4. 4-Bromo-3-fluoro-5-methylbenzaldehyde
##STR00090##
[0547] To a solution of 2-bromo-1-fluoro-3-methyl-5-vinylbenzene
(5.46 g, 25.4 mmol) in acetone (46 mL) and water (4.6 mL) was
sequentially added sodium periodate (21.7 g, 102 mmol) and a 4%
aqueous solution of osmium tetroxide (8.07 mL, 1.27 mmol). The
reaction was stirred at r.t. for 2 h. The reaction mixture was then
filtered over a pad of celite, diluted with water, and extracted
with ethyl acetate. The combined organic phases were washed with
brine, dried over magnesium sulfate, and concentrated under reduced
pressure. The crude product was purified by Biotage Isolera.TM.
(3.22 g, 58%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.93 (d,
J=1.8 Hz, 1H), 7.55 (d, J=1.8 Hz, 1H), 7.44 (dd, J=1.8, 7.8 Hz,
1H), 2.52 (s, 3H) ppm.
Step 5. 1-(4-Bromo-3-fluoro-5-methylphenyl)-N-methylmethanamine
##STR00091##
[0549] In a 20 mL scintillation vial equipped with a magnetic stir
bar, 4-bromo-3-fluoro-5-methylbenzaldehyde (1.46 g, 6.70 mmol) was
dissolved in MeOH (6.70 mL) and the solution was placed under a
nitrogen environment. A 33% solution of methanamine (3.15 g, 33.5
mmol) in ethanol and titanium(IV) isopropoxide (0.982 mL, 3.35
mmol) were added and the reaction mixture was stirred at room
temperature for 3 hours. Sodium borohydride (1.01 g, 26.8 mmol) was
then added to the reaction mixture portion wise and stirring was
continued at room temperature for an additional 1.5 hours. The
reaction mixture was treated with NH.sub.4OH (30% aqueous solution)
and stirring continued for another 15 minutes. The reaction was
then acidified with 1 N HCl and extracted with ethyl acetate. The
separated aqueous phase was then made basic and extracted with
ethyl acetate. The combined organic phases were washed with brine,
dried over magnesium sulfate, and concentrated under reduced
pressure to afford
1-(4-bromo-3-fluoro-5-methylphenyl)-N-methylmethanamine (1.32 g,
85%) as a light yellow oil. The crude product was used in the next
step without further purification. LCMS calculated for
C.sub.9H1.sub.2BrFN (M+H).sup.+ m/z=232.0; found 231.9.
Step 6. tert-Butyl
4-bromo-3-fluoro-5-methylbenzyl(methyl)carbamate
##STR00092##
[0551] To a solution of
1-(4-bromo-3-fluoro-5-methylphenyl)-N-methylmethanamine (1.32 g,
5.67 mmol) and triethylamine (1.58 mL, 11.34 mmol) in THF (18.9 mL)
was added di-tert-butyl dicarbonate (1.58 mL, 6.80 mmol). The
reaction mixture was stirred at ambient temperature for 1 hour. The
reaction mixture was then diluted with water and extracted with
ethyl acetate. The combined organic phases were dried with
magnesium sulfate and concentrated under reduced pressure. The
crude product was purified by Biotage Isolera.TM. (1.42 g, 78%).
LCMS calculated for C.sub.10H.sub.12BrFNO.sub.2
(M+H-C.sub.4H.sub.8).sup.+ m/z=276.0; found 276.0.
Step 7. tert-Butyl
3-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl))benzyl(-
methyl)carbamate
##STR00093##
[0553] In an 20 mL scintillation vial, tert-butyl
(4-bromo-3-fluoro-5-methylbenzyl)(methyl)-carbamate (573 mg, 1.73
mmol) was dissolved in THF (11.5 mL). The solution was then cooled
to -78.degree. C. and n-BuLi (1.6 M solution in hexanes, 1.19 mL,
1.90 mmol) was added dropwise. The reaction mixture was then
allowed to stir for 3 minutes before
2-isopropyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (427 .mu.L,
2.25 mmol) was added dropwise. The mixture was warmed to room
temperature and stirred for an additional 5 hours. The reaction was
then treated with water, acidified to pH 5-6 using 1 N HCl, and
extracted with ethyl acetate. The combined organic phases were
washed with brine, dried over magnesium sulfate, and concentrated
to afford tert-butyl
3-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl(m-
ethyl)-carbamate. The crude product was used in the next step
without further purification. LCMS calculated for
C.sub.16H.sub.24BrFNO.sub.4 (M+H-C.sub.4H8).sup.+ m/z=324.2; found
324.1.
Example 61.
1-(3,5-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-b-
]pyridin-5-yl)phenyl)-N-methylmethanamine
##STR00094##
[0554] Step 1. tert-Butyl 3,5-difluorobenzyl(methyl)carbamate
##STR00095##
[0556] To a solution of 3,5-difluorobenzaldehyde (15.0 g, 106 mmol)
in methanol (528 ml) was added 2M solution of methylamine in THF
(79.0 ml, 158 mmol) and the reaction mixture was stirred at room
temperature for 1 hour. Then sodium borohydride (7.99 g, 211 mmol)
was added and the reaction mixture was stirred at room temperature
until gas evolution had stopped. The solvents were evaporated in
vacuo and residue was dissolved in 300 mL of DCM. Sodium
bicarbonate solution was added and the reaction mixture was stirred
at room temperature for 1 hour. The organic phase was separated,
dried over MgSO.sub.4, filtered and concentrated to dryness. To a
solution of the resulting residue in DCM (528 ml) was added DIPEA
(18.4 ml, 106 mmol) and di-tert-butyl dicarbonate (24.51 ml, 106
mmol). The mixture was stirred at room temperature for 1 hour,
concentrated in vacuo to dryness and the residue purified by silica
gel chromatography using 0-70% ethyl acetate in hexanes. The
desired product was isolated as a colorless oil (15.0 g, 55.4%).
LC-MS calculated for C.sub.13H.sub.18F.sub.2NO.sub.2 (M+H).sup.+:
m/z=258.2; found 258.2.
Step 2.
1-(3,5-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazol-
o[4,3-b]pyridin-5-yl)phenyl)-N-methylmethanamine
[0557] To a solution of tert-butyl
(3,5-difluorobenzyl)(methyl)carbamate (0.500 g, 1.94 mmol) in THF
(8.6 ml) under nitrogen was added 2.5M solution of n-butyllithium
in hexane (0.933 ml, 2.33 mmol) dropwise at -78.degree. C. The
reaction mixture was stirred at that temperature for 1 hour. Then
2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.542 g, 2.92
mmol) was added and the reaction mixture was allowed to warm to
room temperature over 1 hour. The resulting mixture was treated
with water and extracted with ethyl acetate. The combined organic
phases were washed with brine, dried over MgSO.sub.4, filtered and
concentrated to dryness. To a solution of the resulting residue in
dioxane (8.64 ml) and water (2.159 ml) was added intermediate 1
(0.089 g, 0.19 mmol) and potassium phosphate, tribasic (0.338 g,
1.94 mmol). The reaction mixture was degassed by bubbling nitrogen
through the mixture for 10 minutes and then
chloro(2-dicyclohexylphosphino-2',4',6'-tri-1-propyl-1,1'-biphenyl)(2'-am-
ino-1,1'-biphenyl-2-yl) palladium(II) (0.076 g, 0.097 mmol) was
added. The reaction mixture was stirred at 60.degree. C. for 1 hour
followed by addition of 5 mL of 4N HCl in dioxane and 4 mL of
water. The resulting mixture was stirred at 80.degree. C. for 2
hours, cooled to room temperature, diluted with acetonitrile,
filtered and purified by prep-LCMS (XBridge C18 column, eluting
with a gradient of acetonitrile/water containing 0.1% TFA, at flow
rate of 60 mL/min). LC-MS calculated for
C.sub.25H.sub.27F.sub.2N.sub.6 (M+H).sup.+: m/z=449.2; found
449.2.
Example 62.
5-(2-Fluoro-6-methylphenyl)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-
-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00096##
[0558] Step 1. 6-Bromo-1-trityl-1H-pyrazolo[4,3-b]pyridine
##STR00097##
[0560] To a suspension of NaH (60% in mineral oil, 755.4 mg, 18.89
mmol) in DMF (20.0 mL) at 0.degree. C. was added a solution of
6-bromo-1H-pyrazolo[4,3-b]pyridine (2.469 g, 12.47 mmol) in DMF
(20.0 mL) dropwise. The mixture was allowed to warm to room
temperature and stirred for 30 min. The reaction mixture was cooled
back to 0.degree. C. before a solution of
(chloromethanetriyl)-tribenzene (4.20 g, 15.07 mmol) in DMF (20.0
mL) was added dropwise. The reaction mixture was allowed to warm to
room temperature and was stirred for 16 h. The reaction mixture was
treated with sat. NH.sub.4Cl (aq) and extracted with DCM. The
combined organic phases were concentrated and the residue was
purified on silica gel (120 g, 0-50% EtOAc in hexanes) to give the
desired product as a white solid (4.80 g, 87%). LCMS calculated for
C.sub.25H.sub.19BrN.sub.3 (M+H).sup.+: m/z=440.1; found 440.0.
Step 2. 6-Bromo-1-trityl-1H-pyrazolo[4,3-b]pyridine 4-oxide
##STR00098##
[0562] To a solution of 6-bromo-1-trityl-1H-pyrazolo[4,3-b]pyridine
(3.240 g, 7.36 mmol) in DCM (60.0 ml) was added m-CPBA (5.83 g,
26.0 mmol) portionwise. After stirring at room temperature for 16
h, the reaction mixture was treated with a solution of sodium
thiosulfate (30.0 g, 190 mmol) in water (100 ml). The organic phase
was washed with 2 M K.sub.2CO.sub.3 (aq), dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified on silica gel (120 g, 0-100% EtOAc in DCM) to give the
desired product as a white foamy solid (3.22 g, 96%). LCMS
calculated for C.sub.25H1.sub.9BrN.sub.3O (M+H).sup.+: m/z=456.1;
found 456.0.
Step 3. 6-Cyano-1-trityl-1H-pyrazolo[4,3-b]pyridine 4-oxide
##STR00099##
[0564] A vial was charged with
6-bromo-1-trityl-1H-pyrazolo[4,3-b]pyridine 4-oxide (1.623 g, 3.56
mmol), dicyanozinc (1.691 g, 14.40 mmol),
tris(dibenzylideneacetone)dipalladium(0) (376.8 mg, 0.411 mmol) and
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (455.4 mg, 0.787
mmol). The vial was sealed, evacuated and backfilled with nitrogen
(this process was repeated a total of three times). A solution of
TMEDA (341.5 mg, 2.94 mmol) in DMF (15.0 ml) was added. The
reaction mixture was stirred at 110.degree. C. for 2 h. After
cooling to room temperature, the reaction mixture was filtered. The
filter cake was washed with DCM. The filtrate was concentrated. The
resultant residue was purified on silica gel (120 g, 0-100% EtOAc
in DCM) to give the desired product as a yellow foamy solid (894.5
mg, 63%). LCMS calculated for C.sub.26H.sub.18N.sub.4NaO
(M+Na).sup.+: m/z=425.1; found 425.1.
Step 4.
5-Chloro-1-trityl-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00100##
[0566] To a solution of 6-cyano-1-trityl-1H-pyrazolo[4,3-b]pyridine
4-oxide (447.3 mg, 1.1 mmol) in DCM (10.0 ml) at 0.degree. C. was
added Et.sub.3N (264.9 mg, 2.62 mmol) followed by the dropwise
addition of a solution of oxalyl chloride (317.6 mg, 2.5 mmol) in
DCM (3.0 ml). After stirring at 0.degree. C. for 30 min, the
mixture was diluted with DCM and washed with sat. NaHCO.sub.3. The
organic phase was dried over anhydrous Na.sub.2SO.sub.4, filtered
and concentrated. The residue was purified on silica gel (40 g,
0-100% EtOAc in hexanes) to give the desired product as a white
foamy solid (446.7 mg, 95%). LCMS calculated for
C.sub.26H.sub.17ClN.sub.4Na (M+Na).sup.+: m/z=443.1; found
443.1.
Step 5.
5-(2-Fluoro-6-methylphenyl)-1-trityl-1H-pyrazolo[4,3-b]pyridine-6--
carbonitrile
##STR00101##
[0568] A screw-cap vial was charged with
5-chloro-1-trityl-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile (362.4
mg, 0.861 mmol),
chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-
-1,1'-biphenyl)]palladium(II) (SPhos Pd G2, 57.8 mg, 0.080 mmol)
and cesium carbonate (869.3 mg, 2.67 mmol). The vial was sealed,
evacuated and backfilled with nitrogen (this process was repeated a
total of three times). A solution of
(2-fluoro-6-methylphenyl)boronic acid (184.5 mg, 1.2 mmol) in
1,4-dioxane (10.0 ml) was added, followed by water (2.0 ml). The
reaction mixture was stirred at 50.degree. C. for 16 h. The
reaction mixture was concentrated. The resultant residue was
purified on silica gel (40 g, 0-100% EtOAc in hexanes) to give the
desired product as a pale yellow solid (406.1 mg, 95%). LCMS
calculated for C.sub.33H.sub.24FN.sub.4 (M+H).sup.+: m/z=495.2;
found 495.2.
Step 6.
5-(2-Fluoro-6-methylphenyl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitr-
ile
##STR00102##
[0570] To a solution of
5-(2-fluoro-6-methylphenyl)-1-trityl-1H-pyrazolo[4,3-b]pyridine-6-carboni-
trile (406.1 mg, 0.821 mmol) in DCM (10.0 ml) was added TFA (5.0
ml). The reaction was stirred at room temperature for 30 min, and
then concentrated. The residue was dissolved in DCM and washed with
sat. NaHCO.sub.3 (aq). The organic phase was dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified on silica gel (40 g, 0-100% EtOAc in DCM) to give the
desired product as a white solid (140.1 mg, 68%). LCMS calculated
for C.sub.14H.sub.10FN.sub.4 (M+H).sup.+: m/z=253.1; found
253.1.
Step 7. tert-Butyl
6-cyano-5-(2-fluoro-6-methylphenyl)-3-iodo-1H-pyrazolo[4,3-b]pyridine-1-c-
arboxylate
##STR00103##
[0572] To a solution of
5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
(140.1 mg, 0.555 mmol) in DMF (8.0 ml) was added N-iodosuccinimide
(175.2 mg, 0.779 mmol). The mixture was stirred at 80.degree. C.
for 2 h. After cooling to room temperature, Boc-anhydride (168.1
mg, 0.770 mmol) was added followed by DMAP (24.9 mg, 0.204 mmol).
The reaction was stirred at room temperature for 30 min, and then
concentrated. The residue was purified on silica gel (40 g, 0-100%
EtOAc in hexanes) to give the desired product as a white foamy
solid (244.3 mg, 92%). LCMS calculated for
C.sub.19H1.sub.7FIN.sub.4O.sub.2(M+H).sup.+: m/z=479.0; found
479.0.
Step 8.
5-(2-Fluoro-6-methylphenyl)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-
-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
[0573] A vial was charged with
1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)p-
iperazine (20.4 mg, 0.067 mmol),
chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-
-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 5.3 mg, 6.74
.mu.mol) and cesium carbonate (53.3 mg, 0.164 mmol). The vial was
sealed, evacuated and backfilled with nitrogen (this process was
repeated a total of three times). A solution of tert-butyl
6-cyano-5-(2-fluoro-6-methylphenyl)-3-iodo-1H-pyrazolo[4,3-b]pyridine-1-c-
arboxylate (20.0 mg, 0.042 mmol) in 1,4-dioxane (2.00 ml) was
added, followed by water (200.0 .mu.L). The reaction mixture was
heated to 50.degree. C. for 16 h. The reaction mixture was
concentrated. To the resultant residue was added CH.sub.2Cl.sub.2
(2.0 mL) followed by TFA (2.0 mL). The mixture was stirred at room
temperature for 15 min, and then concentrated. The residue was
purified using prep-LCMS (XBridge C18 column, eluting with a
gradient of acetonitrile/water containing 0.1% TFA, at flow rate of
60 mL/min) to afford the desired product. LCMS calculated for
C.sub.24H.sub.23FN.sub.7 (M+H).sup.+: m/z=428.2; found: 428.2.
Example 63.
5-(2-Fluoro-6-methylphenyl)-3-(2-morpholinopyrimidin-5-yl)-1H-pyrazolo[4,-
3-b]pyridine-6-carbonitrile
##STR00104##
[0575] This compound was prepared according to the procedure
described in Example 62, using
4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholi-
ne instead of
1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)p-
iperazine as the starting material. LCMS calculated for
C.sub.22H1.sub.9FN.sub.7O (M+H).sup.+: m/z=416.2; found: 416.1.
.sup.1H NMR (TFA salt, 400 MHz, DMSO) .delta. 14.18 (br, 1H), 9.23
(s, 2H), 8.94 (s, 1H), 7.55-7.44 (m, 1H), 7.28 (d, J=7.7 Hz, 1H),
7.23 (t, J=8.9 Hz, 1H), 3.81-3.72 (m, 4H), 3.69-3.62 (m, 4H), 2.14
(s, 3H).
Example 64.
3-(4-(4-Ethylpiperazin-1-yl)phenyl)-5-(2-fluoro-6-methylphenyl)-1H-pyrazo-
lo[4,3-b]pyridine-6-carbonitrile
##STR00105##
[0577] This compound was prepared according to the procedure
described in Example 62, using
1-ethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazi-
ne instead of
1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)p-
iperazine as the starting material. LCMS calculated for
C.sub.26H.sub.26FN.sub.6 (M+H).sup.+: m/z=441.2; found: 441.2.
Example 65.
5-(6-Cyano-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-N--
methylpicolinamide
##STR00106##
[0579] This compound was prepared according to the procedure
described in Example 62, using
N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinamide
instead of
1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)p-
iperazine as the starting material. LCMS calculated for
C.sub.21H1.sub.6FN.sub.6O (M+H).sup.+: m/z=387.1; found: 387.1.
Example 66.
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(1-methyl-1H-pyrazo-
l-4-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00107##
[0580] Step 1. tert-Butyl
4-(6-cyano-1-trityl-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-fluoro-5-methylbenz-
yl(methyl) carbamate
##STR00108##
[0582] A vial was charged with
5-chloro-1-trityl-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile (see
step 4 in example 62, 449.7 mg, 1.068 mmol),
bis(di-tert-butyl(4-dimethylaminophenyl)-phosphine)dichloropalladium(II)
(76.2 mg, 0.108 mmol) and CsF (668.8 mg, 4.40 mmol). The vial was
sealed, evacuated and backfilled with nitrogen (this process was
repeated a total of three times). A solution of tert-butyl
(3-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-
(methyl)carbamate (Intermediate 2, 557.8 mg, 1.471 mmol) in
butan-1-ol (9.00 ml) was added, followed by water (3.00 ml). After
stirring at 60.degree. C. for 90 min, the reaction mixture was
concentrated. The residue was purified on silica gel (40 g, 0-100%
EtOAc in hexanes) to give the desired product as a yellow
semi-solid (585.9 mg, 86%). LCMS calculated for
C.sub.40H.sub.37FN.sub.5O.sub.2(M+H).sup.+: m/z=638.3; found:
638.3.
Step 2. tert-Butyl
4-(6-cyano-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-fluoro-5-methylbenzyl(methyl-
)carbamate
##STR00109##
[0584] To a solution of tert-butyl
(4-(6-cyano-1-trityl-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-fluoro-5-methylben-
zyl)(methyl)carbamate (585.9 mg, 0.919 mmol) in DCM (10.0 ml) was
added TFA (5.0 ml). The reaction was stirred at room temperature
for 30 min, and then concentrated. The residue was dissolved in DCM
and washed with sat. NaHCO.sub.3 (aq). The organic phase was dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated. The
residue was dissolved in DCM (10.0 ml), and treated with a solution
of Boc-anhydride (199.1 mg, 0.912 mmol) in DCM (10.0 ml). The
mixture was stirred at room temperature for 15 min, and
concentrated. The residue was purified on silica gel (40 g, 0-100%
EtOAc in hexanes) to give the desired product as a yellow foamy
solid (252.3 mg, 69%). LCMS calculated for
C.sub.21H.sub.22FN.sub.5NaO.sub.2 (M+Na).sup.+: m/z=418.2; found:
418.2.
Step 3. tert-Butyl
5-(4-((tert-butoxycarbonyl(methyl)amino)methyl)-2-fluoro-6-methylphenyl)--
6-cyano-3-iodo-H-pyrazolo[4,3-b]pyridine-1-carboxylate
##STR00110##
[0586] To a solution of tert-butyl
(4-(6-cyano-1H-pyrazolo[4,3-b]pyridin-5-yl)-3-fluoro-5-methylbenzyl)(meth-
yl)carbamate (252.3 mg, 0.638 mmol) in DMF (6.0 ml) was added
N-iodosuccinimide (201.2 mg, 0.894 mmol). The mixture was stirred
at 80.degree. C. for 2 h. After cooling to room temperature,
Boc-anhydride (208.6 mg, 0.956 mmol) was added followed by DMAP
(28.5 mg, 0.233 mmol). The reaction mixture was stirred at room
temperature for 30 min, and then concentrated. The residue was
purified on silica gel (40 g, 0-100% EtOAc in hexanes) to give the
desired product as a yellow foamy solid (269.3 mg, 68%). LCMS
calculated for C.sub.26H3.sub.0FIN.sub.5O.sub.4(M+H).sup.+:
m/z=622.1; found: 622.1.
Step 4.
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(1-methyl-1H-
-pyrazol-4-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
[0587] A vial was charged with
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(11.0 mg, 0.053 mmol),
chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-
-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 4.8 mg, 6.10
.mu.mol) and cesium carbonate (33.2 mg, 0.102 mmol). The vial was
sealed, evacuated and backfilled with nitrogen (this process was
repeated a total of three times). A solution of tert-butyl
5-(4-(((tert-butoxycarbonyl)(methyl)amino)methyl)-2-fluoro-6-methylphenyl-
)-6-cyano-3-iodo-1H-pyrazolo[4,3-b]pyridine-1-carboxylate (18.1 mg,
0.029 mmol) in 1,4-dioxane (2.00 ml) was added, followed by water
(200.0 .mu.l). The reaction mixture was heated to 50.degree. C. for
16 h. The reaction was concentrated. To the residue was added
CH.sub.2Cl.sub.2 (2.0 mL) followed by TFA (2.0 mL). The mixture was
stirred at room temperature for 15 min, and then concentrated. The
resultant residue was purified using prep-LCMS (XBridge C18 column,
eluting with a gradient of acetonitrile/water containing 0.1% TFA,
at flow rate of 60 mL/min) to afford the desired product. LCMS
calculated for C.sub.20H1.sub.9FN.sub.7 (M+H).sup.+: m/z=376.2;
found: 376.2.
Example 67.
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(6-(4-methylpiperaz-
in-1-yl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00111##
[0589] This compound was prepared according to the procedure
described in Example 66, using
1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)p-
iperazine instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.26H.sub.28FN.sub.8 (M+H).sup.+: m/z=471.2; found: 471.1.
Example 68.
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(2-(4-methylpiperaz-
in-1-yl)pyrimidin-5-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00112##
[0591] This compound was prepared according to the procedure
described in Example 66, using
2-(4-methylpiperazin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-
)pyrimidine instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for C.sub.25H27FN.sub.9
(M+H).sup.+: m/z=472.2; found: 472.2.
Example 69.
3-(4-(4-Ethylpiperazin-1-yl)phenyl)-5-(2-fluoro-6-methyl-4-((methylamino)-
methyl)phenyl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00113##
[0593] This compound was prepared according to the procedure
described in Example 66, using
1-ethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazi-
ne instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.28H3.sub.1FN.sub.7 (M+H).sup.+: m/z=484.3; found: 484.2.
Example 70.
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(2-morpholinopyrimi-
din-5-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00114##
[0595] This compound was prepared according to the procedure
described in Example 66, using
4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholi-
ne instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.24H.sub.24FN.sub.8O (M+H).sup.+: m/z=459.2; found: 459.1.
Example 71.
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(6-(2-hydroxypropan-
-2-yl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00115##
[0597] This compound was prepared according to the procedure
described in Example 66, using
2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)propan-2-o-
l instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.24H.sub.24FN.sub.6O (M+H).sup.+: m/z=431.2; found: 431.1.
Example 72.
5-(6-Cyano-5-(2-fluoro-6-methyl-4-((methylamino)methyl)phenyl)-1H-pyrazol-
o[4,3-b]pyridin-3-yl)-N-methylpicolinamide
##STR00116##
[0599] This compound was prepared according to the procedure
described in Example 66, using
N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinamide
instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.23H.sub.21FN.sub.7O (M+H).sup.+: m/z=430.2; found: 430.1.
.sup.1H NMR (TFA salt, 400 MHz, DMSO) .delta. 14.62 (br, 1H), 9.57
(m, 1H), 9.06 (s, 1H), 8.95 (br, 2H), 8.84 (dd, J=8.2, 2.1 Hz, 1H),
8.83-8.77 (m, 1H), 8.17 (d, J=8.2 Hz, 1H), 7.41 (m, 2H), 4.23 (t,
J=5.1 Hz, 2H), 2.83 (d, J=4.8 Hz, 3H), 2.65 (t, J=4.8 Hz, 3H), 2.20
(s, 3H).
Example 73.
5-(2-Fluoro-6-methyl-4-((methylamino)methyl)phenyl)-3-(pyridin-3-yl)-1H-p-
yrazolo[4,3-b]pyridine-6-carbonitrile
##STR00117##
[0601] This compound was prepared according to the procedure
described in Example 66, using
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.21H1.sub.8FN.sub.6 (M+H).sup.+: m/z=373.2; found: 373.1.
Example 74.
5-(6-Fluoro-1,2,3,4-tetrahydroisoquinolin-5-yl)-3-(1-methyl-1H-pyrazol-4--
yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00118##
[0602] Step 1. 5-Bromo-6-fluoro-, 2,3,4-tetrahydroisoquinoline
##STR00119##
[0604] To a solution of 5-bromo-6-fluoroisoquinoline (1.0 g, 4.4
mmol) in acetic acid (20.0 mL) at room temperature was added sodium
tetrahydroborate (592.0 mg, 15.65 mmol) portionwise. The mixture
was stirred at room temperature for 16 h, and then concentrated.
The residue was diluted with CH.sub.2Cl.sub.2 and washed with
aqueous Na.sub.2CO.sub.3 (2 M). The separated organic phase was
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to
give a yellow oil which was used directly in the next step without
further purification. LCMS calculated for C.sub.9H.sub.10BrFN
(M+H).sup.+ m/z=230.0; found 230.1.
Step 2. tert-Butyl
5-bromo-6-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate
##STR00120##
[0606] To a solution of
5-bromo-6-fluoro-1,2,3,4-tetrahydroisoquinoline (1.0 g, 4.3 mmol)
in CH.sub.2Cl.sub.2 (12.0 mL) was added di-tert-butyl dicarbonate
(1.617 g, 7.409 mmol). The mixture was stirred at room temperature
for 1 h, and then concentrated. The residue was purified on silica
gel (120 g, 0-100% EtOAc in hexanes) to give the desired product as
a white solid (1.119 g, 76% over two steps). LCMS calculated for
C.sub.14H.sub.17BrFNNaO.sub.2 (M+Na).sup.+ m/z=352.0; found
352.0.
Step 3. tert-Butyl
6-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoqu-
inoline-2(1H)-carboxylate
##STR00121##
[0608] A vial was charged with tert-butyl
5-bromo-6-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.119
g, 3.389 mmol),
4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl]
(1.358 g, 5.348 mmol), potassium acetate (1.101 g, 11.22 mmol), and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),
complexed with dichloromethane (1:1) (298.6 mg, 0.366 mmol). The
vial was sealed, evacuated and backfilled with nitrogen (this
process was repeated a total of three times). 1,4-Dioxane (15.0 mL)
was added and the mixture was heated at 100.degree. C. for 16 h.
After cooling to room temperature, the reaction mixture was diluted
with CH.sub.2Cl.sub.2 and filtered. The filtrate was concentrated.
The residue was purified on silica gel (40 g, 0-100% EtOAc in
hexanes) to give the desired product as a pale yellow oil (1001 mg,
78%). LCMS calculated for C.sub.20H.sub.29BFNNaO.sub.4 (M+Na).sup.+
m/z=400.2; found 400.2.
Step 4. tert-Butyl
5-(6-cyano-1-trityl-H-pyrazolo[4,3-b]pyridin-5-yl)-6-fluoro-3,4-dihydrois-
oquinoline-2(1H)-carboxylate
##STR00122##
[0610] A vial was charged with
5-chloro-1-trityl-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile (see
step 4 in example 62, 569.3 mg, 1.353 mmol),
bis(di-tert-butyl(4-dimethylaminophenyl)-phosphine)dichloropalladium(II)
(99.8 mg, 0.141 mmol) and CsF (822.2 mg, 5.41 mmol). A solution of
tert-butyl
6-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoqu-
inoline-2(1H)-carboxylate (666.7 mg, 1.767 mmol) in butan-1-ol
(9.00 ml) was added, followed by water (3.00 ml). After stirring at
60.degree. C. for 3 h, the reaction was concentrated. The residue
was purified on silica gel (40 g, 0-100% EtOAc in hexanes) to give
the desired product (860 mg). LCMS calculated for
C.sub.40H3.sub.4FN.sub.5NaO.sub.2 (M+Na).sup.+: m/z=658.3; found:
658.2.
Step 5. tert-Butyl
5-(6-cyano-1H-pyrazolo[4,3-b]pyridin-5-yl)-6-fluoro-3,4-dihydroisoquinoli-
ne-2(1H)-carboxylate
##STR00123##
[0612] To a solution of tert-butyl
5-(6-cyano-1-trityl-1H-pyrazolo[4,3-b]pyridin-5-yl)-6-fluoro-3,4-dihydroi-
soquinoline-2(1H)-carboxylate (860 mg, 1.353 mmol) in DCM (10.0 ml)
was added TFA (6.0 ml). The reaction was stirred at room
temperature for 30 min, and then concentrated. The residue was
dissolved in DCM, washed with sat. NaHCO.sub.3 (aq). The aqueous
phase was extracted with DCM (10Ox). The combined organic phases
were dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated. The residue was dissolved in DCM (10.0 ml) and
treated with a solution of Boc-anhydride (300.0 mg, 1.375 mmol) in
DCM (10.0 ml). The mixture was stirred at room temperature for 15
min and concentrated. The residue was purified on silica gel (40 g,
0-100% EtOAc in hexanes) to give the desired product as a yellow
foamy solid (354.7 mg, 67%). LCMS calculated for
C.sub.21H.sub.20FN.sub.5NaO.sub.2 (M+Na).sup.+: m/z=416.1; found:
416.1.
Step 6. tert-Butyl
5-(1-(tert-butoxycarbonyl)-6-cyano-3-iodo-1H-pyrazolo[4,3-b]pyridin-5-yl)-
-6-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate
##STR00124##
[0614] To a solution of tert-butyl
5-(6-cyano-1H-pyrazolo[4,3-b]pyridin-5-yl)-6-fluoro-3,4-dihydroisoquinoli-
ne-2(1H)-carboxylate (354.7 mg, 0.902 mmol) in DMF (6.0 ml) was
added N-iodosuccinimide (304.2 mg, 1.352 mmol). The mixture was
stirred at 80.degree. C. for 2 h, and cooled to room temperature.
Boc-anhydride (306.1 mg, 1.403 mmol) was added, followed by DMAP
(31.6 mg, 0.259 mmol). The reaction was stirred at room temperature
for 30 min, and then concentrated. The residue was purified on
silica gel (40 g, 0-100% EtOAc in hexanes) to give the desired
product as a yellow foamy solid (407.4 mg, 73%). LCMS calculated
for C.sub.26H.sub.27FIN.sub.5NaO.sub.4 (M+Na).sup.+: m/z=642.1;
found: 642.0.
Step 7.
5-(6-Fluoro-1,2,3,4-tetrahydroisoquinolin-5-yl)-3-(1-methyl-1H-pyr-
azol-4-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
[0615] A vial was charged with
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(11.2 mg, 0.054 mmol),
chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-
-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 4.5 mg, 5.72
.mu.mol) and cesium carbonate (38.3 mg, 0.118 mmol). The vial was
sealed, evacuated and backfilled with nitrogen (this process was
repeated a total of three times). A solution of tert-butyl
5-(1-(tert-butoxycarbonyl)-6-cyano-3-iodo-1H-pyrazolo[4,3-b]pyridin-5-yl)-
-6-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate (20.0 mg, 0.032
mmol) in 1,4-dioxane (2.00 ml) was added, followed by water (200.0
.mu.l). The reaction mixture was heated to 50.degree. C. for 16 h.
The reaction mixture was concentrated. The residue was dissolved in
CH.sub.2C.sub.2(2.0 mL) and treated with TFA (2.0 mL). The mixture
was stirred at room temperature for 15 min, and then concentrated.
The residue was purified using prep-LCMS (XBridge C18 column,
eluting with a gradient of acetonitrile/water containing 0.1% TFA,
at flow rate of 60 mL/min) to afford the desired product. LCMS
calculated for C.sub.20H.sub.17FN.sub.7 (M+H).sup.+: m/z=374.2;
found: 374.1.
Example 75.
3-(4-(4-Ethylpiperazin-1-yl)phenyl)-5-(6-fluoro-1,2,3,4-tetrahydroisoquin-
olin-5-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00125##
[0617] This compound was prepared according to the procedure
described in Example 74, using
1-ethyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazi-
ne instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.28H.sub.29FN.sub.7 (M+H).sup.+: m/z=482.2; found: 482.2.
Example 76.
5-(6-Fluoro-1,2,3,4-tetrahydroisoquinolin-5-yl)-3-(6-(4-methylpiperazin-1-
-yl)pyridin-3-yl)-1H-pyrazolo[4,3-b]pyridine-6-carbonitrile
##STR00126##
[0619] This compound was prepared according to the procedure
described in Example 74 (step 7), using
1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)p-
iperazine instead of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
as the starting material. LCMS calculated for
C.sub.26H.sub.26FN.sub.8 (M+H).sup.+: m/z=469.2; found: 469.2.
Example 77.
5-(2-Fluoro-6-methylphenyl)-3-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3--
b]pyridine-6-carbonitrile
##STR00127##
[0621] This compound was prepared according to the procedure
described in Example 62 (step 8), using
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
instead of
1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)p-
iperazine as the starting material. LCMS calculated for
C.sub.18H1.sub.4FN.sub.6 (M+H).sup.+: m/z=333.1; found: 333.1.
.sup.1H NMR (TFA salt, 600 MHz, DMSO) .delta. 13.89 (br, 1H), 8.85
(s, 1H), 8.36 (s, 1H), 8.05 (s, 1H), 7.49 (m, 1H), 7.28 (d, J=7.7
Hz, 1H), 7.23 (t, J=8.9 Hz, 1H), 3.91 (s, 3H), 2.14 (s, 3H).
Example A. HPK1 Kinase Binding Assay
[0622] A stock solution of 1 mM test compound was prepared in DMSO.
The compound plate was prepared by 3-fold and 11-point serial
dilutions. 0.1 .mu.L of the compound in DMSO was transferred from
the compound plate to the white 384 well polystyrene plates. The
assay buffer contained 50 mM HEPES, pH 7.5, 0.01% Tween-20, 5 mM
MgCl.sub.2, 0.01% BSA, and 5 mM DTT. 5 .mu.l of 4 nM active HPK1
(SignalChem M23-11G) prepared in the buffer was added to the plate.
The enzyme concentration given was based on the given stock
concentration reported by the vender. 5 .mu.l of 18 nM tracer 222
(ThermoFisher PV6121) and 4 nM LanthaScreen Eu-Anti GST antibody
(ThermoFisher PV5595) were added. After one hour incubation at
25.degree. C., the plates were read on a PHERAstar FS plate reader
(BMG Labtech). Ki values were determined.
[0623] Compounds of the present disclosure, as exemplified in
Examples, showed the Ki values in the following ranges:
+=Ki.ltoreq.100 nM; ++=100 nM<Ki.ltoreq.500 nM; +++=500
nM<Ki.ltoreq.10000 nM.
TABLE-US-00001 TABLE 1 Example HPK1 Ki (nM) 1 ++ 2 ++ 3 + 4 + 5 + 6
+ 7 + 8 + 9 + 10 + 11 + 12 + 13 + 14 ++ 15 ++ 16 ++ 17 ++ 18 +++ 19
+ 20 +++ 21 +++ 22 ++ 23 + 24 + 25 ++ 26 + 27 + 28 + 29 + 30 +++ 31
+ 32 + 33 + 34 + 35 + 36 ++ 37 + 38 ++ 39 ++ 40 + 41 + 42 + 43 + 44
+ 45 ++ 46 + 47 + 48 + 49 + 50 + 51 +++ 52 +++ 53 ++ 54 ++ 55 + 56
+++ 57 +++ 58 ++ 59 +++ 60 +++ 61 + 62 + 63 + 64 + 65 + 66 + 67 +
68 + 69 + 70 + 71 + 72 + 72 + 74 + 75 + 76 + 77 +
Example B. p-SLP76S376 HTRF Assay
[0624] One or more compounds of the invention can be tested using
the p-SLP76S376 HTRF assay described as follows. Jurkat cells
(cultured in RPMI1640 media with 10% FBS) are collected and
centrifuged, followed by resuspension in appropriate media at
3.times.10.sup.6 cells/ml. The Jurkat cells (35 ul) are dispensed
into each well in a 384 well plate. Test compounds are diluted with
cell culture media for 40-fold dilution (adding 39 ul cell culture
media into 1 ul compound). The Jurkat cells in the well plate are
treated with the test compounds at various concentrations (adding 5
ul diluted compound into 35 ul Jurkat cells and starting from 3 uM
with 1:3 dilution) for 1 hour at 37.degree. C., 5% CO.sub.2),
followed by treatment with anti-CD3 (5 ug/ml, OKT3 clone) for 30
min. A 1:25 dilution of 100.times. blocking reagent (from p-SLP76
ser376HTRF kit) with 4.times.Lysis Buffer (LB) is prepared and 15
ul of the 4.times.LB buffer with blocking reagent is added into
each well and incubated at room temperature for 45 mins with gentle
shaking. The cell lysate (16 ul) is added into a Greiner white
plate, treated with p-SLP76 ser376HTRF reagents (2 ul donor, 2 ul
acceptor) and incubated at 4.degree. C. for overnight. The
homogeneous time resolved fluorescence (HTRF) is measured on a
PHERAstar plate reader the next day. IC.sub.50 determination is
performed by fitting the curve of percent inhibition versus the log
of the inhibitor concentration using the GraphPad Prism 5.0
software.
Example C. Isolation of CD4+ or CD8+ T Cells and Cytokine
Measurement
[0625] Blood samples are collected from healthy donors. CD4+ or
CD8+ T cells are isolated by negative selection using CD4+ or CD8+
enrichment kits (lifetech, USA). The purity of the isolated CD4+ or
CD8+ T cells is determined by flow cytometry and is routinely
>80%. Cells are cultured in RPMI 1640 supplemented with 10% FCS,
glutamine and antibiotics (Invitrogen Life Technologies, USA). For
cytokine measurement, Jurkat cells or primary CD4+ or CD8+ T cells
are plated at 200 k cells/well and are stimulated for 24 h with
anti-CD3/anti-CD28 beads in the presence or absence of testing
compounds at various concentrations. 16 .mu.L of supernatants are
then transferred to a white detection plate and analyzed using the
human IL2 or IFN.gamma. assay kits (Cisbio).
Example D. Treg Assay
[0626] One or more compounds can be tested using the Regulatory
T-cell proliferation assay described as following. Primary
CD4+/CD25- T-cells and CD4+/CD25+ regulatory T-cells are isolated
from human donated Peripheral Blood Mononuclear Cells, using an
isolated kit from Thermo Fisher Scientific (11363D). CD4+/CD25-
T-cells are labeled with CFSE (Thermo Fisher Scientific, C34554)
following the protocol provided by the vendor. CFSE labeled T-cells
and CD4+/CD25+ regulatory T-cells are re-suspended at the
concentration of 1.times.10.sup.6 cells/ml in RPMI-1640 medium. 100
.mu.l of CFSE-labeled T-cells are mixed with or without 50 .mu.l of
CD4+/CD25+ regulatory T-cells, treated with 5 .mu.l of
anti-CD3/CD28 beads (Thermo Fisher Scientific, 11132D) and various
concentrations of compounds diluted in 50 .mu.l of RPMI-1640
medium. Mixed populations of cells are cultured for 5 days
(37.degree. C., 5% CO.sub.2) and proliferation of CFSE-labeled
T-cells is analyzed by BD LSRFortessa X-20 using FITC channel on
the 5th day.
[0627] Various modifications of the invention, in addition to those
described herein, will be apparent to those skilled in the art from
the foregoing description. Such modifications are also intended to
fall within the scope of the appended claims. Each reference,
including without limitation all patent, patent applications, and
publications, cited in the present application is incorporated
herein by reference in its entirety.
* * * * *